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Abstract
The essential, vertebrate-specific RanBP2/RanGAP1*SUMO1/Ubc9 complex is a
fascinating macromolecular machine positioned at the nuclear pore complex during
interphase. It is a unique composite SUMO E3 ligase and serves as a docking site
for nuclear transport complexes. Moreover, the RanBP2 complex can stimulates
Ran-GTP hydrolysis via its four Ran binding domains and the associated RanGAP
activity.
In the first part of this work, I wanted to obtain insight into the molecular mecha-
nism of this composite E3 ligase. In order to unravel how it interacts with and acti-
vates its cognate E2 conjugating enzyme, I created a stable Ubc9∼SUMO thioester
mimic that allowed in vitro interaction studies. I found evidence that SUMOylation
via the RanBP2 complex depends on the formation of the catalytically productive,
folded-back thioester conformation, similarly to ubiquitination. In collaboration
with the group of Teresa Carlomagno (EMBL, Heidelberg), we mapped the interac-
tion surfaces of the thioester mimic on the RanBP2 complex via NMR. Our analyses
suggest that thioester-binding is not only achieved by the suspected interaction with
RanBP2 itself, but also by a backside interaction between the SUMO1 molecule in
the complex and the thioester-Ubc9. For this interaction, the complex opens up at
its Ubc9/SUMO1-interface suggesting that it is not a static, but structurally dy-
namic entity during catalysis.
In the second part of this work, I investigated possible roles of the RanBP2 com-
plex for nuclear transport complexes, using a reconstituted version that contained
RanGAP1, the SUMO E3 ligase region, two FG-repeat clusters and two Ran binding
domains. I could show that the RanBP2 complex specifically binds and disassembles
export complexes formed with the prototypic export receptor Crm1. The two FG-
repeat clusters mediate RanBP2’s tight association with Crm1, which is followed
by Ran binding domain-dependent cargo release and Ran-GTP hydrolysis. As the
Crm1/RanBP2 interaction is compatible with RanBP2’s SUMO E3 ligase activ-
ity, my work also allows speculating about a possible Crm1-dependent substrate
recruitment mechanism for the RanBP2 E3 ligase complex.
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Zusammenfassung
Der RanBP2/RanGAP1*SUMO1/Ubc9 Komplex ist eine faszinierende makromo-
lekulare Maschine an der Kernpore, welche essentiell und spezifisch für Vertebraten
ist. Er stellt sowohl eine einzigartige, zusammengesetzte SUMO E3 Ligase dar als
auch eine Bindestelle für Kerntransport Rezeptoren. Darüber hinaus ist der Kom-
plex in der Lage, Ran-GTP Hydrolyse mit seinen vier Ran-Bindedomämen und der
assoziierten RanGAP Aktivität zu stimulieren.
Im ersten Teil dieser Arbeit versuche ich Einblicke in the katalytischen Mechanis-
mus der zusammengesetzten E3 Ligase zu erlangen. Vor allem hat mich diesbezüglich
interessiert, wie der Komplex mit dem E2 konjugierenden Enzym Ubc9 interagiert
und es aktiviert. Um die dazu nötigen in vitro Interaktionsstudien druchführen zu
können, habe ich zunächst einen stabilen Ubc9∼SUMO Thioester Mimik herge-
stellt. Mit diesem konnte ich Hinweise darauf finden, dass, ähnlich der Ubiquitinie-
rung, SUMOylierung durch den RanBP2 Komplex von der Bildung einer katalytisch
produktiven, sog. zurück-gefalteten Konfomration Thioesters abhängig ist. In Kol-
laboration mit der Gruppe von Teresa Carlomagno (EMBL, Heidelberg), konnten
wir die Interaktionsoberfläche des Thioester Mimiks auf dem RanBP2 Komplex über
NMR bestimmen. Unsere Analyse wies darauf hin, dass die Thioester-Bindung nicht
nur über die vermutete Interktion mit RanBP2 selbst vermittelt wird, sondern auch
über eine Rückseiten-Interaktion zwischen dem SUMO1 Molekül im Komplex und
dem Thioester-Ubc9. Für diese zusätzliche Interaktion öffnet sich der Komplex an
seiner Ubc9/SUMO1 Kontaktfläche, was zeigt, dass er nicht statisch, sondern eine
strukturell dynamische Einheit während der Katalyse ist.
Im zweiten Teil dieser Arbeit habe ich eine mögliche Rolle des RanBP2 Kom-
plexes im Kerntransport untersucht. Dazu habe ich eine rekonstituierte Version des
Komplexes verwendet, die sowohl RanGAP1 als auch die SUMO E3 Ligase Region,
zwei FG-Repeat Cluster und zwei Ran-Bindedomänen beinhaltet. So konnte ich zei-
gen, dass der RanBP2 Komplex spezifisch Exportkomplexe mit dem prototypischen
Export Rezeptor Crm1 binden und zerlegen kann. Die zwei FG-Repeat Cluster ver-
mitteln dabei die enge Bindung zwischen RanBP2 und Crm1. In nachgeschalteten
Schritten kann dann das Exprotkomplex-Substrat durch die Ran-Bindedomänen dis-
soziieren und Ran-GTP Hydrolyse erfolgen. Da die Crm1/RanBP2 Interaktion mit
III
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der SUMO E3 Ligase Aktivität von RanBP2 kompatible ist, erlaubt meine Arbeit
Spekualtionen über einen Crm1-vermittelten Substrat-Rekrutierungsmechanismus
für den RanBP2 E3 Ligase Komplex.
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Chapter 1
Introduction
1.1 SUMOylation
The diversity and functional bandwidth of the proteome can be greatly expanded
by covalent post-translational modifications, as they are able to change biochem-
ical properties of proteins fast and reversibly. For a long time, the field of post-
translational modification has been dominated by small molecule modifications like
phosporylation, methylation or acetylation. However, covalent attachment of entire
proteins has become a major theme in the field starting with the discovery of the 76
amino acid polypeptide ubiquitin. Its canonical function is the targeting of proteins
for proteasomal degradation. Ubiquitination occurs at lysine residues in substrate
proteins and requires an enzymatic cascade.
In the wake of its discovery, not only have other regulatory functions of ubiquitin
been reported, but also an array of ubiquitin-like modifiers has emerged [Kerscher
et al., 2006, Komander and Rape, 2012, Welchman et al., 2005]. They resemble
ubiquitin not only in their structure, but also in the mechanism of conjugation. Yet,
they commonly all feature a specific modification cascade as well as a distinct set of
functions. Probably the best characterized ubiquitin-like modifiers are the proteins
of the SUMO (small ubiquitin-like modifier) family.
In this part, the the main characteristics of SUMO (1.1.1 and 1.1.2) and its con-
jugation and de-conjugation machinery (1.1.3) will be discussed. A special focus
is placed on E3 ligases as crucial regulators of modification and their molecular
mechanism of action (1.1.4 and 1.1.5).
1.1.1 SUMO
Post-translational modification of proteins by members of the SUMO family reg-
ulates diverse cellular processes, including transcription, replication, chromosome
segregation and DNA (deoxyribonucleic acid) repair [Geiss-Friedlander and Mel-
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chior, 2007, Johnson, 2004]. SUMO is a small protein of about 11 kDa that is
highly conserved among eukaryotes. SUMOylation is an essential process for almost
all organism . While lower eukaryotes like Saccharomyces cerevisiae, Drosophila
melanogaster, and Caenorhabditis elegans have only a single SUMO gene, plants and
vertebrates feature several paralogs. Humans express four SUMO proteins: while
SUMO2 and SUMO3 differ only in three amino acids and are hence commonly re-
ferred to as SUMO2/3, SUMO1 shares only about 47% sequence identity with these
paralogs, but is structurally very similar. The functional significance of SUMO4 is
currently debated, as it is unclear whether SUMO4 can be processed or conjugated
in cells [Bohren et al., 2004, Owerbach et al., 2005]. In many cases, SUMO paralog
function is redundant or at least the loss of one paralog can be compensated by
another [Alkuraya et al., 2006, Evdokimov et al., 2008, Wang et al., 2011, Yuan
et al., 2010].
Although SUMO proteins share only roughly 18% sequence homology with ubiqui-
tin, they feature a β-grasp fold (Figure 1), which comprises a four-stranded β-sheet
in antiparallel fashion and the amphipatic α1-helix, which is rotated by about 45◦
relative to the β-sheet [Bayer et al., 1998]. Prominent in SUMO (in comparison to
ubiquitin) is the long and flexible N-terminus, which is prone to SUMOylation itself
resulting in SUMO chains [Bylebyl et al., 2003, Tatham et al., 2001]. SUMO chain
formation can occur both substrate-dependently and -independently, however the
signaling properties of this process are far less well understood than in the case of
ubiquitin [Komander and Rape, 2012].
ubiquitin
N
C
β2-strand
N
C
SUMO1
Figure 1: Comparison of the structures of ubiquitin and SUMO1. Top: Ribbon structure
of ubiquitin (PDB: 1UBQ) with its C-terminal tail (cyan) and the terminal Gly-Gly motif. The N-
and C-terminus are indicated; so is isoleucine 44, which is part of a surface that many interacting
proteins bind to (see 1.1.2). Bottom: Ribbon structure of SUMO1 (PDB: 1A5R.1) with its flexible
N-terminus (orange) (depiction otherwise corresponding to ubiquitin). Leucine 65, which is the
structural analog to isoleucine 44 in ubiquitin is indicated; so is the β2-strand, to which the so
called SUMO interacting motives bind (see 1.1.2).
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1.1.2 Consequences of SUMOylation
Most substrates are subject to rapid cycles of SUMO modification and de-modifi-
cation, often resulting in very low steady-state levels of the SUMOylated species.
However, upstream signals like e.g. DNA damage can strongly influence the ra-
tio of SUMOylated to non-SUMOylated substrates. While the functional outcomes
of SUMOylation are manifold, reaching from transcriptional regulation over macro-
molecular assembly to protein homeostasis and signal transduction [Flotho and Mel-
chior, 2013], they are hard to predict a priori. On a molecular level however, the
effect of SUMO modification can be more easily classified into either:
(1) the induction of an allosteric change that regulates protein activity, as observed
e.g for the enzyme thymidine glycosylase [Baba et al., 2005, Hardeland et al., 2002]
(2)the elimination of a binding interface e.g. to prevent the binding of a transcrip-
tion factor to chromatin [Wu and Chiang, 2009]
(3) or most commonly the creation of a binding interface, e.g. to recruit the tran-
scription co-regulator Daxx (death-associated protein 6) to SUMOylated transcrip-
tion factors in order to repress their action [Lin et al., 2006].
Particularly the last effect requires dedicated SUMO-binding motifs. The most
common SUMO-binding motif is the so-called SIM (SUMO interaction motif). The
SUMO/SIM interaction is of low affinity (low µM range [Namanja et al., 2012, Song
et al., 2004, 2005]) so that it commonly cooperates with additional binding site to
enable specific protein-protein interactions [Armstrong et al., 2012]. Typically, ef-
fectors of SUMOylated proteins, but also some SUMO substrates contain SIMs [Lin
et al., 2006, Meulmeester et al., 2008, Takahashi et al., 2005]. Enzymes of the SUMO
modification pathway (see Section 1.1.4) have been shown to utilizes SIMs during
modification [Guervilly et al., 2015, Reverter and Lima, 2005, Song et al., 2004].
At its core, a SIM consist of a short stretch of hydrophobic amino acids, which
interacts with SUMO by β augmentation, i.e. addition of the SIM as a β-strand to
the β-sheet of SUMO at its β2-strand (see also Figure 1). Currently, SIM consen-
sus motifs are classified by their residue conservation into three major SIM-types
[Uzunova et al., 2007, Vogt and Hofmann, 2012]:
SIMa is characterized by four consecutive hydrophobic residues, in which the third
position is variable in accommodating also non-hydrophobic amino acids. This patch
is immediately followed by a cluster of serine, aspartate or glutamate residues.
SIMr resembles SIMa only in reverse order. For SIMa and SIMr, hydrophobic inter-
actions (central residues of the SIM and isoleucine 34, phenylalanine 36 and valine
38 of SUMO1) as well as hydrophilic interactions (acidic residues of the SIM and
lysines 37, 39 and 46 of SUMO) play a role.
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SIMb is usually characterized by the V-I-D-L-T consensus sequence with some vari-
ability at the first two positions.
While recent studies have identified additional SUMO-binding motives [Danielsen
et al., 2012, Pilla et al., 2012], the number of interaction motives and correspond-
ing interaction surfaces on SUMO is (still) much smaller than for ubiquitin [Scott
et al., 2015]. Of note, in ubiquitin the prominent hydrophobic patch centered around
isoleucine 44, which mediates most of its non-covalent interactions [Scott et al., 2015],
has no equally prominent functional equivalent in SUMO (leucine 65 of SUMO1 cor-
responds structurally to isoleucine 44 - see also Figure 1).
1.1.3 SUMO conjugation and deconjugation
The SUMOylation cascade
SUMOylation requires the action of an enzymatic cascade (Figure 2), which is
similar to that of ubiquitination, yet features SUMO-specific enzymes. In the first
step of the cascade, the carboxy group of the C-terminal di-glycine motif of SUMO
is activated by the formation of a SUMO-adenylate intermediate in an ATP con-
suming reaction. This reaction is catalyzed by a heterodimer of Aos1 (activator of
SUMO 1) and Uba2 (ubiquitin-activating Enzyme E1-like 2), also known as SAE1
and SAE2 (SUMO1 activating enzyme). The Aos1/Uba2 dimer constitutes the sole
E1 activating enzyme identified so far for SUMO. The SUMO-adenylate interme-
diate quickly reacts to a thioester linkage between the carboxyl group of SUMO
and the catalytic cysteine of Uba2, which entails drastic conformational changes
within the E1 activating enzyme. The next step is a trans-esterification reaction, in
which the SUMO moiety is handed over to the catalytic cysteine of Ubc9 (ubiquitin
conjugating 9), which interacts with the ubiquitin-fold domain in Uba2. Ubc9 is
the only known E2 conjugating enzyme for SUMO. It performs the crucial step of
transferring SUMO to the ε-amino group of a lysine residue in the substrate protein
resulting in the formation of a covalent isopeptide bond.
While the Ubc9∼SUMO thioester in some cases is competent in bringing about
the SUMO transfer to the substrate on its own (see next Section), this last step
commonly requires the action SUMO E3 ligases for efficient and selective modifica-
tion [Hershko and Ciechanover, 1998]. While several factors have been identified,
which enhance SUMOylation, only a small number of proteins have clearly been
demonstrated to possess SUMO E3 ligase activity, i.e. to act as enzymes at far
substoichiometric concentrations to promote SUMOylation. Among those are the
SP (Siz/PIAS) E3 ligases and the nucleoporin RanBP2 (rat sarcoma-related nuclear
protein binding protein, also known as Nup358 - for details see Section 1.1.5).
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Figure 2: Schematic overview of SUMO conjugation and deconjugation. SUMO is
synthesized as an immature precursor protein, which is processed by SUMO proteases to expose
the C-terminal di-glycine (GG) motif. Mature SUMO is activated in an ATP-dependent way
through thioester formation (∼) by the only SUMO E1 activating enzyme, a heterodimer of Aos1
and Uba2. From there it is transfered to to the E2 conjugating enzyme, Ubc9. In the final step,
the Ubc9∼SUMO thioester discharges SUMO onto a lysine residue in a substrate protein. In
most cases, this step is catalyzed by SUMO E3 ligases, while in some rare cases the Ubc9∼SUMO
thioester is sufficient for modification. Such substrates are exemplified here by the substrate
RanGAP1, which consists of an N-terminal, catalytic domain (depicted by a large oval), a flexible
acidic linker region and a C-terminal domain (depicted by a small oval), which is SUMOylated.
SUMOylation is counteracted by the action of SUMO proteases in a highly dynamic manner.
SUMO proteases
The removal of SUMO from substrates is accomplished by SUMO proteases,
which makes conjugation/deconjugation a highly dynamic process. Aside from their
isopeptidase activity, SUMO proteases are also required for the maturation of newly
synthesized SUMO (Figure 2): the SUMO paralogs are expressed with a C-terminal
extension, which is cleaved by SUMO proteases to expose the di-glycine motif for
conjugation. All identified SUMO proteases are cysteine proteases. They differ in
their maturation and isopeptidase activities as well as their SUMO paralog speci-
ficity. While the catalytic domain of most SUMO proteases does not appear to
discriminate between the individual SUMOylated substrates, regions other than the
catalytic domain and intracellular localization bring about substrate specificity.
The largest family of SUMO proteases is the Ulp/SENP family: it includes six
proteins in mammals (the Sentrin-specific protease SENP1, -2, -3, -5, -6, and -7)
and two in yeast (the essential ubiquitin-like-specific protease Ulp1 and the non-
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essential Ulp2). Ulp2, SENP1, SENP6, and SENP7 are found in the nucleoplasm,
while Ulp1 and SENP2 are anchored to the nuclear basket of the NPC [Li and
Hochstrasser, 2003, Takahashi et al., 2000]. By contrast, SENP3 and SENP5 are en-
riched in the nucleolus. Recent addition to the catalog of SUMO proteases are DeSI1
(De-SUMOylating isopeptidase 1), DeSI2 [Shin et al., 2012] and Uspl-1 (ubiquitin-
specific protease-like 1) [Schulz et al., 2012].
The SUMO E2 conjugating enzyme Ubc9
Ubc9 is the linchpin enzyme of the SUMOylation cascade: in addition to handing
over the chemically activated SUMO from the E1 enzyme to the substrate, Ubc9
is actively involved in the selection of many specific SUMO substrates. Commonly,
these substrates carry a SUMOylation consensus motif (Ψ-K-X-[E/D], where Ψ is a
branched hydrophobic amino acid and X is any amino acid). Ubc9 can bind directly
to this motif, commonly with low affinity. Hence, such substrates can be SUMOy-
lated in vitro with high concentrations of Ubc9 (low µM range) in the absence of
an E3 ligase. A notable exception of SUMO substrates with a consensus motif is
RanGAP1 (rat sarcoma-related nuclear protein GTPase activating protein 1), which
binds Ubc9 with nM affinity at its C-terminal domain due to an additional interac-
tion surface; RanGAP1 is hence SUMOylated independently of an E3 ligase even at
low Ubc9 concentrations (see also Figure 2) [Bernier-Villamor et al., 2002].
Ubc9 shares sequence homology and a common globular fold with other members
of the Ubc enzyme family. The so-called Ubc domain consists of 4 α-helices, a short
310-helix, and a 4-stranded, antiparallel β-sheet (Figure 3) [van Wijk and Timmers,
2010]. The β-sheet together with the α2-helix forms a central region, bordered by
the α1-helix at one side and the α3- and the α4-helix at the other side. The cat-
alytic cysteine at amino acid position 93 lies in a highly conserved loop C-terminal of
the β4-strand. This loop together with the surrounding helices forms the catalytic
groove of Ubc9, which provides a chemical environment to lower the pKa of the
substrate lysine and thus to promote nucleophilic attack. Critical residues in this
context are asparagine 85, tyrosine 87 and aspartate 127 [Bernier-Villamor et al.,
2002, Yunus and Lima, 2006].
Aside from the use of the SUMO consensus site as a contribution to substrate
selection, SUMOylation of Ubc9 itself has also been reported in that regard: while
SUMOylation of lysine 14 of Ubc9 was shown to alter its activity on substrates like
RanGAP1 and Sp100 [Knipscheer et al., 2008], modification of lysine 153 seems to
promote SUMO chain formation [Klug et al., 2013]. An important interaction that
has been implicated mechanistically in the latter process is a non-covalent binding
of SUMO to Ubc9 [Klug et al., 2013, Knipscheer et al., 2007]. This interaction in-
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volves the β-sheet of SUMO and the loop between the α1-helix and the β1-strand
of Ubc9, which is located at the opposite site of the catalytic groove providing the
name “backside” interaction (Figure 3). A similar non-covalent interaction has been
documented between ubiquitin and some of its E2 enzymes [Brzovic et al., 2006]. In-
terestingly, here the surface covered by the ubiquitin is slightly shifted with respect
to the Ubc9/SUMO backside interaction covering the plain of the E2’s β-sheet. Al-
though the Ubc9/SUMO backside interaction is a second type of interaction, next to
the SUMO/SIM interaction, in which SUMO engages, both are fundamentally dif-
ferent: while the former features an intricate network of interacting residues, which
results in a high affinity (KD = 82 ± 23 nM [Knipscheer et al., 2007]), the latter is
a low-affinity interaction that often cooperates with other interaction.
SUMO1
Ubc9
α1-helix
α2-helix
α3-helix
α4-helix
310-helix
loop 1
loop 2
N
C
Figure 3: Structural overview of Ubc9 and the backside interaction. Ribbon structure
of Ubc9 (light green - PDB: 2UYZ) showing its principle 4 α-helices, its short 310 helix, and the
4-stranded, antiparallel β-sheet. The catalytic cysteine at position 93 (yellow), the central α2-helix
(grey) and residues at position 85, 87 and 127, which are crucial to the catalytic groove, are marked.
The loop between β-strands 3 and 4 (loop 1) and between the α2- and the 310-helix (loop 2) are
involved in E3 ligase binding (see 1.1.4). The N- and C-terminus are indicated. The non-covalent
backside interaction between Ubc9 and SUMO1 is shown on the right. SUMO1 is displayed in
olive. Magenta sequence regions denote the residues involved in the backside interaction. Central
resiudes involved in this interaction are for instance arginine 13, 17, aspartate 19 and histidine 20
of Ubc9 as well as isoleucine 27, glutamate 67, 83 and aspartate 86 of SUMO1.
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1.1.4 Mechanistic insight into E3 ligase-mediated
ubiquitination
While Ubc9 (for SUMO) or E2 enzymes in general assume a central role in the
modification cascades, the E3 ligases confer specificity and versatility to the modi-
fication reaction. A mechanistic understanding of their action is hence imperative.
The best studied E3 ligases so far are those of the ubiquitin field. This section will
hence provide a description of the current state of research on the catalytic mecha-
nism of ubiquitin E3 ligases before their less-well characterized SUMO counterparts
are discussed.
In general, the role of E3 ligases is dual: they function by interacting with the
E2∼ubiquitin thioester to catalyze the discharge of the modifier on the one hand and
with the substrate on the other. The best studied E3 ligases so far are those of the
ubiquitin field. Three principle types of ubiquitin E3 ligases exist: HECT E3 ligases
(homologous to the E6-AP carboxyl terminus), the RING/U-box E3 ligases (really
interesting new gene) and the RBR E3 ligases (RING-in-between-RING) [Komander
and Rape, 2012].
Both HECT and RBR E3 ligases chemically participate in the ubiquitin transfer
from the E2 enzyme to the substrate via a catalytic cysteine to which ubiquitin
is intermediatly transferred. Both classes of enzymes have no equivalent in the
SUMO field. RING/U-box E3 ligases work by bridging the interaction between the
E2∼ubiquitin thioester and the substrate in a way that favors ubiquitin transfer.
Thioester binding is commonly achieved by the RING (or the closely related U-box)
domain, which is characterized by a cross-braced arrangement of eight residues co-
ordinating two Zn2+ ions [Jackson et al., 2000]. However, RING domains not simply
recruit the thioester, but also activate it, as seen by their acceleration of substrate-
independent ubiquitin-discharge from the thioester onto free lysine [Pickart and
Rose, 1985].
RING-type E3 ligases come in different architectural flavors. (1) Monomeric
RING-type E3 ligases bind the thioester via their RING domain and the substrate
by an N- or C-terminal region. (2) Dimeric RING-type E3 ligases bind each other ei-
ther through their RING domain like RNF4 (RING finger portein) or through other
regions like BRCA1/BARD1 (breast cancer 1/BRCA1-associated RING domain pro-
tein 1). (3) Multi-subunit RING E3 ligases of the CRL (Cullin RING E3 ligase)
superfamily are protein complexes that feature a Cullin protein as a scaffold, to
which a small RING domain protein and a bridging protein bind [Hua and Vierstra,
2011]. The bridging proteins interact with an interchangeable substrate adaptor,
which recruits ubiquitination substrates. By this modular architecture CRL E3 lig-
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ases are able to affect an enormous substrate spectrum. Thus far, five types of CRLs
have been identified, which are distinguished by their substrate adaptors and their
associated cullin protein. Of these five, the best characterized type is the SCF (SKP1
Cullin1 F-box) CRL, which features the RING domain protein RBX1 (RING box
1), Cullin1, the bridging protein SKP1 (S-phase kinase-associated protein 1) and
interchangeable F-box proteins as substrate adaptors.
Recent structural studies have yielded a comprehensive picture of the catalytic
mechanism by which RING-type E3 ligases bind and prime their cognate E2∼ubiquitin
thioester for discharge (selected works: [Dou et al., 2012, Plechanovová et al., 2011,
2012, Pruneda et al., 2012, 2011, Saha et al., 2011, Wickliffe et al., 2011]; reviewed by
[Metzger et al., 2013]). Structural studies of stable E2∼ubiquitin thioester mimics in
complex with a RING domain revealed snapshots of an E3/E2∼ubiquitin complex
poised to transfer ubiquitin. As a specific example, I will refer to the structure of
the homodimeric RING-type E3 ligase RNF4 in complex with a UbcH5A∼ubiquitin
thioester mimic throughout this text [Plechanovová et al., 2012] (see Figure 4A);
other examples may differ in detail, are however conceptually very similar. The
RING domain contacts ubiquitin at the C-terminal end of its α1-helix. Contacts
to the E2 enzyme involve a canonical surface on the latter formed by the α1-helix,
loop 1 and 2, which is notably distant from the active site (see Figure 4B).
This mode of E3 ligase-binding appears to stabilize the E2∼ubiquitin thioester in
a particular spatial orientation, the so-called folded-back conformation (Figure 4B).
This conformation primes the thioester for the nucleophilic attack by the substrate
lysine [Soss et al., 2013]. In this conformation, the C-terminal tail of ubiquitin is
extended and exposed at the catalytic groove. The folded-back conformation entails
a defined interface between the two proteins involving residues of the 310- and the
α2-helix of the E2 (particularly the central leucine residue of the α2-helix; leucine
104 in UbcH5A) and the hydrophobic isoleucine 44 surface of ubiquitin. While the
thioester may adopt an array of different, catalytically non-productive conformations
in solution [Hamilton et al., 2001, Pruneda et al., 2011, Sakata et al., 2010, Wickliffe
et al., 2011], binding to the RING domain promotes a population shift in the highly
flexible thioester towards the productive, folded-back conformation. In line with this
notion, E2∼ubiquitin thioester variants that populate folded-back conformations to
a significant extent in the absence of an E3 ligase (e.g. Ubc13 [Pruneda et al., 2011]
and Ubc1 [Hamilton et al., 2001]) are competent in E3-independent ubiquitination.
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A
B
RING
ubiquitin
UbcH5A
ubiquitin
UbcH5A
ubiquitin
UbcH5A
RING
RNF4 
(RING)
RNF4 
(RING)
α1-helix
loop 1
loop 2
α1-helix
canonical 
E3/E2 
interaction 
Figure 4: Structural view on a RING E3/E2∼ubiquitin complex. (A) Surface structure of
a complex between the dimeric RING-type E3 ligase RNF4 and two UbcH5A∼ubiquitin thioester
mimics (PDB: 4AP4). RNF4 is a homodimeric RING-type E3 ligase: both RING domains (black
and grey) bind a UbcH5A∼ubiquitin thioester. The thioester is represented by a stable mimic, in
which ubiquitin (olive) and UbcH5A (light green) are connected by an isopeptide bond via genetic
replacement of the catalytic cysteine 85 with a lysine (see (B)). (B) Ribbon structure of the
folded-back UbcH5A∼ubiquitin thioester conformation stabilized by RNF4. The structure of one
UbcH5A∼ubiquitin thioester from (A) in complex with both RNF4 RING domains is displayed.
The E2-binding RING domain (black) contacts the E2 enzyme at its α1-helix, loop1 and loop
2 (canonical surface - purple): Ubiquitin is contacted at the C-terminus of its α1-helix. Via
this binding, the E2 enzyme and ubiquitin assume the so called folded-back conformation. This
conformation creates a defined binding interface between the E2 enzyme and ubiquitin at the
center of which is hydrophobic isoleucine 44 patch (grey) of ubiquitin and leucine 104 in the α2-
helix (grey) of UbcH5A. Importantly, the C-terminal tail of ubiquitin (cyan) is extended along the
catalytic groove of UbcH5A and at the end is connected to the catalytic cysteine 85 (here lysine
85 - yellow).
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1.1.5 SUMO E3 ligases
SP E3 ligases
The same conceptual mechanism of stabilizing the folded-back thioester confor-
mation is assumed for SUMO E3 ligase and the Ubc9∼SUMO thioester [Flotho and
Melchior, 2013, Metzger et al., 2013]. The assumption is mainly based on the struc-
tural similarities between ubiquitin and SUMO, ubiquitin E2 enzymes and Ubc9 as
well as RING-type ubiquitin E3 ligases and the family of SP SUMO E3 ligases, which
feature a so-called SP-RING domain. In humans, six members of the SP family have
been identified as SUMO E3 ligases: the PIAS (protein inhibitor of activated signal
transducer and activator of transcription) proteins, PIAS1 and its isoforms PIASxα
and PIASxβ, PIAS3, PIASy, and Nse2/Mms21 [Flotho and Melchior, 2013]; the
most prominent function of the PIAS proteins is their roles in transcriptional regu-
lation. In yeast, this family comprises of Siz1 (scaffold attachment factor, Acinus and
PIAS, and Miz-finger domain-containing protein 1), Siz2 and Nse2 (non-structural
maintenance of chromosomes element 2) [Flotho and Melchior, 2013].
A structural comparison between RING and SP-RING domains reveals a high de-
gree of overall similarity (RING domain of c-Cbl and SP-RING domain of Siz1 have
a root-mean-square deviation of atomic positions of 1.8 Å over 48 residues with 18%
sequence identification [Yunus and Lima, 2009]). Importantly, biochemical analyses
fueled by modeling approaches suggested that the SP-RING domain of Siz1 binds to
the canonical E3/E2 interaction surface of Ubc9 (α1-helix, loop1 and loop2). This
has prompted the view that the SP-RING domain is a structural and functional ho-
molog of the RING domain for SUMOylation [Johnson and Gupta, 2001, Weissman,
2001, Yunus and Lima, 2009].
RanBP2 as a SUMO E3 ligase
In contrast to the family of SP proteins with its various members, the other family
of confirmed SUMO E3 ligases consists of only one member: RanBP2. So far, only
a small number of endogenous substrates of RanBP2 could be identified, namely
Topoisomerase IIα [Dawlaty et al., 2008] and the chromosomal passenger complex
protein Borealin [Klein et al., 2009].
RanBP2 is a 358 kDa, flexible nucleoporin that resides as the major component
of the cytoplasmic filaments of the NPC (nuclear pore complex) directly at the exit
of the nucleus during interphase [Wu et al., 1995, Yokoyama et al., 1995]. RanBP2
contains multiple domains, which are interspersed with natively unfolded regions
(Figure 5).
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Insight into the mechanism of IR1+M-mediated catalysis largely stems from a
crystal structure (PDB: 1Z5S, [Reverter and Lima, 2005], Figure 6A), which was
interpreted as a trapped product complex of IR1 (E3 ligase), the SUMOylated C-
terminal domain of RanGAP1 (SUMOylated substrate, also referred to as GAP-
tail*SUMO1) and Ubc9 (E2 conjugating enzyme). Intriguingly, the overall Ubc9/
SUMO1 conformation in this complex (although both proteins are not covalently
connected) resembles the folded-back E2∼ubiquitin thioester conformations (Fig-
ure 7). Most prominently, the C-terminal tail of SUMO1 threaded along the surface
of Ubc9 and into its catalytic groove. Also the Ubc9/SUMO1 interface involves
the α2-helix of Ubc9 with leucine 114 as its central residue. This structural finding
supported the view that the folded-back conformation not only plays an important
role in ubiquitination, but also in SUMOylation.
Interestingly, leucine 114 of Ubc9 does not seem to interact with leucine 65 of
SUMO1, which corresponds to isoleucine 44 of ubiquitin (compare Figure 1). In-
stead the spatial position of isoleucine 44 of ubiquitin is taken up by tyrosine 91 of
the C-terminal tail of SUMO1 (Figure 7A). The fact that IR1 does not contact Ran-
GAP1, the model substrate, predicted that IR1 (like the RING domains) not only
accomplishes Ubc9∼SUMO thioester recruitment, but also its activation. Indeed,
activity assays showed a stimulation of Sp100 SUMOylation in vitro by RanBP2
despite a lack of interaction of the latter with this substrate [Pichler et al., 2004].
In contrast to its natively unfolded state in isolation, the IR1 region intimately
wraps around SUMO1 and Ubc9 (Figure 6B). IR1 adopts a non-globular and ex-
tended structure, which appears to hold Ubc9 and SUMO1 like a clamp in the cat-
alytically productive conformation [Reverter and Lima, 2005]. The structure of IR1
has little secondary structure content, which entails a close contact between many
residues of IR1 with Ubc9 and SUMO1. For comparison, IR1 and Ubc9/SUMO1
bury about 900 Å2 of surface area between them, while the area buried between the
dimer RNF4 and UbcH5A/ubiquitin is only about 400 Å2.
Consequently, binding between IR1 and Ubc9/SUMO1 is achieved by different
means than in the case of (SP-)RING-type E3 ligases. The N-terminal part of IR1
features a SIMr motif, which binds to SUMO1 in antiparallel orientation (Figure 6B
and C; see also Figure 25A). The hydrophobic residues of the SIM (2632-V-L-I-V-
2635) interact with the C-terminal part of the the β2-strand of SUMO1. Of the
three preceding aspartate residues only one is part of the structure; it partakes in
the β-strand formed by the SIM, however, it aligns to a loop SUMO1 rather than its
β2-strand. Instead, the sequence C-terminal of the four hydrophobic residues aligns
to the β2-strand of SUMO1. They thus appear to contribute to binding, although
they are, by definition, not part the classical SIM (see Section 1.1.2).
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Figure 6: IR1 of RanBP2 binds Ubc9 and SUMO1 in a close molecular embrace. (A)
Ribbon structure trapped product complex of IR1 (black) from RanBP2, Ubc9 (light green) and
the C-terminal domain of RanGAP1 (orange) and SUMO1 (olive) (PDB: 1Z5S). For orientation,
the α2-helix of Ubc9 at the center of the Ubc9/SUMO interface is shown in grey, the C-terminal
tail of ubiquitin in cyan and the catalytic cysteine 93 of Ubc9 in yellow. (B) IR1 assumes an
extended, non-globular structure. Structure and basic color code as in (A) with Ubc9 and SUMO1
as surface models and IR1 as ribbon model (RanGAP1 left out - structure flipped and turned with
respect to (A)). The SUMO1-interacting residues of IR1 are shown in blue, the canonical Ubc9-
binding residues in purple and the backside-binding residues in pink. (C) Alignment of IR1 and
IR2 (adapted from [Reverter and Lima, 2005]). Same color code as before; the confirmed α-helices
in IR1 are shown on grey background.
The SIM and the Ubc9-binding site in IR1 are separated by an α-helix. Ubc9-
binding itself is accomplished by two distinct areas in IR1: the N-terminal area
involves residues close to this α-helix, the C-terminal area another small α-helix. Of
note, the N-terminal Ubc9-binding site interacts with the canonical E2-binding re-
gion on Ubc9 (α1-helix, loop1 and loop2) and is crucial for catalysis, as mutational
analyses of this area showed [Pichler et al., 2004]. Mutations in the C-terminal
Ubc9-binding site only moderately affected SUMOylation [Reverter and Lima, 2005,
Tatham et al., 2005]. It contacts mainly the β-sheet of Ubc9, i.e. its backside sur-
face, which potentially can also bind SUMO non-covalently (see Section 1.1.3).
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In sum, this structure indicates that although the sequence and structure of the
IR1 region of RanBP2 is very different from (SP-) RING domains, both classes of
E3 ligases seem to act by stabilizing a folded-back E2∼modifier conformation. Fas-
cinatingly, the canonical E3/E2 interaction is conserved for IR1 and Ubc9, while
IR1 also makes use of a Ubc9 backside interaction as well as a SIM to spatially
coordinate Ubc9 and SUMO1.
RNF4 
(RING)
ubiquitin
UbcH5A
RNF4 
(RING)
IR1
SUMO1
Ubc9
Figure 7: Structural comparison of folded-back thioester conformations. Left: Ribbon
structure of IR1/RanGAP1*SUMO1/Ubc9 complex (RanGAP1 omitted for clarity - PDB: 1Z5S).
Right: Ribbon structure of the RNF4/UbcH5A∼ubiquitin complex structurally aligned to the left
according to the E2 enzyme (PDB: 4AP4). The conformation of Ubc9/UbcH5A (light green) and
SUMO1/ubiquitin (olive) is similar in both structures with an interface formed by the α2-helix
of the E2 enzymes (grey - the central leucine residue is shown). The α2-helices interact with the
hydrophobic isoleucine 44 patch (grey) of ubiquitin and with tyrosine 91 in the C-terminal tail
of SUMO1, respectively. While the E2-interacting RING domain of RNF4 (black) engages in a
canonical E3/E2 interaction with UbcH5A, IR1 binds to Ubc9 in a similar way, but also interacts
with its backside. For orientation, the C-terminal tail of SUMO1/ubiquitin is shown in cyan and
the catalytic residues of the E2 enzymes in yellow.
The RanBP2 SUMO E3 ligase complex
While the IR1/GAPtail*SUMO1/Ubc9 structure provided insight into the cat-
alytic mechanism of SUMOylation, its interpretability is limited by several points.
Firstly, efficient modification of RanGAP1 does not require an E3 ligase [Bernier-
Villamor et al., 2002] indicating that RanGAP1 is not an endogenous substrate of
RanBP2. Secondly, RanBP2, SUMOylated RanGAP1 and Ubc9 are known to form
an isopeptidase-resistant and very stable complex throughout the cell cycle [Joseph,
2002, Mahajan et al., 1997, Matunis et al., 1996, Saitoh et al., 1997, Zhu et al.,
2009]. This complex is known as the “RanBP2/RanGAP1*SUMO1/Ubc9 complex”
or simply the “RanBP2 complex” (Figure 8). The Melchior group showed that in
16 INTRODUCTION CHAPTER 1
cells all RanBP2 molecules are occupied by RanGAP1*SUMO1 and Ubc9, making
the RanBP2 complex and not free RanBP2 the physiologically relevant form of the
nucleoporin [Werner et al., 2012]. Their study showed that stable complex formation
takes place on IR1, which effectively blocks this region for catalysis. Irrespective of
this, the RanBP2 complex has E3 ligase activity [Werner et al., 2012].
Consistent with this interpretation, the Ubc9 molecule in the RanBP2 complex (=
Ubc9C) does not act as an E2 enzyme, but has rather structural functions [Werner
et al., 2012]. In fact, SUMOylation only takes place, when free Ubc9 is added as a
source for SUMO-thioester-loaded Ubc9 (= Ubc9T ) [Werner et al., 2012]. This sug-
gests that the IR1/RanGAP1*SUMO1/Ubc9 crystal structure represents a minimal
version of the RanBP2 complex rather than a E3/E2 complex.
Activity of the RanBP2 complex requires the presence of IR2 [Werner et al., 2012].
This suggests that IR2, which in free RanBP2 shows only very little activity, is en-
abled to promote the productive thioester conformation in the complex. In line
with this view, Gareau and colleagues could show that an IR1 hybrid fragment,
which contains the Ubc9-binding region of IR2, is able to bind Ubc9 (and Ran-
GAP1*SUMO1) very much in the same way as wild-type IR1 does [Gareau et al.,
2012]. Together, these findings revealed that the RanBP2 complex is a multisubunit
SUMO E3 ligase. The gain of activity of IR2 from the free RanBP2 to the RanBP2
complex suggested that the region is somehow altered by RanBP2 complex forma-
tion. One intriguing possibility is that the components of the RanBP2 complex (i.e.
RanGAP1* SUMO1C and/or Ubc9C) provide an additional binding site for an in-
coming Ubc9T∼SUMO1T thioester during catalysis, which would aid the otherwise
“imperfect” IR2 region as an E3 ligase [Werner et al., 2012].
Taken together, the RanBP2 complex seems to feature catalytic properties that
are distinct from free RanBP2, but which remain poorly understood. Explaining
the apparent increase in activity of IR2 after RanBP2 complex formation seems to
be the key in understanding the RanBP2 E3 ligase complex.
RanBP2 complex
Ubc9~SUMO 
thioester
IR1
RanGAP1
S
1C
U
bc
9C
IR2
S1
T
~ 
Ubc9
T
M
Figure 8: Current mechanistic model of the RanBP2 E3 ligase complex. Left: Model of
the IR-region of RanBP2 in complex with RanGAP1*SUMO1C and Ubc9C (= RanBP2 complex).
Right: The Ubc9T∼SUMO1T thioester interacts with the RanBP2 complex during SUMOylation.
While Ubc9T interacts with the IR2 region of RanBP2, the interaction surface of SUMO1T has
not yet been clearly identified. S1 = SUMO1. Figure adapted from [Werner et al., 2012].
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1.2 The Ran GTPase system
The RanBP2 is not only an NPC-associated SUMO E3 ligase, but also a com-
ponent of the nucleocytoplasmic transport machinery in vertebrates. Nucleocyto-
plasmic transport is mediated by transport receptors and regulated by the Ran
(Rat sarcoma-related nuclear protein) GTPase (guanosine-5’-triphosphate) system.
Hence, the main players of the Ran GTPase system (1.2.1), transport receptors
(1.2.2) and the molecular principles of nucleocytoplasmic transport (1.2.3) as well
as the role of RanBP2 in it will be described in the following sections. Finally,
the way in which the same players and mechanisms are involved in mitosis will be
discussed (1.2.4).
1.2.1 The GTPase Ran and its regulation
Ran is a small GTPase (∼25kDa) that belongs to the Ras (Rat sarcoma) protein
superfamily [Fried and Kutay, 2003, Gorlich and Kutay, 1999, Kuersten et al., 2001].
The predominantly nuclear protein [Moore and Blobel, 1994] is not only highly con-
served throughout the eukaryotic branch of life, it is also extremely abundant making
up roughly 0.4% of the total cellular protein [Bischoff and Ponstingl, 1991]. Due to
its guanine nucleotide binding domain, Ran has a strong affinity for GTP and GDP
(guanosine-5’-diphosphate), which is Mg2+-dependent (pM-nM range). Like other
small GTPases, Ran cycles between a GDP- and GTP-bound state: this transition
entails a profound conformational change, which manifests itself in two character-
istic N-terminal regions called switch I and II region as well as in the C-terminal
acidic tail of Ran [Scheffzek et al., 1995]. The conformational change enables Ran
to interact differently with proteins, which results in a change of functional output.
Due to its low intrinsic GTPase activity and its low guanine nucleotide exchange
rate, Ran strictly depends on two sets of unique auxiliary factors to switch between
the two states: RanGAP1 together with the RanBD of RanBP1 or of RanBP2 on
the one hand and the guanosine exchange factor RCC1 (regulator of chromosome
condensation 1) on the other (Figure 9A).
During interphase, RanGAP1 is a cytoplasmic protein that increases the intrinsic
GTPase activity of Ran by a factor of 105 in vitro, thereby converting Ran-GTP to
Ran-GDP [Bischoff et al., 1994, 1995a, Coutavas et al., 1993]. The RanBDs of the
cytoplasmic RanBP1 and RanBP2 act as co-activator of RanGAP1-induced GTPase
activation [Bischoff et al., 1995b] by accelerating the association reaction between
Ran-GTP and RanGAP1 by a factor of 20 [Seewald et al., 2003].
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Figure 9: Regulation of Ran during nucleocytoplasmic transport. (A) In the course
of nucleocytoplasmic transport events, Ran-GTP reaches the cytoplasm through NPCs, where it
binds to RanBDs. This interaction primes Ran-GTP for GTPase activation by RanGAP1 (see (B)).
GTPase activation produces Ran-GDP from Ran-GTP, which effectively severs the interaction with
RanBDs and RanGAP1. Ran-GDP is recycled back into the nucleus via a specific homodimeric
import receptor called NTF2. There, the activity of RCC1 results in an exchange of GDP for GTP
due to higher overall GTP concentrations thus completing the cycle. In that way, the predominantly
nuclear localization of Ran and a steep Ran-GTP gradient from the nucleus to the cytoplasm is
maintained. (B) Ribbon structure of a complex between the catalytic domain of RanGAP, Ran in
the GTP-bound state and a RanBD as an intermediate in RanGAP-induced Ran-GTP hydrolysis
(PDB: 1K5D). The horseshoe-shaped catalytic domain of Rna1 (Ran GTPase activating protein
- yeast RanGAP1 in orange) is shown in complex with human Ran (maroon) bound to the non-
hydrolyzable GTP-analog GMPPNP (5’-guanylyl imidodiphosphate) and the RanBD of human
RanBP1 (light brown). Of functional relevance are the facts that the binding sites of the RanBD
and of Rna1 in Ran are not overlapping and that Ran and the RanBD engage in a close embrace
that particularly involves the C-terminus of the former and the N-terminus of the latter (both
indicated).
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The RanBDs achieve this by binding to a different surface on Ran than RanGAP1
and by engaging particularly the C-terminus of Ran, which would otherwise partially
inhibit the RanGAP1/Ran interaction [Seewald et al., 2002]. Hence, a trimeric in-
termediate between the catalytic domain of RanGAP1, Ran-GTP and the RanBD
forms (Figure 9B), which falls apart after GTP hydrolysis, as the affinity of the
RanBD and of RanGAP1 for Ran-GDP is several orders of magnitude lower than
for Ran-GTP [Kuhlmann et al., 1997, Villa Braslavsky et al., 2000].
RCC1 is a nuclear protein, which binds to chromatin [Nemergut et al., 2001, Oht-
subo et al., 1987]. It accelerates nucleotide exchange on Ran by up to five orders
of magnitude [Bischoff and Ponstingl, 1991], which effectively allows Ran to bind
GTP in the nucleus, as the concentration of free GTP is 10-fold higher than that
of GDP [Bourne et al., 1991]. The asymmetric distribution of these regulators re-
sults in a steep gradient of Ran-GTP (difference by a factor of 1000 [Görlich et al.,
2003, Kalab et al., 2002]) from the nucleus to the cytoplasm [Izaurralde et al., 1997].
1.2.2 Transport receptors
The asymmetric distribution of Ran regulators is the driving force behind nucle-
ocytoplasmic transport, which is harnessed by soluble transport receptors. They
bind Ran as well as cargo proteins. The largest and best studied family of transport
receptors is the importin β-related family. These transport receptors form com-
plexes with Ran-GTP in the nucleus and translocate to the cytoplasm [Mosamma-
parast and Pemberton, 2004, Ström and Weis, 2001]. This relentless eﬄux of Ran
(105 mol/sec per nucleus) [Görlich et al., 2003, Smith et al., 2002] is counteracted
by active Ran-GDP re-import via a specific transport factor called NTF2 (nuclear
transport factor 2) [Ribbeck et al., 1998, Smith et al., 1998] (Figure 9A). On the
nucleoplasmic side, the RCC1-mediated nucleotide exchange reaction causes the dis-
sociation of Ran from NTF2[Stewart et al., 1998].
Importin β-related transport receptors typically have a molecular weight of about
100 kDa. They share a common structural architecture, which is characterized by
tandemly arrayed so-called HEAT repeats (Huntingtin, elongation factor 3, protein
phosphatase 2A, yeast kinase target of rapamycin), a structural motif of two anti-
parallel helices connected by a short linker [Groves et al., 1999]. This architecture
results in a superhelical structure, which, dependent on the Ran-binding state, em-
braces a transport cargo or opens up in a spring-like fashion to release a cargo [Conti
et al., 2006, Stewart, 2006, 2007]. Typically, the N-terminal region of a transport
receptor binds Ran, while cargo accommodation is mediated by the C-terminal part
[Chi and Adam, 1997, Chook and Blobel, 1999, Cingolani et al., 1999, Kutay et al.,
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1997b, Vetter et al., 1999]. Importin β-related transport receptors can interact
with FG-repeats commonly featured by nucleoporins, i.e. components of the NPC
[Damelin and Silver, 2000, Ohno et al., 1998]. These interactions take place at the
outer surface of the transport receptors [Bayliss et al., 2000, Koyama et al., 2014,
Liu and Stewart, 2005] and are usually weak and short-lived, i.e. they have high
off-rates [Stewart, 2007, Stewart et al., 2001]. It is believed that by this property,
transport receptors are able to translocate through the hydrophobic, FG-repeat-rich
central pore of the NPCs [Frey et al., 2006, Terry and Wente, 2009].
1.2.3 Nucleocytoplasmic transport
Import
The varying interaction patterns of transport receptors with Ran in its two states
regulate the binding and release of cargoes in the desired compartments, as detailed
below. Depending on the direction they carry their respective cargo, transport recep-
tors are categorized into import and export receptors. In general, import receptors
recognize their cargo in the cytoplasm via a small peptide sequences, referred to as
NLS (nculear localization signal). Such import complexes translocate through the
NPC into the nucleus, where Ran-GTP displaces the cargo from the import receptor
(Figure 10). The resulting import receptor/Ran-GTP complex migrates back to the
cytoplasm as a recycling export complex.
There, the activity of RanGAP1 elicits GTP hydrolysis on Ran and thus disas-
sembles the recycling export complex, as import receptors have much lower affinity
for Ran-GDP than Ran-GTP [Floer and Blobel, 1996]. However, the binding sites
on Ran for RanGAP1 and for importin β-related transport receptors are mutually
exclusive [Seewald et al., 2003, Vetter et al., 1999], which protects Ran-GTP in com-
plex with transport receptors from RanGAP1 action [Floer and Blobel, 1996]. It is
only by the action of RanBD-proteins like RanBP1 and RanBP2 that the import
receptor/Ran-GTP interaction is loosened and primed for the action of RanGAP1
[Bischoff and Gorlich, 1997]. Again, the RanBD achieves this by binding to a differ-
ent surface on Ran than transport receptors (or RanGAP1 - compare 1.2.1) and by
engaging the auto-inhibitory C-terminus of Ran [Villa Braslavsky et al., 2000]. At
the end of the cycle, the import receptor is ready for another round of import and
Ran-GDP is liberated for recycling.
The best studied import receptor is importin β itself. While it also binds some
cargoes directly or combines with a variety of other import factors to expand its
substrate specificity [Gorlich and Kutay, 1999], it more commonly interacts with
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cargoes via the adaptor protein importin α. Importin α itself is actively re-exported
from the nucleus by the export receptor CAS (cellular apoptosis susceptibility gene)
[Kutay et al., 1997a]. Interestingly, importin α, like the RanBD-proteins, was found
to play an active role in the disassembly of importin β/Ran-GTP recycling export
complexes and in the course of forming a new import complex [Floer et al., 1997].
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Figure 10: Ran-dependent import and export. Left: Schematic depiction of Ran-dependent
protein import. Import receptors form import complexes by binding NLS-cargo in the cytoplasm.
After translocation into the nucleus, the cargo is liberated by displacement with Ran-GTP, which
results in the formation of a recycling export complex. The latter reaches the cytoplasm again,
where it is disassembled by the action of RanBD-proteins and RanGAP1. The import receptor is
then ready for another round of import. Right: Schematic depiction of Ran-dependent export of
proteins. Export receptors form export complexes by cooperative binding of cargo and Ran-GTP
in the nucleus. After translocation into the cytoplasm, the export complex is disassembled by
RanBD proteins and RanGAP1, which leaves the free export receptor to recycle back into the
nucleus for another round of export.
Export
The principles of export are closely related to those of import with the defining
difference that export receptors bind their cargoes in the nucleus in cooperation with
Ran-GTP (Figure 10). The so formed trimeric export complexes translocate to the
cytoplasm, where they are disassembled. This process involves the release of cargo
as well as GTP hydrolysis on Ran with the help of RanBD-proteins and RanGAP1.
The free export receptor can then recycle back into the nucleus.
The prototype of export receptors is Crm1 (chromosome-region maintenance fac-
tor 1), which not only mediates the export of proteins, but also that of selected
RNAs (ribonucleic acid) [Hutten and Kehlenbach, 2007]. Crm1-mediated export
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requires a so-called NES (nuclear export signal) in the cargo, a peptide sequence
characterized by five distinctly spaced hydrophobic residues that fit into the NES-
binding cleft of Crm1 [Güttler et al., 2010]).
Structurally, Crm1 is composed of an array of 21 HEAT repeats [Monecke et al.,
2009]. A slight tilt between consecutive repeats results in the typical crescent-like
shape of Crm1, which in its free from is mostly extended resulting in a superhelical
pitch [Monecke et al., 2012] (Figure 11A). When bound to Ran-GTP and NES-cargo
in an export complex, Crm1 was shown to assume a more compacted conforma-
tion, which brings the N- and C-terminus of the molecule closer together giving the
molecule a toroid-like shape (Figure 11A) [Dong et al., 2009, Güttler et al., 2010,
Koyama and Matsuura, 2010, Monecke et al., 2009].
Crm1 has low affinity for Ran-GTP and NES-cargo alone; trimeric export complex
formation is a cooperative process mediated by an allosteric mechanism in Crm1,
as Ran-GTP and the NES-cargo are not in contact with each other in the export
complex [Monecke et al., 2014] (see also Figure 11B). It is thus not surprising that
trimeric export complex formation is a rate-limiting step in transport [Kehlenbach
et al., 2001]. In the nucleus, Crm1-dependent export complex formation is aided by
an auxiliary factor called RanBP3, which links Crm1 to RCC1 and thus increases
the local concentration of Ran-GTP around Crm1 [Nemergut et al., 2002]. RanBP3
contains a RanBD that shares a fold with the RanBD of RanBP1, but differs from
it significantly at key amino acid position; this results in an overall weakened in-
teraction (KD = 14 ± 0.3 µM for Ran-GTP/RanBP3 [Langer et al., 2011] versus
KD = 1.2 nM for Ran-GTP/RanBP1 [Villa Braslavsky et al., 2000]). The Ran-
GTP/RanBP3 interaction is however strong enough to recruit the small GTPase
directly to Crm1, which in turn primes Crm1 for accommodation of an NES-cargo
[Englmeier et al., 2001, Koyama et al., 2014, Lindsay et al., 2001].
Conversely, the disassembly of Crm1-dependent export complexes in the cyto-
plasm hinges on the action of high-affinity RanBD proteins like RanBP1. Its
RanBDs fulfill a dual role upon binding Ran-GTP in the export complex. (1) It
induces a conformational change in Crm1 by an allosteric mechanism, which results
in the closing of the NES-binding cleft and the expulsion of the cargo; this step
is characterized by the formation of a trimeric Crm1/Ran-GTP/RanBD interme-
diate [Koyama and Matsuura, 2010] (Figure 11C). (2) As alluded to before, the
Ran-GTP/RanBD interaction de-protects Ran-GTP from the action of RanGAP1
[Askjaer et al., 1999, Maurer et al., 2001]; induction of GTP hydrolysis on Ran by
RanGAP1 marks lasting export complex disassembly.
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Figure 11: A structural view on Crm1. (A) Comparison of the compacted and the extended
Crm1 conformation. Left: Surface structure of the conformation of Mus musculus (= M.m.)
Crm1 in an export complex with human Ran-GTP and SNP1 (the latter two are not shown -
PDB: 3GJX). Right: Surface structure of the conformation of Chaetomium thermophilum (= C.t.)
Crm1 in the free form (PDB: 4FGV). The N- and C-termini in both conformations are marked.
Note the distance between the termini on the left and on the right. (B) Ribbon structure of
a Crm1-dependent export complex (PDB: 3GJX). Mus musculus Crm1 (as on the left in (A)
in turquoise) is depicted in complex with Ran-GTP (maroon) and the model NES-cargo SNP1
(Snurportin 1 - green). Of functional relevance is the fact that Ran-GTP and the NES-cargo do
not interact directly. (C) Ribbon structure of a complex between Crm1, Ran in the GTP-bound
state and a RanBD as an intermediate in Crm1-dependent export complex disassembly (PDB:
3M1I). Xpo1 (exportin1 - yeast Crm1 in turquoise) is shown in complex with Gsp1pQ71L-GTP
(genetic suppressor of Prp20 1 protein - a hydrolysis-deficient mutant of the yeast homolog of Ran
bound to GTP in maroon) and the RanBD of Yrb1p (yeast Ran binder 1 protein - yeast homolog
of RanBP1 in light brown). Of functional relevance is the fact that the binding sites of the RanBD
and of Xpo1 in Gsp1p are not overlapping. Note that in this complex, Xpo1 has a compacted
conformation, as on the left in (A) and in (B).
The RanBP2 complex in nucleocytoplasmic transport
While basic mechanisms of the Ran GTPase cycle and of nucleocytoplasmic trans-
port are conserved among all eukaryotes, higher organisms have acquired additional
features that may contribute to the efficiency of the process. One example is the
presence of RanBP2 in vertebrates at the cytoplasmic side of the NPC (see Fig-
ure 5). RanBP2 has four RanBDs that were shown to be equivalent in isolation to
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that of RanBP1 (sequence identity: 45 -55%) in terms of their KD for Ran-GTP
(KD of 1 - 10 nM), their ability to co-stimulate RanGAP1-induced GTP hydrolysis
on Ran and to promote NES-cargo ejection from Crm1-dependent export complexes
[Koyama and Matsuura, 2010, Villa Braslavsky et al., 2000]. Another example is the
re-localization of RanGAP1 from the cytoplasm in yeast to RanBP2 in vertebrates.
This requires the modification of the vertebrate-specific C-terminal domain of Ran-
GAP1 with SUMO1 [Mahajan et al., 1997, Matunis et al., 1996], which allows it to
form a stable complex with RanBP2 and Ubc9 (see Section 1.1.5).
With its incorporation of RanBDs, RanGAP1 and FG-repeats, the RanBP2 com-
plex has been implicated in nucleocytoplasmic transport [Wu et al., 1995, Yokoyama
et al., 1995]. Its transport function [Hamada et al., 2011] was shown to be essential
for embryonic development and cellular viability [Aslanukov et al., 2006, Dawlaty
et al., 2008]. Direct evidence for an interaction between RanBP2 and transport
receptor/Ran-GTP complexes came from a biochemical study by Yaseen and Blo-
bel: here, an importin β/Ran-GTP complex bound in in vitro pulldown assays to a
GST-RanBP2 fragment that included RanBD4, the IR region and the two flanking
FG-repeat patches [Yaseen and Blobel, 1999].
A number of cell biological studies could demonstrate a contribution of RanBP2 in
transport involving importin α/β [Hutten et al., 2008], transportin 1 [Hutten et al.,
2009], transportin 3 [Ocwieja et al., 2011], CAS [Sun et al., 2013] and importin 7
[Frohnert et al., 2014]. Similarly, a role of the RanBP2 complex in Crm1-dependent
export complex disassembly has been suggested [Bernad et al., 2004, Engelsma et al.,
2004]. In line with this view, a possibly direct interaction between the zinc finger
motives of RanBP2 and Crm1 has bee reported [Singh et al., 1999]. Whether the
RanBP2 complex is essential for Crm1-dependent export is a matter of debate and
may highly depend on the model system used. For instance, work in Drosophila
melanogaster revealed a drastic defect of mRNA (messenger RNA) export upon
RanBP2 depletion [Forler et al., 2004], while other studies only showed minor de-
fects in this transport pathway after RanBP2 knock-down/-out [Bernad et al., 2006,
Hamada et al., 2011, Hutten and Kehlenbach, 2006]. In sum, this has prompted the
interpretation that the RanBP2 complex with its associated RanBDs and RanGAP1
has functions redundant to soluble RanGAP1 and RanBP1 during transport. One
function that may be beneficial for very large cells is the ability of RanBP2 to retain
transport factors at the NPC after export complex disassembly and thus prevent
their diffusion prior to nuclear re-import [Bernad et al., 2004, Forler et al., 2004,
Hamada et al., 2011].
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1.2.4 The Ran GTPase system during mitosis
While a focus in research on the Ran GTPase system was set on its role during
interphase, it was originally identified by its functions during mitosis, when the nu-
clear envelope disassembles and hence nucleocytoplasmic transport stops [Coutavas
et al., 1993, Ohtsubo et al., 1989, Ren et al., 1993]. Today, functions of Ran micro-
tubule dynamics [Carazo-Salas et al., 2001, Wilde et al., 2001], kinetochore function
[Arnaoutov and Dasso, 2003, Joseph et al., 2004, Salina, 2003], NPC [Harel et al.,
2003, Ryan et al., 2003, Walther et al., 2003, Zhang et al., 2002] and nuclear en-
velope re-assembly [Clarke and Zhang, 2008] as well as mitotic spindle assembly
[Clarke and Zhang, 2008, Kalab and Heald, 2008] have been established.
Interestingly, it is not only Ran, but also transport receptors that have been
adopted to orchestrate events during mitosis. Mechanistically, the theme of alter-
nating complex formations depending on the local presence of Ran-GTP appears
to be recapitulated during mitosis as well. Spindle assembly factors for instance,
like TPX2 (targeting protein for Xenopus plus end-directed kinesin-like protein 2)
bind to importin α/β via their NLS and are inhibited in their spindle-promoting
activity by this interaction [Gruss et al., 2001]. Binding of Ran-GTP to importin β
displaces these mitotic cargo molecules thereby releasing this inhibition. As RCC1
is associated with chromatin in mitosis as well as interphase [Moore et al., 2002], a
concentration gradient of Ran-GTP and by consequence of spindle promoting activ-
ity is created around mitotic chromosomes [Nachury et al., 2001, Trieselmann and
Wilde, 2002].
In addition to importin α/β, the export receptor Crm1 was also found to have
moonlighting functions during mitosis. Crm1 resides at kinetochores during mitosis
[Arnaoutov et al., 2005] and was shown to interact with the protein Survivin in
an NES-dependent way [Knauer et al., 2006]. Survivin is part of the chromosomal
passenger complex, together with the Aurora B kinase as well as INCENP (inner
centromere protein) and Borealin, which act as regulatory components. The CPC
coordinates essential chromosomal and cytoskeletal events during mitosis [Vagnarelli
and Earnshaw, 2004]; particularly, the Survivin/Crm1-mediated localization to the
centromere regions of the chromosomes appears to be functionally important in this
respect [Knauer et al., 2006].
The RanBP2 complex during mitosis
After nuclear envelope breakdown, the RanBP2 complex stays assembled, but
becomes largely soluble [Swaminathan et al., 2004]; a fraction is localized to the
mitotic spindle and the kinetochores [Joseph, 2002]. It is believed that the RanBP2
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complex finds its way to the kinetochores via the spindle MTs (microtubules), as
its kinetochore localization coincides with MT/kinetochore attachment; addition-
ally, knock-down of Hec1 (highly expressed in cancer protein 1) and Nuf2 (nuclear
filament-containing protein 2), which are required for the attachment, prevents the
kinetochore localization of the RanBP2 complex [Joseph et al., 2004].
Strikingly, Crm1 at kinetochore was identified as a critical loading factor for the
RanBP2 complex onto kinetochores. This recruitment depends on the formation of
an export complex, since treatment with Leptomycin B resulted in loss of kineto-
chore localization of the RanBP2 complex [Arnaoutov et al., 2005]; Leptomycin B
is a small molecule that specifically and irreversibly inhibits Crm1-dependent ex-
port complex formation [Yashiroda and Yoshida, 2003]. Dr. Annette Flotho from
the Melchior group could show in her PhD thesis that Crm1 co-immunprecipitates
with the RanBP2 complex (and vice versa), which speaks in favor of a stable and
prolonged interaction. Over-expression of importin β is able to interfere with the
kinetochore recruitment of the RanBP2 complex, an effect mediated by the FG-
repeats of RanBP2 [Roscioli et al., 2012]. This suggests that in terms of RanBP2
complex recruitment during mitosis, the prototypical export receptor Crm1 and the
major import receptor importin β behave as antagonists.
Functionally, the kinetochore localization of the RanBP2 complex seems to be
important for a stable MT/kinetochore attachment. While this attachment can still
take place without proper localization of the RanBP2 complex, spindle MTs decom-
pose in the cold, a hallmark of defective MT/kinetochore attachment, and spindle
morphology becomes abnormal. This eventually results in the formation of multi-
polar spindles and chromosome missegregation [Joseph et al., 2004]. Additionally, a
number of important kinetochore proteins do not localize properly in the absence of
RanBP2 [Joseph et al., 2004, Salina, 2003]. Interestingly, the IR region of RanBP2
in conjunction with an N-terminal fragment covering the sequence up to the first
RanBD was able to correct mitotic errors in the absence of endogenous RanBP2
[Hamada et al., 2011]. In conclusion, the RanBP2 complex is important for proper
progression of cells through mitosis and this requires similar interaction partners as
during interphase (Crm1 and importin β).
1.3 Aims of this work
As desribed above, the nuclear transport factor RanGAP1 associates with Ubc9
and RanBP2’s 130 amino acids IR region to from a multisubunit E3 ligase. With
two FG-repeat patches and two RanBDs in direct proximity to that region, two key
activities (RanGAP1/RanBD and SUMO E3 ligase activity) are contained in a frag-
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ment that is only about 740 amino acids compared to the entire RanBP2 protein
with 3224 amino acids. This spatial link within RanBP2 has prompted the idea
of a functional link between the seemingly unrelated Ran GTPase and the SUMO
system [Pichler et al., 2002].
This work set out to characterize the RanBP2 complex regarding its two principal
enzymatic activities. In a first part, I wanted to address its catalytic mechanism
as a multisubunit SUMO E3 ligase on a molecular level. In addition to the wealth
of structural information of previous studies, I first wanted to answer the ques-
tion whether the folded-back Ubc9∼SUMO thioester conformation is relevant to
SUMOylation. Secondly, I wanted to address how the multisubunit RanBP2 E3
ligase complex binds the Ubc9∼SUMO thioester, i.e. whether an additional binding
site is provided by RanGAP1*SUMO1 and/or Ubc9C . To address these questions
experimentally, I had to expand my repertoire of biochemical tools by creating a sta-
ble Ubc9∼SUMO1 thioester mimic for binding assays with the RanBP2 complex.
In a second part, I wanted to focus on the role of the RanBP2 complex as a reg-
ulator the GTPase Ran. With its localization at the NPC during interphase, but
also at the kinetochore during mitosis, the RanBP2 complex potentially comes in
contact with a plethora of transport receptor/cargo complexes. Considering that
the RanBP2 complex features several FG-repeats as potential binding sites for im-
portin β-related transport receptors and combines activities that can regulate Ran-
dependent transport, i.e. RanGAP1 and RanBDs, it may be able to autonomously
disassemble transport receptor/Ran-GTP complexes. While this has been sugested
in some studies, it has never benn directly tested. I did so by making use of a recon-
stituted RanBP2 complex [Werner et al., 2012], which incorporates all components
required to disassemble recycling import receptor complexes and cargo-containing
export receptor complexes.

Chapter 2
Results
2.1 Analysis of the catalytic mechanism of the
RanBP2 E3 ligase complex
RanBP2 is one of the few known SUMO E3 ligases and has virtually no se-
quence similarity to other known SUMO nor ubiquitin E3 ligases. Studies on its
catalytic mechanism generally have not yet taken into account that it is not free
RanBP2, but the RanBP2 complex, which is endogenously relevant and acts as a
multisubunit SUMO E3 ligase [Werner et al., 2012]. I hence wanted to unravel the
catalytic mechanism of the RanBP2 complex. As a tool for in vitro analyses, I
used a reconstituted form of the RanBP2 complex containing full-length Ubc9, in
vitro SUMOylated RanGAP1 and an 86 kDa fragment of the C-terminus of RanBP2
(amino acids 2304-3062), which incorporates RanBD3, two FG-repeat patches, the
IR region and RanBD4 (this RanBP2 fragment will simply be referred to as “BD34”
and the corresponding complex as “BD34 complex” - Figure 12).
2.1.1 Stable Ubc9∼SUMO thioester mimics
Studies from the ubiquitin, but also the SUMO field suggest that binding of the
E2∼modifier thioester to the E3 ligase is a crucial step for catalysis. While activity
assays were able to give some idea where Ubc9T would bind in the RanBP2 complex
(i.e. IR2), the existence of a SIM for SUMO-interaction was unclear [Werner et al.,
2012]. To gain insight into this question, I wanted to employ binding assays between
the RanBP2 complex and the Ubc9∼SUMO thioester. Although the Ubc9∼SUMO
can be formed in vitro, it is inherently unstable in the presence of the E3 ligase (see
also Figure 16). It is thus unsuitable for binding studies. I hence sought to create
a Ubc9∼SUMO thioester mimic, which is stable in the presence of the RanBP2
complex and which to my knowledge had not been done before.
The most common strategy in the ubiquitin field to obtain a stable E2∼ubiquitin
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thioester mimic is to generate, with the help of an E1 activating enzyme, a much less
reactive E2-ubiquitin oxyester by genetic replacement of the catalytic cysteine to a
serine [Kamadurai et al., 2009, Sullivan and Vierstra, 1993] [Plechanovová et al.,
2011]. The oxyester has the obvious advantage that it differs from the endogenous
thioester by only one atom. Unfortunately, the corresponding Ubc9 C93S-SUMO
oxyester could not be stably formed ([Knipscheer et al., 2008] and own unpublished
observation). Therefore, I used two other strategies to prepare a stable mimic.
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Figure 12: The BD34 complex - a reconstituted version of the RanBP2 complex. (A)
Schematic depiction of the BD34 complex made up of untagged and full-length Ubc9, in vitro
SUMOylated RanGAP1 and a C-terminally His6-tagged fragment of RanBP2 (= BD34), which
includes RanBD3, the IR region, the two FG-repeat patches flanking (vertical black lines) and
RanBD4. (B) Coomassie-stained SDS-PAGE gel of the BD34 complex (2 µg) and its components
(1 µg each). S1 = SUMO1.
Preparation and purification of a triazole-linked Ubc9-SUMO1 conjugate
In a first attempt, I wanted to employ a synthetically linked Ubc9-SUMO1 con-
jugate as a thioester mimic. I therefore turned to the group of Henning Mootz
(University of Münster), who had previously [Weikart and Mootz, 2010] introduced
a chemical approach to regioselectively attach ubiquitin and SUMO modifiers to
target proteins using CuAAC (Cu(I)-catalyzed azide-alkyne cycloaddition) [Tornøe
et al., 2002]. In this technique, the modifier is functionalized with an alkyne group
e.g. through aminolysis of an intein-generated thioester with propargylamine (Pa)
(see Figure 13). The acceptor lysine in the target protein is altered to contain an
azide functionality, e.g. by genetic replacement with the unnatural amino acid AzF
(p-azidophenylalanine) via the nonsense-suppression technology [Chin et al., 2002].
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Mesna
PA
Figure 13: Preparation of a triazole-linked Ubc9-His6-SUMO1(∆G) conjugate. SUMO1
lacking the last glycine residue (SUMO1(∆G)) was prepared as a SUMO1-intein thioester and
used for C-terminal modification with Pa (propargylamine). Mesna (2-Mercapto-ethanesulfonate
sodium) was added as a thiol catalyst to enable formation of the SUMO-Mesna thioester. The
catalytic cysteine 93 of Ubc9 was genetically replaced by AzF (p-azidophenylalanine). Follow-
ing the CuAAC reaction, the conjugate was purified and the N-terminal SBP-tag (streptavidin-
binding peptide) of Ubc9 was proteolytically removed using TEV protease. The latter step ex-
posed an almost native N-terminus of Ubc9 with the methionine 1 replaced by a glycine residue
being the only sequence alteration. TBTA = Tris(benzyltriazolyl-methyl)amine; TCEP: Tris(2-
carboxyethyl)phosphine. Figure kindly provided by Henning Mootz and Stefanie Sommer [Sommer
et al., 2015].
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A CuAAC reaction between the so altered target protein and the ubiquitin or
SUMO modifier, which lacks the C-terminal glycine residue and harbors the alkyne
functionality at its C-terminus, then installs a triazole linkage as a structural ana-
log or mimic of the isopeptide bond (see Figure 13). Here, we reasoned that the
CuAAC-mediated, chemically stable triazole-linkage should also be able to mimic
the reactive thioester in the active site of Ubc9 in the Ubc9∼SUMO thioester; an
approach that, to our knowledge, had not been reported yet in the SUMO or the
ubiquitin field.
Purification of proteins and their conjugation was performed by Stefanie Sommer
of the Mootz group and is documented in detail in [Sommer et al., 2015]. Here,
the procedure is briefly summarized: the catalytic cysteine at position 93 of Ubc9
was replaced by AzF and the protein purified via an N-terminally streptavidin-
binding peptide-tag (SBP). SUMO1 was purified as a SUMO1(∆G)-intein-CBD
(chitin binding doamin) fusion protein with an N-terminal His6-tag and then func-
tionalized with the alkyne group as described above. His6-SUMO1(∆G)-Pa and
SBP-Ubc9(C93AzF) were incubated in a 1:2 molar ratio for 30 min under CuAAC
conditions, which led to the formation of the triazole-linked protein conjugate. Af-
ter subsequent conjugate purification by affinity chromatography on Ni-NTA and
streptactin sepharose, the N-terminal SBP-tag of Ubc9 was proteolytically removed
by a TEV-protease digest (see Figure 13).
Preparation and purification of an isopeptide-linked Ubc9-SUMO1 adduct
IAs an alternative approach, I wanted to conjugate Ubc9 and SUMO enzymati-
cally via an isopeptide bond. The creation of an isopeptide-linked thioester mimic
by mutating the catalytic cysteine of the E2 enzyme to a lysine has successfully been
employed in the ubiquitin field. The formation of the isopeptide link is catalyzed
by the E1 enzyme and a high pH [Plechanovová et al., 2012]. Initial SUMOylation
experiments with SUMO1 and the SUMO E1 enzyme Aos1/Uba2 at pH 10 revealed
that the Ubc9 C93K mutant was efficiently and almost quantitatively modified with
SUMO1 (Figure 14B). A similar experiment conducted with the Ubc9 C93A mutant,
which cannot be modified at position 93, showed a small degree of modification as
well. This implied that another of the protein’s 14 lysines was used for the formation
of an isopeptide link to SUMO1. Conversely, this observation also suggested that
the Ubc9 C93K variant may not be modified uniformly at residue 93; a possibility
that I wanted to circumvent.
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Figure 14: Specific SUMOylation of Ubc9 at amino acid 93. (A) Ribbon structure of
Ubc9 with the catalytic cysteine (amino acid position 93) shown in yellow and lysine 101 shown
in blue (PDB: 1U9B). (B) A time course of in vitro SUMOylation reactions of Ubc9 variants
(20 µM each) was performed with SUMO E1 enzyme (500 nM) and SUMO1 (200 µM) as indicated
at pH 10.0. Samples were analyzed by Colloidal-Coomassie stained SDS-PAGE. S1 = SUMO1; *
unspecific band from recombinant protein purification. (C) The K101R mutation does not affect
the catalytic activity of Ubc9. FRET assays were performed with reactions containing Ubc9 wild-
type and the K101R variant (4 nM each), the SUMO1 E1 enzyme (25 nM), YFP-SUMO1 (1 µM)
and CFP-GAPtail (500 nM) in SAB+ buffer. Reactions were started by automatic addition of
ATP (5 mM). Fluorescence after excitation at 430 nm was measured every minute at 485 and 527
nm. The ratio of emission (527/485 nm) was plotted versus time.
An inspection of the structure of Ubc9 revealed a lysine at position 101, which
lies in very close proximity to the catalytic pocket of the enzyme and was thus the
prime candidate as a possible unwanted modification site (Figure 14A). When re-
peating the experiment, I observed efficient modification of the Ubc9 C93K/K101R
as before, while no modification was detectable for the Ubc9 C93A/K101R mutant
(Figure 14B). Although position 101 in Ubc9 was shown to be important for sub-
strate recognition by the Ubc9∼SUMO thioester [Tatham et al., 2003], the conserva-
tive exchange to arginine did not change the activity of the SUMO E2 conjugating
enzyme compared to the wild-type in E3 ligase-independent FRET (fluorescence
resonance energy transfer) SUMOylation assays of CFP-GAPtail (Figure 14C).
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Figure 15: The Ubc9-K*SUMO1 adduct can be purified to near homogeneity. (A)
An in vitro SUMOylation reaction of Ubc9 C93K/K101R (50 µM) was performed with SUMO E1
enzyme (500 nM) and SUMO1 (50 µM) at pH 10.0. Samples of the whole reaction (0.2%) were
analyzed by Colloidal-Coomassie stained SDS-PAGE. (B) The in vitro SUMOylation reaction from
(A) was concentrated and applied to a HiLoad 26/600 Superdex75 pg gel filtration column. The
elution profile was recorded at 280 nm (left). Samples of fractions (20 µl each) were analyzed by
Colloidal-Coomassie stained SDS-PAGE (right). (C) Fractions indicated in (B) were pooled and
applied to MonoQ 5/50 GL anion exchange column. Samples of fractions (20 µl each) at indicated
salt concentrations of the elution buffer were analyzed by Colloidal-Coomassie stained SDS-PAGE.
As a final purification step, the indicated, consecutive fractions were pooled, concentrated and again
applied to gel filtration for buffer exchange. S1 = SUMO1
The Ubc9 C93K/K101R mutant was henceforth used to create and purify isopep-
tide-linked Ubc9*SUMO adducts (from hereon termed “Ubc9-K*SUMO”). Quan-
titative amounts of Ubc9-K*SUMO1 could be obtained by incubating equimolar
amounts of Ubc9 C93K/K101R and SUMO1 with E1 and ATP and subsequent
purification steps (Figure 15). This purification strategy was used successfully to
obtain adducts of Ubc9 with SUMO1 as well as SUMO2 (see 18A).
Interestingly, the elution volume of the adduct was concentration-dependent and
generally much smaller, i.e. its apparent Stokes radius much bigger, than suggested
by the molecular weights of its two globular components (the elution volume of the
adduct in the purification shown here was 0.37 CV (column volumes), which cor-
responds to an apparent molecular weight of 110 kDa, while its actual molecular
weight is 29 kDa). Moreover, the elution peak featured a shoulder, which appeared
to contain trace amounts of free Ubc9 C93K/K101R and SUMO1.
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These observations are in line with the formation of the reported non-covalent
backside interaction between SUMO and Ubc9 [Knipscheer et al., 2007]). With a
KD of 82 nM and the given concentrations of Ubc9 C93K/K101R and SUMO1 in
the modification reaction (commonly 50 µM), this interaction should be relevant. It
may thus contribute to the formation of a continuous distribution of adduct multi-
mers, which explains the early elution volume and the asymmetric peak shape, as
well as the co-migration of free Ubc9 C93K/K101R and SUMO1 in the elution peak.
Others have reported similar observations for E2∼ubiquitin thioester mimics [Br-
zovic et al., 2006, Page et al., 2012, Sakata et al., 2010]. Indeed, when isopeptide-
linked adducts were purified, which contained either Ubc9 or SUMO1 variants that
are defective in this non-covalent interaction (Ubc9 H20D and SUMO1 E67R), the
elution peak was symmetric and and its elution volume was much more compatible
with the calculated molecular weight of the adduct (elution volume of 0.5 CV which
corresponds to a molecular weight of 36 kDa - data not shown).
Ubc9-SUMO adducts are chemically stables
With two different Ubc9-SUMO1 conjugates in hand, I next tested their stabil-
ity. As expected and in contrast to the endogenous thioester, the triazole- and
isopeptide-linked conjugates were stable under reducing conditions, as incubation
with DTT-containing sample buffer showed (Figure 16A and B).
While the thioester was labile in the presence of the BD34 E3 ligase complex
(causing auto-SUMOylation of the BD34 fragment), both conjugates as well as the
E3 ligase in their presence remained stable (Figure 16C and D). To confirm that
the bond between Ubc9 and SUMO1 in the Ubc9-K*SUMO1 adduct was indeed
an isopeptide bond, it was incubated with increasing amounts of the catalytic frag-
ment of the SUMO isopeptidase SENP1. As expected, the adduct was sensitive to
SENP1-treatment, while the triazole-linked conjugate was not cleaved (Figure 16E).
Ubc9-SUMO adducts act as stable Ubc9∼SUMO thioester mimics
Subsequently, I assessed whether the Ubc9-SUMO conjugates mimic the endoge-
nous thioester in terms of binding to the BD34 E3 ligase complex. The very early
elution volume of the reconstituted BD34 complex due to its partially unfolded na-
ture allowed clear separation of bound and unbound proteins on gel filtration (see
Section 4.4.8). As described below, both conjugates function as thioester mimics.
Their binding properties allowed confirmation and extension of previous findings.
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Figure 16: Stability of Ubc9-SUMO1 conjugates. (A) Comparison of DTT stability of
the triazole-linked Ubc9-His6-SUMO1(∆G) conjugate and the Ubc9∼SUMO1 thioester. The
Ubc9∼SUMO1 thioester was pre-formed with 1.6 µM SUMO E1 enzyme, 8 µM Ubc9 and 24 µM
SUMO1 at 30◦C for 10 min. The pre-forming reaction was quenched by EDTA. Thioester forma-
tion showed a yield of about 20% (first lane). According to this estimation, 3.2 pmol thioester
and triazole-linked Ubc9-His6-SUMO1(∆G) were analyzed with non-reducing (-DTT) and reducing
(+DTT) sample buffer by αUbc9 immunoblot. (B) Comparison of DTT stability of the isopeptide-
linked Ubc9-K*SUMO1 adduct and the Ubc9∼SUMO1 thioester. Experiments were conducted in
analogy to (A). (C) Comparison of the stability of the triazole-linked Ubc9-His6-SUMO1(∆G) con-
jugate and the Ubc9∼SUMO1 thioester towards the BD34 E3 ligase complex. The Ubc9∼SUMO1
thioester was pre-formed as in (A); 300 nM thioester and triazole-linked Ubc9-His6-SUMO1(∆G)
were incubated with 50 nM BD34 complex at 30◦C for 15 min. Samples were analyzed with
non-reducing sample buffer by αUbc9 (bottom) and αRanBP2 immunoblot (top). (D) Compari-
son of stability of the isopeptide-linked Ubc9-K*SUMO1 adduct and the Ubc9∼SUMO1 thioester
towards the BD34 E3 ligase complex. Experiments were conducted in analogy to (C). (E) The
isopeptide-linked adduct is sensitive towards SUMO isopeptidase activity, while the triazole-linked
Ubc9-His6-SUMO1(∆G) conjugate is stable. The Ubc9-K*SUMO1 adduct and the triazole-linked
Ubc9-His6-SUMO1(∆G) conjugate (1 µM each) were incubated with indicated concentrations of
SENP1 (SENP1 419-644 = catalytic fragment) at 30◦C for 30 min. Reactions were analyzed by
αUbc9 immunoblot. S1 = SUMO1; Ubc9∼S1 = Ubc9∼SUMO1 thioester; Ubc9-tri-S1 = triazole-
linked Ubc9-His6-SUMO1(∆G) conjugate.
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At concentrations of 2 µM, the triazole- and isopeptide-linked conjugate displayed
co-migration with the BD34 complex, while SUMO1, His6-SUMO1 and Ubc9 alone
did not (Figures 17, 18A and B). For the binding of Ubc9, a BD34 complex variant
was used, which was built with a C-terminally HA-tagged Ubc9 in order to distin-
guish it in SDS-PAGE from free Ubc9. This complex variant bound the conjugates
to a similar level as the wild-type complex and displayed no obvious catalytic de-
fects as a SUMO E3 ligase (data not shown). These findings support the notion
that the thioester binds in a distinct orientation to the E3 ligase complex to which
both Ubc9T and SUMO1T contribute.
Previous findings based on activity assays suggested that SUMO1T engages in a
SUMO/SIM-like interaction with the RanBP2 complex for efficient catalysis [Werner
et al., 2012]. This notion could now be tested using conjugates built with the SUMO1
F36L mutant, which is defective in SUMO/SIM-interaction. In line with previous
findings, both conjugates featuring this SUMO1 mutant displayed severely decreased
binding to the BD34 complex (Figures 17, 18A and B).
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Figure 17: The triazole-linked conjugate mimics the thioester in binding to the BD34
complex. (A) Gel filtration binding assays were performed with the BD34 complex, SUMO
and triazole-linked Ubc9-His6-SUMO1(∆G) conjugate variants (2 µM each) as indicated. Pre-
incubated proteins were run over Superdex200 5/150 GL gel filtration column. Samples were
collected at 0.42 CV and analyzed together with 10% of the input by Colloidal Coomassie-stained
SDS-PAGE gel. (B)Gel filtration binding assays were performed as in (A) with the BD34 Ubc9-HA
complex, Ubc9 and triazole-linked Ubc9-His6-SUMO1(∆G) conjugate (2 µM each) as indicated.
GAP*S1 = RanGAP1*SUMO1; Ubc9-tri-S1 = triazole-linked Ubc9-His6-SUMO1(∆G) conjugate;
* ovalbumin from buffer. Although always collected and analyzed, input samples for gel filtration
binding assays will only be shown in selected experiments for clarity reasons from here on out.
The RanBP2 complex was reported to exhibit a paralog preference for SUMO1
over SUMO2 [Gareau et al., 2012, Tatham et al., 2005]. Similarly, an isopeptide-
linked Ubc9-K*SUMO2 conjugated displayed less binding to the BD34 complex than
the Ubc9-K*SUMO1 adduct (Figure 18A and B).
A direct comparison of both the triazole- and the isopeptide-linked conjugates
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showed equal levels of co-migration with the BD34 complex (Figure 18C). This
demonstrated the suitability of the chemically-linked mimic for future studies. Due
to its accessibility in larger quantities, the Ubc9-K*SUMO1 adduct was used for
further analyses and henceforth also referred to as the “Ubc9∼SUMO1 thioester
mimic”. With these tools in addition to in vitro SUMOylations assays, I set out to
dissect the catalytic mechanism of SUMOylation mediated by the RanBP2 SUMO
E3 ligase complex.
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Figure 18: The isopeptide-linked conjugate mimics the thioester in binding to the
BD34 complex. (A) Gel filtration binding assays were performed with the BD34 complex,
SUMO and Ubc9-K*SUMO variants (2 µM each) as indicated. Pre-incubated proteins were run
over Superdex200 5/150 GL gel filtration column. Samples were collected at 0.42 CV and analyzed
by Colloidal Coomassie-stained SDS-PAGE gel. (B)Gel filtration binding assays were performed as
in (A) with the BD34 Ubc9-HA complex, Ubc9 and Ubc9-K*SUMO1 (2 µM each) as indicated. (C)
Gel filtration binding assays were performed as in (A) with the BD34 complex, Ubc9-K*SUMO1
and the triazole-linked Ubc9-His6-SUMO1(∆G) conjugate (2 µM each) as indicated. GAP*S1
= RanGAP1*SUMO1; S1 = SUMO1; S2 = SUMO2; Ubc9-tri-S1 = triazole-linked Ubc9-His6-
SUMO1(∆G) conjugate.
2.1.2 The folded-back thioester conformation in
SUMOylation
As outlines in the introduction, the folded-back E2∼ubiquitin thioester confor-
mation seems to be a central entity in productive modification events. Although
structural data have supported the importance of an equivalent conformation of the
Ubc9∼SUMO thioester for SUMOylation, functional data in this respect is largely
missing. In order to test a role of the folded-back thioester conformation in SUMOy-
lation, I wanted to disrupt this conformation by mutation. I therefore designed mu-
tants based on the structure of the closed conformation of Ubc9 and SUMO1 in the
RanBP2 complex (PDB: 1Z5S). As discussed in the introduction, the orientation of
Ubc9 and SUMO1 in the complex strongly resembles the folded-back conformation
of E2∼ubiquitin thioesters.
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\textbf{Mutations at the possible interface of the Ubc9$_{\textasciitilde}$SUMO1 thioester affect SUMOylation.}
\textbf{(A)} Structural model of the folded-back conformation of the UbcH5A$_{\textasciitilde}$ubiquitin thioester in a 
complex with the RING E3 ligase RNF4 (PDB: 4AP4). Left: Surface structure of the RNF4/UbcH5A/ubiquitin structure 
with UbcH5A (light green), ubiquitin (olive) and RNF4 (black). Middle: Ribbon structure of the folded-back 
UbcH5A/ubiquitin conformation (without RNF4); the $\alpha$2 helix of UbcH5A and its central residue leucine 104 as 
well as the contacting isoleucine 44 of ubiquitin are shown in grey. Right: zoom on the UbcH5A/ubiquitin interface 
(structure from the middle turned clockwise by about 100$^\circ$).   
\textbf{(B)} Structural model of the folded-back conformation of the Ubc9$_{\textasciitilde}$SUMO1 thioester deduced 
from the Ubc9/SUMO1 conformation in the RanBP2 complex (PDB: 1Z5S). Left: Surface sturcutre of the RanBP2 
complex with Ubc9 (light green), SUMO1 (olive) and the IR1 sequence of RanBP (black); the C-terminal domain of 
RanGAP1 is in the back (orange). Middle: Ribbon structure of the folded-back Ubc9/SUMO1 conformation (without 
IR1 and RanGAP1); the $\alpha$2 helix of Ubc9 and its central residue leucine 114 as well as the contacting tyrosine 
91 of C-terminal tail of SUMO1 are shown in grey. Glutamine 94 of the C-terminal tail of SUMO1, which fits into the 
groove provided by glycine 115 of the $\alpha$2 helix of Ubc9, is shown in orange. the lgutamates at position 118 and 
122 of Ubc9 (blue) contact argenine 63 (red) of SUMO1. Right: zoom on the Ubc9/SUMO1 interface (structure from 
the middle turned clockwise by about 100$^\circ$).
\textbf{(C)} A time course of \textit{in vitro} SUMOylation reactions of YFP-Sp100 under single turnover conditions was 
performed. First, Ubc9$_{\textasciitilde}$SUMO1 thioester variants were preformed with 1.6 $\mu$M E1 enzyme, 8 
$\mu$M Ubc9 variants and 24 $\mu$M SUMO1 variants as indicated. Preforming reactions were quenched by EDTA 
and analyzed by $alpha$Ubc9 immunoblot (bottom). Preforming ractions were diluted 1:3.2 into SUMOylation reac-
tions containing 1 $\mu$M YFP-Sp100. SUMOylation reactions were analyzed by $\alpha$GFP (top) immunoblot. 
Pairs of Ubc9 and SUMO1 variants later on used in this work are shown in bold.
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Figure 19: The Ubc9/SUMO1 interface is involved in SUMOylation. (A) Struc-
tural model of the folded-back conformation of the Ubc9∼SUMO1 thioester deduced from the
Ubc9/SUMO1 conf rmation in the R nBP2 complex (PDB: 1Z5S). Left: Surface structure of
the RanBP2 co plex with Ubc9 (light green), SUMO1 (olive) and the IR1 sequence of RanBP2
(black); the C-terminal domain of RanGAP1 is in the back (orange). Middle: Ribbon structure
of the folded-back Ubc9/SUMO1 conformation (without IR1 and RanGAP1). Right: Close-up on
the Ubc9/SUMO1 interface. Th α2-helix of Ubc9 and its central leucine 114 and glyc ne 115 as
well as the contacting tyrosine 91 of C-terminal tail of SUMO1 are shown in grey. Glutamine 94
of the C-terminal tail of SUMO1, which fits into the groove provided by glycine 115 of Ubc9, is
shown in orange. The glutamates at position 118 and 122 of Ubc9 (red) contact arginine 63 (blue)
of SUMO1. (B) A time c rse of in vitro SUMOylation reactions of YFP-Sp100 under single
turnover conditions was performed. First, Ubc9∼SUMO1 thioester variants were pre-formed with
1.6 µM E1 enzyme, 8 µM Ubc9 variants and 24 µM SUMO1 variants as indicated. Pre-forming
reactions were quenched by EDTA and analyzed by αUbc9 immunoblot (bottom). Pre-forming re-
actions were diluted 1:3.2 into SUMOyl ion reactions containing 1 µM YFP-Sp100. SUMOylation
reactions were analyzed by αGFP (top) immunoblot after indicated time points. S1 = SUMO1;
Ubc9∼S1 = Ubc9∼SUMO1 thioester. Pairs of Ubc9 and SUMO1 variants later on used in this
work are shown in bold.
As shown in the close-up in Figure 19A, several residues contribute to stabilize the
Ubc9/SUMO1 interface in the folded-back conformation. Glutamate 118 and 122
of Ubc9 form a salt bridge with arginine 63 of SUMO1 (these residues correspond
to aspartate 112 in UbcH5A and arginine 42 in ubiquitin in the UbcH5A∼ubiquitin
thioester mimic structure - PDB: 4AP4, [Plechanovová et al., 2012]). Also, leucine
114 in the α2-helix of Ubc9 interacts with tyrosine 91 of SUMO1 and the adja-
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cent glycine 115 of Ubc9, which creates a small groove, accommodates the side
chain of glutamine 94 of SUMO1. Mutating these residues should thus prevent
the folded-back confirmation. I Therefore generated the following mutants: Ubc9
E118R/E122R, Ubc9 L114Q/G115S (corresponding to UbcH5A L104Q in [Pruneda
et al., 2012]) and SUMO1 R63E.
I then tested the activity of these mutants in E3-independent SUMOylation assays
where a thioester was pre-formed and then used to SUMOylate the model substrate
YFP-Sp100 (= single turnover conditions). The mutant thioesters were to various
degrees impaired in SUMOylating YFP-Sp100 with regard to the wild-type (Fig-
ure 19B). A combination of the Ubc9 L114Q/G115S and SUMO1 R63E mutation
displayed an additive detrimental effect (this mutant combination will henceforth
be referred to as “Ubc9/SUMO1 open” for “opening mutation” - see Table 1).
To finally prove that loss of activtiy was due to loss of the folded-back conforma-
tion rather than due to some other mutant effect, I decided to also test the effect of a
combination of the Ubc9 E118R/E122R and SUMO1 R63E mutant, which restored
the salt bridge at the interface (“charge swap”). Indeed, the charge swap showed
a regain of SUMOylation activity that was comparable to the wild-type proteins
(this mutant combination will henceforth be referred to as “Ubc9/SUMO1 closed ”
for “closed mutation” - see Table 1). Of note, thioester formation with these mutants
or their combinations was comparable to that of the wild-type proteins suggesting
that the mutations did not affect E1-dependent loading of the E2. Taken together,
these findings prove the importance of the folded-back Ubc9∼SUMO thioester con-
formation for SUMOylation and show that the introduced mutations can be used to
tweak the propensity to form this conformation.
2.1.3 The IR1 region of free RanBP2 as a SUMO E3 ligase
The SUMO1- and Ubc9-binding sites of IR1 are prerequisites for thioester
mimic binding and catalysis
In a next step, I wanted to address the catalytic mechanism of RanBP2 in more
detail. Previous studies by the Melchior lab and other have already shown that in
the free RanBP2 catalysis is mainly mediated by IR1 and not by IR2 [Pichler et al.,
2004, Reverter and Lima, 2005]. This was shown by mutating residues crucial for
SIM/SUMO (I2634A/V2635A) and the Ubc9 interaction (L2651A/L2653A/F2658A),
underlining that binding of both components of the thioester is important for catal-
ysis. Here, I could reproduce this finding using combined mutants (mIR1 = I2634A/
V2635A/L2651A/L2653A/F2658A and the corresponding mutant mIR2 = I2712A/
V2713A/L2729A/L2731A/F2736A - see Table 1) in in vitro SUMOylation assays
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under multiple turnover conditions (Figure 20A). In this case, multiple turn over
conditions were used because reactions only differed by the employed E3 ligase (and
not by the E2 or SUMO - compare to Section 2.1.2).
To correlate activity with binding, the same mutants were subsequently tested for
interaction with the Ubc9-K*SUMO1 thioester mimic. The mimic displayed robust
binding to the BD34 wild-type fragment as well as the mIR2 mutant, while it did
not interact with a fragment with mutations in both IR1 and IR2 (Figure 20B).
Intriguingly, the BD34 mIR1 fragment, which has a drastic catalytic defect, still
showed Ubc9-K*SUMO1 mimic binding comparable to the wild-type. While this
finding is in line with the conservation of SUMO1- and Ubc9-interacting residues
in IR1 and IR2, it implies that binding of the thioester is not per se sufficient for
catalytic activity [Reverter and Lima, 2005].
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Figure 20: In free RanBP2, the SUMO- and the Ubc9-binding sites of IR1 are crucial
for catalysis and binding of the thioester mimic. (A) A time course of in vitro SUMOy-
lation reactions of YFP-Sp100 (500 nM) was performed with the SUMO E1 enzyme (100 nM),
Ubc9 (50 nM), SUMO1 (10 µM) and free BD34 variants (25 nM) as indicated. Samples were
analyzed by αGFP (top) and αRanBP2 immunoblot (bottom). (B) Gel filtration binding as-
says were performed with BD34 variants and the Ubc9-K*SUMO1 thioester mimic (2 µM each)
as indicated. Pre-incubated proteins were run over Superdex200 5/150 GL gel filtration col-
umn. Samples were collected at 0.46 CV and analyzed by Colloidal Coomassie-stained SDS-
PAGE gel. S1 = SUMO1; mIR1 = I2634A/V2635A/L2651A/L2653A/F2658A and mIR2 =
I2712A/V2713A/L2729A/L2731A/F2736A; * BD34 degradation fragment.
The folded-back thioester conformation affects catalysis by IR1, but not
binding of the thioester mimic
If binding is not sufficient for catalysis, relative orientation of the binding sites
may matter. One reason for this may be the the need to stabilize the folded-back
thioester conformation. In a next set of experiments, I hence wanted to test the role
of the folded-back thioester conformation in RanBP2-mediated catalysis. To do so,
I conducted single turnover SUMOylation reactions and gel filtration binding assays
with the Ubc9 and SUMO1 mutants impaired in forming the folded-back thioester
conformation (see Section 2.1.2). To avoid any ambiguities between the two IR re-
42 RESULTS CHAPTER 2
gions, the BD34 mIR2 fragment was used for these experiments.
Single turnover reactions demonstrated that, in comparison to wild-type Ubc9
and SUMO1, RanBP2 mIR2-mediated SUMOylation of YFP-Sp100 was impaired
compared to the wild-type proteins by the use of the Ubc9/SUMO1 open mutants,
which synergistically act to disfavor the folded-back conformation (Figure 21A and
also Figure 19C). Importantly, the charge swap in the Ubc9/SUMO1 closed mutants
could in part restore SUMOylation levels, which suggests that indeed the folded-back
conformation of the Ubc9∼SUMO thioester is important for IR1-mediated catalysis.
time (min) 80 2 822 8
αGFP
αUbc9
A
BD34 mRI2 (E3) +
Ubc9T/SUMO1T wt closedopen
82
- E3
wt
130 kDa
100 kDa YFP-
Sp100
YFP-
Sp100*S1
preformed 
thioester 
35 kDa
15 kDa
Ubc9~S1
Ubc9
clo
se
d
wt op
en
B
Ubc9-K*S1
130 kDa
40 kDa
35 kDa
100 kDa
BD34 mIR2
*
BD34
Ubc9-K*S1
Figure 21: The conformation of the Ubc9∼SUMO1 thioester affects IR1-mediated
catalysis, but not binding of the thioester mimic. (A) A time course of in vitro SUMOyla-
tion reactions of YFP-Sp100 under single turnover conditions was performed. First, Ubc9∼SUMO1
thioester variants were pre-formed with 1.6 µM E1 enzyme, 8 µMUbc9 variants and 24 µM SUMO1
variants as indicated. Pre-forming reactions were quenched by EDTA and analyzed by αUbc9 im-
munoblot (bottom). Pre-forming reactions were diluted 1:16 into SUMOylation reactions contain-
ing 1 µM YFP-Sp100 and 25 nM BD34 mIR2. SUMOylation reactions were analyzed by αGFP
(top) immunoblot. (B) Gel filtration binding assays were performed with free BD34 mIR2 and
thioester mimic variants (2 µM each) as indicated. All Ubc9 variants used for thioester mimic for-
mation contain the C93K/K101R mutations. Pre-incubated proteins were run over Superdex200
5/150 GL gel filtration column. Samples were collected at 0.46 CV and analyzed by Colloidal
Coomassie-stained SDS-PAGE gel. S1 = SUMO1; Ubc9∼S1 = Ubc9∼SUMO1 thioester; * BD34
degradation fragment.
Of note, SUMOylation in these reactions is E3 ligase dependent, since a reaction
without RanBP2, but with wild-type Ubc9 and SUMO1 showed no SUMOylation;
this is in contrast to the E3-independent single turnover reactions of Section 2.1.2,
where the concentration of pre-formed thioester was 5-fold higher.
While the Ubc9/SUMO1 open mutants showed a defect in catalysis, a thioester
mimic built with the same mutants displayed comparable binding to the BD34 mIR2
fragment as the mimic built with wild-type proteins (Figure 21B). The same was true
for a mimic built with the Ubc9/SUMO1 closed mutants. These findings underline
the notion that thioester-binding (or mimic-binding, respectively) is not sufficient
for catalysis.
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The integrity of the αC-helix in IR1 is crucial for catalysis
So far, I could show that binding of the thioester mimic depends on its SIM and
Ubc9-interacting residues, but not on the conformation of the mimic. From these
observations, I inferred that after thioester binding, a second step must take place
during catalysis, which involves promotion of the folded-back thioester conformation.
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Figure 22: In free RanBP2, the integrity of the αC-helix is crucial for catalysis, yet does
not influence binding of the thioester mimic. (A) A time course of in vitro SUMOylation
reactions of YFP-Sp100 (500 nM) was performed with the SUMO E1 enzyme (100 nM), Ubc9
(50 nM), SUMO1 (10 µM) and free BD34 variants (25 nM) as indicated. Samples were analyzed
by αGFP (top) and αRanBP2 immunoblot (bottom). (B) Gel filtration binding assays were
performed with BD34 variants and the Ubc9-K*SUMO1 thioester mimic (2 µM each) as indicated.
Pre-incubated proteins were run over Superdex200 5/150 GL gel filtration column. Samples were
collected at 0.46 CV and analyzed by Colloidal Coomassie-stained SDS-PAGE gel. S1 = SUMO1;
* BD34 degradation fragment. (C) Structural model of the αC-helix within IR1 (black) bound to
Ubc9 (light green) and SUMO1 (olvie) in the folded-back conformation (from PDB: 1Z5S). Lysine
2645 within the αC-helix is shown in blue.
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In isolation, the E3 ligase region of RanBP2 is largely unfolded [Pichler et al.,
2004], yet it adopts a non-globular, extended structure when bound to SUMO1 and
Ubc9 in the folded-back conformation [Reverter and Lima, 2005]. Conspicuous in
the IR1 structure is the α-helix between the SIM and the canonical Ubc9-binding
site (from here on called the “αC-helix” for “catalytic helix” - Figure 22C). In contrast
to much of the rest of the IR1 sequence, which very tightly wraps around SUMO1
and Ubc9 without significant secondary structure content, the αC-helix breaks with
the theme of a close-fitting entwinement and features several amino acids, which are
not in contact with SUMO1 and Ubc9.
I hypothesized that the integrity of the αC-helix is crucial to hold Ubc9 and
SUMO1 in the folded-back conformation and hence crucial for catalysis. To test
this hypothesis, I sought to create RanBP2 mutants that are unable to form the
αC-helix by mutating a conserved lysine residue in the middle of the helix to a pro-
line (K2645P in IR1 and K2723P in IR2). This lysine was chosen, as its side chain
points away from SUMO1 and Ubc9. Moreover mutations of this lysine to alanine
(K2645A) did not show any catalytic defects [Pichler et al., 2004].
Indeed, the BD34 K2645P mutant (as well as the K2645P/ K2723P double mu-
tant) was catalytically almost inactive (Figure 22A). The K2723P variant showed
similar activity as the wild-type protein, which is in line with the idea that the
IR2 region is inactive in free RanBP2. The catalytic phenotype of these helix-
breaking mutants mirrors the effect of the SUMO1- and Ubc9-binding deficient
mutants (mIR1 and mIR2 - Figure 20A). In sharp contrast to the binding deficient
mutants however, the helix-breaking mutants showed almost no defect in thioester
mimic binding (Figure 22B). This suggests that the ability to form the αC-helix is
crucial to IR1-mediated catalysis, yet not for binding of the thioester mimic.
2.1.4 The RanBP2 complex as a SUMO E3 ligase
The findings above explain nicely how IR1 in free RanBP2 exerts E3 ligase activity.
However, the endogenously relevant SUMO E3 ligase is the RanBP2 complex, where
IR1 is permanently occupied by RanGAP1*SUMO1 and Ubc9 [Werner et al., 2012].
I hence went on to study the catalytic mechanism of this complex. The insights and
tools from above served to guide the analysis described below.
In the RanBP2 complex, the putative SIM and canonical Ubc9-binding sites
of IR2 are important for catalysis and binding of the thioester mimic
In the RanBP2 complex, the IR1 region is permanently occupied by RanGAP1*
SUMO1 and Ubc9 and is thus not available for catalysis. The IR2 region, which
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is inactive in free RanBP2, takes over [Werner et al., 2012]. The canonical binding
site for Ubc9 in IR2 (involving e.g. L2729, L2731 and F2736 of IR2) was shown to
be crucial for catalysis. Mutation of the hydrophobic residues of the putative SIM
in IR2 (mSIM2 = I2711A/I2712A - see Table 1) was found to have no significant
effect on SUMOylation of the substrate Borealin. This view was supported by the
fact that the cluster of three N-terminal acidic residues of SIM1, which defines it
as a SIMr motif (compare to Section 1.1.2), is not conserved in the putative SIM2;
here, the second residue is a basic lysine (see Figure 6C and 25A). Yet, mutations in
the SIM-interacting β2-strand of SUMO1 decreased SUMOylation efficiency com-
pared to wild-type SUMO1, which suggests the involvement of a SIM-like interaction
[Werner et al., 2012].
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Figure 23: Residues in the potential SIM of IR2 in the BD34 complex are
important for catalysis. (A) Time course of in vitro SUMOylation reactions of the
His6Borealin/Survivin/INCENP(1-58) complex (500 nM) were performed with the SUMO E1
enzyme (50 nM), Ubc9 (100 nM), SUMO1 (10 µM) and BD34 complex variants (25 nM each)
as indicated. Samples were analyzed for substrate SUMOylation by αBorealin (left) and auto-
SUMOylation by αRanBP2 immunoblot (right). S1 = SUMO1; mSIM2 = I2711A/I2712A. (B)
SUMOylation reactions as in (A) with different BD34 complex variants. Only auto-SUMOylation
was analyzed here. Bor = Borealin; S1 = SUMO1; BD34*xS1 = multiply SUMOylated BD34;
mSIM2 = I2711A/I2712A; mSIM2* = I2712A/V2713A; mUbc9 = L2729A/L2731A/F2736A; mIR2
= I2712A/V2713A/L2729A/L2731A/F2736A.
When trying to reproduce these findings in in vitro SUMOylation assays, I ob-
served a mild, but reproducible catalytic defect for the BD34 mSIM2 complex variant
in SUMOylation of Borealin (about 2-3 fold less active than wild-type); however,
auto-SUMOylation was severely impaired (Figure 23A). Since the mSIM2 mutation
does not exactly correspond to the mutations in SIM1 (I2634A/V2635A - see also
Figure 6C and 25A), I also generated and tested the corresponding mSIM2* mutant
(= I2712A/V2713A - see Table 1 and Figure 23B). Again, the mSIM2* mutation in
the BD34 complex caused a striking catalytic defect in BD34 auto-SUMOylation,
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which was comparable to the one caused by mutation of the canonical Ubc9-binding
site in IR2 (mUbc9 = L2729A/L2731A/F2736A - see Table 1) (Figure 23B). In line
with this finding, a BD34 complex variant with the combined mutations (mIR2 =
I2712A/V2713A/L2729A/L2731A/F2736A - see Table 1) displayed an even stronger
defect in BD34 auto-SUMOylation.
How can the difference between earlier findings of our group and my work be recon-
ciled? The most likely explanation is that in substrate SUMOylation other aspects,
such as substrate recognition may become rate-limiting, thereby masking a reduc-
tion of E3 ligase efficiency in earlier experiments. Analysis of auto-SUMOylation is
the most direct indicator for E3 ligase activity.
My observations clearly indicate an involvement of the putative SIM2 in RanBP2
complex-mediated catalysis. To confirm this on the binding-level, I performed gel
filtration binding assays with the BD34 complex variants described above and ob-
served a defect in binding of the Ubc9-K*SUMO1 thioester mimic in case of the
mSIM2* complex variant as well as for the mUbc9 complex variant; the combined
mIR2 mutation caused an additive defect (Figure 24). These findings suggest that
in the RanBP2 complex, the putative SIM2 cooperates with the Ubc9-binding site
of IR2 in interacting with the thioester.
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Figure 24: The canonical Ubc9-binding site and the potential SIM of IR2 in the
BD34 complex are involved in thioester mimic binding. Gel filtration binding assays were
performed with free BD34 variants, BD34 complex variants and the Ubc9-K*SUMO1 thioester
mimic (2 µM each) as indicated. Pre-incubated proteins were run over Superdex200 5/150
GL gel filtration column. Samples were collected at 0.46 CV for the free BD34 variants, at
0.42 CV for the BD34 complex variants and analyzed by Colloidal Coomassie-stained SDS-PAGE
gel. S1 = SUMO1; mSIM2* = I2712A/V2713A; mUbc9 = L2729A/L2731A/F2736A; mIR2 =
I2712A/V2713A/L2729A/L2731A/F2736A.
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In an in silico approach, I modeled the binding of the putative SIM2 to the
β2-strand of SUMO1 based on the antiparallel binding of the SIM1 (modeling by
SWISS-Model based in PDB: 1Z5S - Figure 25A).
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Figure 25: Structural model of a SUMO/SIM interaction involving IR2. (A) Top left:
Ribbon structure of the SIM of IR1 (grey) binding to SUMO1 (olive) (PDB: 1Z5S). Those residues
whose side chains are involved in the SUMO/SIM interaction are shown and labeled. Interactions
are denoted by dashed lines. Bottom left: Alignments of IR1 an SUMO1 residues based on binding
(see top). Vertical lines indicate a hydrophobic interaction or salt bridge; a diagonal line denotes
a hydrogen bond between side chains; grey boxes refer to β-strands in the structure; blue residues
are part of the SIMr consensus motif; green residues take part in the β-augmentation, but are not
part of the SIMr consensus motif. Top right: Structural model of the N-terminal sequence of IR2
(grey) binding to SUMO1 (based on PDB: 1Z5S). Bottom right: Alignments of IR2 an SUMO1
resides based on binding. Coloring an symbols as on the left; the red lysine 2708 denotes a clear
break with the SIMr consensus motif. (B) Time course of in vitro SUMOylation reactions of
the His6Borealin/Survivin/INCENP(1-58) complex (500 nM) were performed with the SUMO E1
enzyme (50 nM), Ubc9 (100 nM), SUMO1 (10 µM) and BD34 complex variants (25 nM each) as
indicated. Samples were (Figure 25B) analyzed for auto-SUMOylation by αRanBP2 immunoblot.
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As alluded to in the introduction, a striking feature of the SUMO1/SIM1 inter-
action is the fact that the β-augmentation involves the hydrophobic residues of the
SIMs as well as the residues C-terminal of it, which by definition are part of the
SIMr consensus motif (see also Section 1.1.5). The modeled putative SIM2 aligned
in a similar way: aside from the main chain hydrogen bonds by β-augmentation,
hydrophobic interactions ([SUMO1]H35-[SIM1]Y2636/[SIM2]W2714, [SUMO1]F36-
[SIM1]I2634/[SIM2]I2712, [SUMO1]V38-[SIM1]I2632/[SIM2]C2710), a hydrogen bond
([SUMO1]E33-[SIM1]Y2636/[SIM2]W2714) and a salt bridge ([SUMO1]K39-[SIM1]
D2631/[SIM2] E2709) between side chains were visible in the model.
In order to evaluate the in silico model, I tested a BD34 complex variant, in
which tryptophan 2714 C-terminal of the putative SIM2 was mutated (W2714A -
the model predicted an interaction between this residue and histidine 35 of SUMO1).
I observed a clear catalytic defect of this complex variant in auto-SUMOylation (Fig-
ure 25B).
Interestingly, the model showed an additional salt bridge ([SUMO1]E33-[SIM2]
K2716), which has no equivalent in the SUMO1/SIM1 interaction. A BD34 complex
variant, which should not be able to form this alleged salt bridge (BD34 K2716A),
indeed showed a catalytic defect in comparison to the wild-type (Figure 25B). Taken
together, these observations validate the in silico model on the one hand an on the
other show that the residues C-terminal of the hydrophobic SIM residues integrally
partake in binding. This as well as the lysine in the N-terminal acidic patch is atyp-
ical for a classical SIMr motif, which is why the interaction between SUMO1 and
the putative SIM2 will be continued to be referred to a SIM-like interaction.
IR2 in the BD34 complex is less crucial for catalysis and thioester mimic
binding than IR1 in the free BD34.
As previously shown [Werner et al., 2012], a direct comparison of activities of the
free BD34 fragment and the BD34 complex showed higher E3 ligase activity of the
former (Figure 26A - not auto-, but substrate SUMOylation was chosen as a measure
of E3 ligase activity here, as substrate lysine residues in BD34 might be occluded by
complex formation). Yet, the catalytic defect of the BD34 mIR2 complex appeared
to be less pronounced than that of the corresponding free BD34 mIR1 fragment.
In binding assays, the thioester mimic co-migrated with the BD34 complex, but
co-migration was less pronounced than for the free BD34 fragment. The mIR2
mutation in the BD34 complex resulted in a decrease of stable thioester mimic
binding (Figure 26B), which is in line with results from activity assays.
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Figure 26: IR2 in the BD34 complex is less crucial for catalysis than IR1 in the
free BD34. (A) Time course of in vitro SUMOylation reactions of YFP-Sp100 (500 nM) were
performed with the SUMO E1 enzyme (100 nM), Ubc9 (50 nM), SUMO1 (10 µM), free BD34
variants and BD34 complex variants (25 nM each) as indicated. Samples were analyzed by αGFP
(top) and αRanBP2 immunoblot (bottom). (B) Gel filtration binding assays were performed
with free BD34, BD34 complex variants and the Ubc9-K*SUMO1 thioester mimic (2 µM each)
as indicated. Pre-incubated proteins were run over Superdex200 5/150 GL gel filtration column.
Samples were collected at 0.46 CV for the free BD34 variants, at 0.42 CV for the BD34 complex
variants and analyzed by Colloidal Coomassie-stained SDS-PAGE gel. S1 = SUMO1; * BD34
degradation fragment. Of note, the left panels in are identical to Figure 20 (shown for comparison).
In the RanBP2 complex, the integrity of the αC-helix of IR2 is involved, but
not crucial for catalysis and binding of the thioester mimic
Having confirmed the principle involvement of SUMO1- and Ubc9-binding by
residues in IR2 for RanBP2 complex-mediated catalysis, I wanted to address the
role of a potential αC-helix in IR2. The sequence of the αC-helix in IR1 is conserved
in IR2 with two proline residues flanking the sequences (Figure 6C). The crystal
structure of a minimal version of the RanBP2 complex was published using an IR1
fragment, in which the sequence of the αC-helix had been swapped for that of IR2
[Gareau et al., 2012]. Also in this structure, the α-helix formed indicating that IR2
has at least the same potential to form a corresponding helix.
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Comparing the E3 ligase activity of a RanBP2 complex built with a BD34 frag-
ment in which the αC-helix of IR2 cannot form (K2723P) with the wild-type, I
observed only a slight catalytic defect (Figure 27A). This as surprising, as the free
BD34 K2645P variant is completely inactive. In binding assays, I observed that the
BD34 K2723P complex bound the thioester mimic a less stably than the wild-type
complex, which is again in contrast to the results for free BD34 fragments where the
K2645P mutation in IR1 did not have an effect on binding (Figure 27B).
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Figure 27: The integrity of the αC-helix of IR2 in the RanBP2 complex is impor-
tant, but not crucial for catalysis and thioester mimic binding. (A) Time course of in
vitro SUMOylation reactions of YFP-Sp100 (500 nM) were performed with the SUMO E1 enzyme
(100 nM), Ubc9 (50 nM), SUMO1 (10 µM), free BD34 variants and BD34 complex variants (25 nM
each) as indicated. Samples were analyzed by αGFP (top) and αRanBP2 immunoblot (bottom).
(B) Gel filtration binding assays were performed with free BD34 variants, BD34 complex vari-
ants and the Ubc9-K*SUMO1 thioester mimic (2 µM each) as indicated. Pre-incubated proteins
were run over Superdex200 5/150 GL gel filtration column. Samples were collected at 0.46 CV
for the free BD34 variants, at 0.42 CV for the BD34 complex variants and analyzed by Colloidal
Coomassie-stained SDS-PAGE gel. S1 = SUMO1; GAP*S1 = RanGAP1*SUMO1; * BD34 degra-
dation fragment. Of note, the left panels in (A) (B) is identical to Figure 22; they are shown for
comparison.
The folded-back thioester conformation affects catalysis and binding of the
thioester mimic to the RanBP2 complex
Lastly, I wanted to assess the effect of the folded-back thioester conformation
for the RanBP2 complex. As for the free BD34 fragment, mutants affecting the
folded-back thioester conformation also influenced catalysis mediated by the BD34
complex. While the Ubc9/SUMO1 open mutants clearly decreased SUMOylation
efficiency in single turnover assays, the charge swap Ubc9/SUMO1 closed mutation
restored SUMOylation efficiency to some degree (Figure 28A). Results from binding
assays mirrored those from the activity assays with the Ubc9/SUMO1 open mimic
binding less stably to the BD34 complex and the Ubc9/SUMO1 closed mimic dis-
playing an even stronger binding than the wild-type mimic (Figure 28B).
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Figure 28: The conformation of the Ubc9∼SUMO1 thioester affects binding to and
catalysis mediated by the RanBP2 complex. (A) A time course of in vitro SUMOylation
reactions of YFP-Sp100 under single turnover conditions was performed. First, Ubc9∼SUMO1
thioester variants were pre-formed with 1.6 µM E1 enzyme, 8 µM Ubc9 variants and 24 µM
SUMO1 variants as indicated. Pre-forming reactions were quenched by EDTA and analyzed by
alphaUbc9 immunoblot (bottom). Pre-forming reactions were diluted 1:16 into SUMOylation
reactions containing 1 µM YFP-Sp100 and 25 nM BD34 complex. SUMOylation reactions were
analyzed by αGFP (top) immunoblot. (B) Gel filtration binding assays were performed with
the BD34 complex and Ubc9-K*SUMO1 thioester mimic variants (2 µM each) as indicated. Pre-
incubated proteins were run over Superdex200 5/150 GL gel filtration column. Samples were
collected at 0.42 CV and analyzed by Colloidal Coomassie-stained SDS-PAGE gel. S1 = SUMO1;
GAP*S1 = RanGAP1*SUMO1; Ubc9∼S1 = Ubc9∼SUMO1 thioester.
Particularly the results from the binding assays revealed a key difference between
the BD34 complex and the free BD34 fragment: while the latter appeared to be
able to bind the thioester in multiple conformations and subsequently stabilize the
folded-back conformation (Figure 29A), my results for the BD34 complex suggested
more stable binding of the catalytically productive folded-back conformation. This
suggests a catalytic mechanism for the RanBP2 complex where thioester binding
and catalysis are much more intimately connected.
Compatible with this finding, the integrity of the αC-helix was not as crucial to
catalysis for the complex as for the free BD34. Consequently, the key to catalysis
mediated by the RanBP2 complex lies in the binding of the thioester, which depends
on IR2. Interestingly, the IR2 region in the free BD34 fragment supported stable
thioester binding, but features hardly any catalytic activity (Figure 29B), while the
RanBP2 complex bound the thioester comparably weak, yet was active as an E3
ligase. The catalytic defect of the mIR2 mutation in the BD34 complex was much
less pronounced than that of the IR1 mutation for the free BD34.
Taken together these findings are compatible with a model where the RanBP2
complex, apart from IR2, features at least a second binding surface for the thioester,
possibly provided by the components of the complex, i.e. RanGAP1*SUMO1 and/or
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Ubc9 [Werner et al., 2012]. This would explain the decreased dependency of catal-
ysis on IR2 in the RanBP2 complex. This second binding surface has to be shaped
in a way that does not allow flexible binding of the thioester regardless of its confor-
mation (like for IR2 in the free BD34 fragment), but that preferentially samples the
folded-back conformation (Figure 29C). In that way it would account for the nega-
tive effect of Ubc9/SUMO1 open mimic on binding as well as also for the decreased
stability of binding of the thioester mimic to IR2 in the complex.
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Figure 29: Working model of thioester binding and catalysis by free RanBP2 and the
RanBP2 complex. Schematic depicting the binding of the Ubc9∼SUMO1 thioester (green) to
IR1 (A) and IR2 (B) to free RanBP2 as well as to the RanBP2 complex (C). Left: thioester in the
open conformations. Right: thioester in the folded-back conformation. IR1 and IR2 in the free
RanBP2, possibly due to their unfolded nature, can interact with the thioester in a great variety
of flexible conformations. IR1 is able to stabilize the folded-back conformation after thioester
binding, possibly due to the formation of the αC-helix, which results in catalysis. IR2 seems to
be defective in this respect. The RanBP2 complex, possibly due to steric restraints imposed by
its overall structure (grey oval), cannot accommodate every thioester conformation, but rather
specifically samples the folded-back conformation. This immediately entails catalysis. In the
RanBP2 complex, IR2 is involved in binding of the thioester, yet since IR2 alone is not able to
stabilize the folded-back conformation, an additional binding site is suspected (red star).
2.1.5 Mapping thioester interaction sites within the RanBP2
complex by NMR (in collaboration with teh group of
Teresa Carlomagno)
In order to map the potential additional binding surface of the thioester within
the RanBP2 complex, I wanted to employ methyl chemical shift experiments us-
ing NMR (nuclear magnetic resonance). For this, a collaboration was established
with the group of Teresa Carlomagno (EMBL, Heidelberg). Isotope-labeled proteins
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for these experiments were expressed together with Gerry Meese from the Melchior
group (see below); measurements and analyses were performed by Léo Nesme of the
Carlomagno group.
In these experiments, the thioester mimic and a small version of the RanBP2
complex was used, which featured Ubc9, SUMOylated GAPtail (i.e. the C-terminal
domain of RanGAP1) and the ∆FG fragment (Figure 30). The ∆FG fragment is
a 32 kDa fragment from amino acids position 2553 to 2838, which contains the IR
region excluding the flanking FG-repeat patches; the corresponding 72 kDa variant
of the RanBP2 complex will simply be referred to as “RanBP2 ∆FG complex” or
simply “∆FG complex”. One set of proteins was expressed as 2H,15N-labeled pro-
teins and thus do not give rise to signals in NMR. Ubc9, SUMO1 and GAPtail were
also expressed as IVL-labeled proteins, i.e. in addition to the general 2H,15N-label,
isoleucine, valine and leucine residues in these proteins contained one 2H,12C-labeled
and one 1H,13C-labeled methyl group (in isoleucine it is always the δ1 methyl group
which is 1H,13C-labeled and the γ2 methyl group which is 2H,12C; for leucine and
valine the methyl groups were not stereoselectively labeled). The IVL-labeled pro-
teins give rise to signals in NMR spectra due to their 1H,13C-labeled methly groups.
With these proteins, complex variants were reconstituted: each contained either
GAPtail, Ubc9 or SUMO1 with the IVL-label. The methly chemical shift spec-
tra of these complexes were recorded before and upon titration with 2H,15N-labeled
thioester mimic to detect CSPs (chemical shift perturbations, i.e. alterations of the
chemical shifts) as well as possible intensity losses in the chemical shift peaks. These
alterations may be indicative of a change in interaction. A RanBP2 ∆FG complex
with an IVL-labeled ∆FG variant was not measured, since the protein is largely
unfolded and hence is not expected to yield an analyzable spectrum in NMR.
In order to assign peaks in the spectra to the isoleucine, valine and leucine
side chain residues, firstly the backbone assignments of free 13C/15N-labeled GAP-
tail, Ubc9 and SUMO1 were confirmed from deposited chemical shift spectra using
classical NMR experiments (BMRB accession number for SUMO1(NH): 6304, for
GAPtail(HCN): 6305, for GAPtail*SUMO1(NH): 6306 [Macauley et al., 2004]; for
Ubc9(HCN): 4132 [Liu et al., 1999]; for SUMO with SIM(HCN): 17536 [Namanja
et al., 2012]). All peaks could be assigned for the free proteins. Secondly, in or-
der to follow the chemical shift peaks from the free form to the state within the
RanBP2 ∆FG complex, reference titration experiments were performed: free IVL-
labeled Ubc9 was titrated with 2H,15N-labeled GAPtail*SUMO1 and SUMOylated
IVL-labeled GAPtail was titrated with 2H,15N-labeled Ubc9, respectively (the chem-
ical shifts of SUMO1 in the RanBP2 ∆FG complex showed sufficient similarity to
the free form to assign them confidently without a reference titration).
54 RESULTS CHAPTER 2
Building of differently labe-
led RanBP2 complex vari-
ants  and the thioster mimic
recording of methly chemical 
shift spectra of the RanBP2 com-
plex variants  before and upon 
titration of thioester mimic 
IR1 IR2
GAPtail
SUMO1 Ub
c9
IR1 IR2
GAPtail
SUMO1 Ub
c9
_ SUMO1
Ubc9
IR1 IR2
GAPtail
SUMO1 Ub
c9
+
0.00.51.0
15
20
25
Protein expression with
 different isotope labeles
Ubc9
IR1 IR2
GAPtail
SUMO1
Ubc9
GAPtail
SUMO1
completely deuterated proteins
deuterated proteins with 
13C,1H-labeled methyl groups 
of Ile, Val and Leu
“invisible” in NMR “visible” in NMR
Figure 30: Schematic depiction of IVL-labeling scheme and NMR experiments. Top:
For NMR experiments a RanBP2 complex variant was used which contained the ∆FG fragment,
full-length Ubc9 and SUMOylated GAPtail. Proteins for this complex as well as the thioester
mimic were 2H,15N-labeled by expression in minimal medium in 2H2O using 2H-glycerol as the
main carbon source and 15N4Cl as the nitrogen source (grey proteins). These proteins did not
give rise to peaks in NMR spectra. Additionally, 2H,15N-labeled Ubc9, SUMO1 and GAPtail were
expressed in the presence of precursors of the amino acids isoleucine, valine and isoleucine, in which
one methyl group each is labeled 1H,13C and 2H,12C (= IVL-labeling). For these proteins, methyl
peaks were detected in NMR spectra (colored proteins). Bottom: Three 2H,15N labeled RanBP2
complex versions were built with either GAPtail, Ubc9 or SUMO1 IVL-labeled; a completely
2H,15N labeled thioester mimic was built. Due to the distance between GAPtail and RanBP2
in the crystal structure of the RanBP2 complex, we did not expect any contacts between them.
Therefore, we decided to express the ∆FG fragment in the RanBP2 complex with IVL-labeled
GAPtail was expressed unlabeled in LB medium. Methly spectra of each RanBP2 complex version
alone as well as upon titration of the thioester mimic were recorded and subsequently peaks were
assigned to the isoleucine, valine and leucine side chains in the proteins. Proteins were expressed
by myself together with Gerry Meese from the Melchior group. Measurements and analyses were
performed by Léo Nesme of the Carlomagno group.
In the reference titrations, we decided to omit ∆FG fragment in fear of partly
forming a complex in which RanBP2 binds two molecules of Ubc9 and GAPtail*SUMO1
on IR1 and IR2; moreover, Ubc9 and GAPtail*SUMO1 form a stable complex on
CHAPTER 2 RESULTS 55
their own ([Bernier-Villamor et al., 2002], PDB: 1KPS), the structure of which is
very similar to the conformation of Ubc9 and GAPtail*SUMO1 within the RanBP2
complex ([Reverter and Lima, 2005], PDB: 1Z5S).
In that way, most of the chemical shift peaks could unequivocally be re-assigned
within the RanBP2 ∆FG complex. However for some, the signal was lost so that
they could not be used in the following analysis. In the reference titration experi-
ments, SUMOylated, IVL-labeled GAPtail showed some CSPs upon titration with
Ubc9: they largely mapped to the interface of the to α-helical bundles within GAP-
tail and to the interface with Ubc9 in the RanBP2 complex; particularly the latter
finding was to be expected. IVL-labeled Ubc9 showed numerous CSPs upon GAP-
tail*SUMO1 titration, which is also understandable given its locked position within
the RanBP2 complex between GAPtail, SUMO1 and IR1.
In the following paragraphs, changes of the methyl chemical shift spectra of Ubc9,
SUMO1 and GAPtail within the RanBP2 complex upon thioester mimic titration
are discussed. In the RanBP2 complex with IVL-labeled-GAPtail, no significant
CSPs were observed upon mimic titration (Figure 31A and B). For several chemical
shift peaks a considerable loss of intensity (more than 50%) was observed, which
clustered to the N-terminal helix bundle and the C-terminal helix bundle, which
faces Ubc9 (Figure 31C and Table 2). However, the median of these intensity losses
(50.4%) was substantially lower than for the RanBP2 complexes with IVL-labeled
Ubc9 (82.0%) or SUMO1 (69.3% - see sections below).
Taken together, the changes in GAPtail were thus considered not to be caused by
relevant interactions of the thioester mimic with GAPtail in the RanBP2 complex.
This interpretation is in line with the large distance between RanBP2 and GAPtail.
Of note, due to the lack of contacts between GAPtail and RanBP2 and their dis-
tance in the crystal structure of the RanBP2 complex, the ∆FG fragment for the
RanBP2 complex with IVL-labeled GAPtail was expressed unlabeled in standard
LB medium. The high flexibility of the ∆FG fragment and the natural abundance
of 13C gave rise to additional methyl peaks from the ∆FG fragmentat the positions
observed in the free form of RanBP2. These cross peaks were however distinguish-
able from the GAPtail peaks which allowed us to discount them (Figure 31A).
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Figure 31: Summary of changes in the RanBP2 complex with IVL-labeled GAP-
tail upon titration of the thioester mimic. (A) Methyl chemical shift spectra of the
RanBP2 complex with IVL-labeled GAPtail (60 µM) were recorded before and upon titration
with 2H,15N-labeled thioester mimic (0.2, 0.33, 0.5, 0.67, 1.0, 2.0 and 4.0 molar equivalents) using
(H)CC(CO)NH-TOCSY and H(CCCO)NH-TOCSY. The spectra before (red), upon titration with
0.5 (green) and with 4.0 (blue) molar equivalents of the mimic are displayed. Unlabeled peaks
stem from unlabeled RanBP2 ∆FG, which was used in this particular experiment (see text). (B)
Mapping of CSPs onto the GAPtail structure. Structure of the RanBP2 complex (PDB: 1Z5S) is
shown with the 2H,15N-labeled proteins shown in grey and the IVL-labeled GAPtail in orange. The
labeled methly groups are represented by spheres. No considerable CSPs were detected in GAP-
tail; a chemical shift peak for valine 529 (black) couldn’t be assigned. (C) Mapping of intensity
losses onto the GAPtail structure. Structure as in (B). Residues of GAPtail with chemical shift
peak intensity losses are colored in dark blue (drastic intensity losses of more than 80%) or cyan
(moderate intensity losses between 50% and 80%). Measurements and analyses were performed by
Léo Nesme of the Carlomagno group.
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Table 2: Intensity losses of chemical shift peaks for IVL-labeled GAPtail upon
thioester mimic titration
Residue Intensity Residue Intensity Residue Intensity
I414 0.496 V476.a 0.454 L535.b 0.299
L415.a 0.795 V476.b 1.955 L539.a 1.664
L415.b 0.806 V479.a 0.543 L539.b 0.423
V425.a 0.801 V479.b 0.096 L542.a 0.391
V425.b 0.768 V486.a 0.459 L542.b 1.618
L426.a 0.807 V486.b 0.684 V546.a 0.168
L426.b 0.748 V490.a 0.438 V546.b 1.131
V434.a 0.500 V490.b 0.386 L555.a 0.420
V434.b 0.499 V494.a 0.520 L555.b 2.877
L438.a 0.631 V494.b 0.520 L558.a 0.864
L438.b 0.590 L497.a 0.641 L558.b 0.473
L446.a 0.463 L497.b 0.412 L559.a 0.516
L446.b 0.407 L513.a 1.354 L559.b 0.543
L447.a 3.418 L513.b 0.637 L560.a 0.481
L447.b 1.010 L516.a 0.351 L560.b 0.596
L449.a 0.468 L516.b 0.120 V563.a 0.375
L449.b 0.472 L517.a 0.203 V563.b 0.375
V455.a 0.531 L517.b 0.686 L570.a 0.260
V455.b 0.481 V518.a 0.176 L570.b 0.260
L456.a 0.389 V518.b 0.327 L580.a 3.537
L456.b 0.388 L522.a 0.635 L580.b 3.537
I457 0.416 L522.b 0.435 L581.a 0.319
V469.a 0.477 L523.a 0.630 L581.b 0.432
V469.b 0.460 L523.b 0.821 L584.a 0.629
V470.a 0.377 V529.a N/A L584.b 1.004
V470.b 0.398 V529.b N/A V587.a 0.583
L474.a 0.892 I532 0.815 V587.b 0.496
L474.b 0.892 L535.a 0.307
Intensity is expressed as a ratio of peak intensity before and after titration of 4.0 molare equiva-
lents of the thioester mimic. “N/A” signifies that this residue could not be re-assigned within the
RanBP2 complex and hence not analyzed. The non-stereoselectively labeled γ methly groups of
valine and the δ methyl groups of leucine are referred to by “.a” and “.b”. Table provided by Léo
Nesme of the Carlomagno group.
In contrast, multiple CSPs were observed in the RanBP2 complex with IVL-
labeled Ubc9 upon mimic titration. The most prominent CSPs were found in the
C-terminus of Ubc9 (isoleucine 125 and 136), near the Ubc9-backside (valine 27)
and clustering at the interface of Ubc9 and SUMO1 within the RanBP2 complex
(leucine 60, isoleucine 107, leucine 114 and 119 - Figure 32A, B and Table 3).
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Figure 32: Summary of changes in the RanBP2 complex with IVL-labeled Ubc9 upon
titration of the thioester mimic. (A) Methyl chemical shift spectra of the RanBP2 complex
with IVL-labeled Ubc9 (77 µM) were recorded before and upon titration with 2H,15N-labeled
thioester mimic (0.2, 0.4, 0.8, 1.0, 1.5 and 3.0 molar equivalents) using (H)CC(CO)NH-TOCSY
and H(CCCO)NH-TOCSY. The spectra before (red), upon titration with 0.4 (green) and with 3.0
(blue) molar equivalents of the mimic are displayed. Arrows indicate CSPs upon titration. (B)
Mapping of CSPs onto the Ubc9 structure. Structure of the RanBP2 complex (PDB: 1Z5S) is
shown with the 2H,15N-labeled proteins shown in grey and the IVL-labeled Ubc9 in plum. The
labeled methly groups are represented by spheres. Residues of Ubc9 which displayed CSPs are
colored in red (drastic CSPs larger than 0.1 ppm) or orange (moderate CSPs between 0.01 and
0.1 ppm). Chemical shift peaks that could not be assigned are shown in black. (C) Mapping of
intensity losses onto the Ubc9 structure. Structure as in (B). Residues of Ubc9 with chemical shift
peak intensity losses are colored in dark blue (drastic intensity losses of more than 80%) or cyan
(moderate intensity losses between 50% and 80%). Measurements and analyses were performed by
Léo Nesme of the Carlomagno group.
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In addition to the CSPs at residues at the Ubc9C/SUMO1C interface, drastic
losses in chemical shift peak intensities were observed for these residues (Figure 32C
and Table 3). Particularly, the changes at leucine 114 and 119 as well as isoleucine
107, which are part of or near the central α2-helix that interacts with SUMO1 in the
complex, were surprising: given a static and rigid structure of the RanBP2 complex,
theses residues are not accessible for thioester mimic binding. This finding suggested
that the RanBP2 complex changed its structure upon thioester mimic titration, i.e.
that it opened up at the Ubc9C/SUMO1C interface.
This notion is supported by the following observation. Isoleucine 125 of Ubc9
displayed a CSP from the free form to the GAPtail*SUMO1-bound form (which
mimics the RanBP2 complex) and then again upon thioester mimic titration to the
complex. Interestingly, the second CSP resembled the first CSP, but in reverse,
suggesting that isoleucine 125 within the RanBP2 complex upon thioester mimic
binding assumes a similar state as in the free Ubc9 (Figure 33) .
In SUMO1, no IVL residues are directly involved in this Ubc9C/SUMO1C inter-
face, so that complementary CSPs in the RanBP2 complex with IVL-labeled SUMO1
are not to be expected. However, an opening of this interface would inevitably result
in a (at least small) structural rearrangement of IR1 in RanBP2, particularly near
the αC-helix, as it forms the hinge between Ubc9 and SUMO1 in the complex. In
turn, this rearrangement should be relayed to the bound Ubc9 and SUMO1 in the
complex. Indeed, several residues in Ubc9 that contact IR1 displayed CSPs and
chemical shift peak intensity losses (valine 27 and to a lesser degree also isoleucine
4 and leucine 57), which is compatible with the structural changes described above.
Ubc9 (in complex) + 3.0x Mimic
Ubc9 (free) + 3.0x GAPtail*SUMO1
Ubc9 (free)
13C
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Figure 33: Methyl chemical shift spectra of isoleucine 125 in Ubc9. Methyl chemical shift
spectra of isoleucine 125 in IVL-labeled Ubc9 were recorded in the free form (83 µM) before (or-
ange) and upon titration (red) with 2H,15N-labeled GAPtail*SUMO1 (3.0 molar equivalents) using
(H)CC(CO)NH-TOCSY and H(CCCO)NH-TOCSY. Also shown is the spectrum of the RanBP2
complex with IVL-labeled Ubc9 (77 µM) titrated with 3.0 molar equivalents of 2H,15N-labeled
thioester mimic (blue spectrum - identical to spectrum shown in Figure 32A). Colored arrows
indicate CSPs upon titration. Measurements and analyses were performed by Léo Nesme of the
Carlomagno group.
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Table 3: CSPs and intensity losses of chemical shift peaks for IVL-labeled Ubc9 upon
thioester mimic titration
Residue CSP (ppm) Intensity Residue CSP (ppm) Intensity
I4 0.316 0.054 L94.a 0.141 0.005
L6.a 0.205 0.003 L94.b 0.122 0.019
L6.b 0.217 0.004 I96 0.136 0.003
L9.a 0.000 0.000 L97.a 0.114 0.022
L9.b 0.000 0.000 L97.b 0.224 0.015
V25.a 0.149 0.005 I107 0.080 0.113
V25.b 0.160 0.004 I109 0.129 0.010
V27.a 0.054 0.312 I112 0.168 0.006
V27.b 0.172 0.003 L113.a N/A N/A
L38.a N/A N/A L113.b N/A N/A
L38.b N/A N/A L114.a 0.186 0.188
I45 0.259 0.007 L114.b 0.000 0.244
L57.a 0.147 0.017 I116 0.152 0.008
L57.b 0.292 0.001 L119.a 0.187 0.140
L60.a 0.193 0.109 L119.b 0.535 0.166
L60.b 0.264 0.004 L120.a 0.289 0.041
L63.a 0.248 0.001 L120.b 0.289 0.041
L63.b 0.220 0.005 I125 0.292 0.472
L81.a 0.159 0.053 I136 0.311 0.278
L81.b 0.226 0.001 V142.a 0.193 0.005
V86.a 0.000 0.000 V142.b 0.180 0.003
V86.b 0.180 0.016 V148.a N/A N/A
V92.a 0.174 0.018 V148.b N/A N/A
V92.b 0.166 0.008
Intensity is expressed as a ratio of peak intensity before and after titration of 3.0 molar equiva-
lents of the thioester mimic. “N/A” signifies that this residue could not be re-assigned within the
RanBP2 complex and hence not analyzed. The signal of residues marked in red was lost upon
mimic titration. The non-stereoselectively labeled γ methly groups of valine and the δ methyl
groups of leucine are referred to by “.a” and “.b”. Table provided by Léo Nesme of the Carlomagno
group.
Mimic titration of the RanBP2 complex with IVL-labeled SUMO1 only resulted
in a clear CSPs for valine 87 (Figure 34C). In addition, several residues which faced
the same surface (e.g. isoleucine 27) displayed chemical shift intensity losses. In-
terestingly, these residues are positioned at a surface in SUMO1 that is known to
be involved in the non-covalent backside interaction with Ubc9; in fact, valine 87
and isoleucine 27 are the only two IVL residues in SUMO1 whose side chains are
involved in the backside interaction [Knipscheer et al., 2007].
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Figure 34: Summary of changes in the RanBP2 complex with IVL-labeled SUMO1
upon titration of the thioester mimic. (A) Methyl chemical shift spectra of the RanBP2
complex with IVL-labeled SUMO1 (73 µM) were recorded before and upon titration with 2H,15N-
labeled thioester mimic (0.2, 0.4, 0.8, 1.0, 2.0 and 4.0 molar equivalents) using (H)CC(CO)NH-
TOCSY and H(CCCO)NH-TOCSY (Spectra were obtained by Léo Nesme, group of Teresa Carlo-
magno at the EMBL, Heidelberg). The spectra before (red), upon titration with 0.4 (green) and
with 4.0 (blue) molar equivalents of the mimic are displayed. X and Y denote unassigned peaks
(possibly contaminations from the thioester mimic). (B)Mapping of CSPs onto the SUMO1 struc-
ture. Structure of the RanBP2 complex (PDB: 1Z5S) is shown with the 2H,15N-labeled proteins
shown in grey and the IVL-labeled SUMO1 in purple. The labeled methly groups are represented
by spheres. Valine 87 (red) was the only residue which displayed a CSPs upon thioester mimic
titration. A chemical shift peak for valine 26 (black) couldn’t be assigned. (C) Mapping of inten-
sity losses onto the SUMO1 structure. Structure as in (B). Residues of SUMO1 with chemical shift
peak intensity losses are colored in dark blue (drastic intensity losses of more than 80%) or cyan
(moderate intensity losses between 50% and 80%). Measurements and analyses were performed by
Léo Nesme of the Carlomagno group.
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The NMR data hence seemed to indicate that, upon titration of the thioester
mimic to the RanBP2 complex, the SUMO1 molecule in the complex (= SUMO1C)
engaged in a backside interaction with a Ubc9 molecule. While in principle, this in-
teraction could have involved Ubc9C , I deemed this possibility highly unlikely, since
in the structure of the RanBP2 complex the backside surface of Ubc9C faces away
from SUMO1C and is moreover engaged in an interaction with IR1 (of note, there
are no IVL side chains involved in the backside interaction surface of Ubc9).
In turn, this prompts the hypothesis, that SUMO1C engages in a backside inter-
action with Ubc9T . However, while the surface on SUMO1C is solvent-accessible
in the RanBP2 complex, Ubc9C is positioned in front of it. In fact, a rigid-body
modeling approach of the backside interaction between SUMO1C and Ubc9T using
the structure of the RanBP2 complex (PDB: 1Z5S) and the Ubc9/SUMO1 backside
interaction (PDB: 2UYZ) yielded major steric clashes between Ubc9T and Ubc9C
(Figure 35).
In combination, the NMR data motivate a model where the potential opening of
the RanBP2 complex at the Ubc9C/SUMO1C interface makes a backside interaction
between SUMO1C and Ubc9T during thioester binding possible.
Table 4: Intensity losses of chemical shift peaks for IVL-labeled SUMO1 upon thioester
mimic titration
residue Intensity residue Intensity residue Intensity
L13.a 0.609 V38.b 0.149 L65.b 0.430
L13.b 0.587 L44.a 0.447 I71 0.307
I22 0.266 L44.b 0.447 L80.a 0.339
L24.a 0.169 L47.a 0.402 L80.b 0.288
L24.b 0.169 L47.b 0.193 V87.a 0.271
V26.a N/A V57.a 0.335 V87.b 0.228
V26.b N/A V57.b 0.365 I88 0.191
I27 0.312 L62.a 0.223 V90.a 0.333
I34 0.241 L62.b 0.223 V90.b 0.217
V38.a 0.481 L65.a 0.483
Intensity is expressed as a ratio of peak intensity before and after titration of 4.0 molare equivalents
of the thioester mimic. “N/A” signifies that this residue could not be re-assigned within the RanBP2
complex and hence not analyzed. The non-stereoselectively labeled γ methly groups of valine and
the δ methyl groups of leucine are referred to by “.a” and “.b”. Table provided by Léo Nesme of
the Carlomagno group.
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Figure 35: Rigid-body modeling of the backside interaction between the SUMO1C
and the Ubc9T reveals steric clashes. Left: ribbon structure of the RanBP2 complex with
the SUMO1C in purple and the Ubc9C in plum (IR1 in black and GAPtail in orange - PDB: 1Z5S).
Right: Ribbon structure of the Ubc9/SUMO1 backside interaction with the potential SUMO1C in
purple and the potential Ubc9T in light green (PDB: 2UYZ). Isoleucine 27 and valine 87 of SUMO1,
which are involved in the backside interaction, are shown in dark green. Middle: Superposition of
the structures from left and right aligned to SUMO1.
2.1.6 A partial opening of the RanBP2 complex at the
Ubc9C/SUMO1C interface
In the next steps, I wanted to verify the opening of the RanBP2 complex at
the Ubc9C/SUMO1C interface as well as an interaction between the SUMO1C and
the Ubc9T by other methods. In order to test the effect of a potential opening
of the RanBP2 complex, I reconstituted BD34 complex variants using the Ubc9
and SUMO1 mutants that were able to tweak the folded-back conformation (Ubc9
L114Q/G115S and SUMO1 R63 = Ubc9C/SUMO1C open; Ubc9 E118R/E112R and
SUMO1 R63E = Ubc9C/SUMO1C closed). I reasoned that since Ubc9 and SUMO1
adopt a folded-back-like conformation in the RanBP2 complex, these mutants are
able to affect this conformation as well.
In order to test the potential of these complex variants, I performed isopeptidase
protection assays: within the RanBP2 complex, the isopeptide bond between Ran-
GAP1 and SUMO1 is largely protected from the action of SUMO proteases like
SENP1 [Werner et al., 2012, Zhu et al., 2009]. This protection is believed to stem
from the intimate and stable interaction between RanGAP1*SUMO1, Ubc9 and IR1
[Reverter and Lima, 2005, Werner et al., 2012].
As expected, when treated with a three-fold molar excess of the catalytic domain
of SENP1, RanGAP1*SUMO1 of the wild-type BD34 complex displayed only minor
deSUMOylation (Figure 36). The fraction of deSUMOylated RanGAP1*SUMO1
is believed to stem from improperly formed complex, as deSUMOylation did not
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increase proportionally over time (2 min, 30 min and 3 h). In contrast, free Ran-
GAP1*SUMO1 was deSUMOylated almost completely after 30 min.
time (min) 300 2 18030 02180 0 2
BD34 complex with
Ubc9C/SUMO1C 
30 180 0 30
wt open free RanGAP1*S1
A
B
closed
αRanGAP1
100 kDa
70 kDa
SUMO1C Ubc9C RanGAP1
Figure 36: The Ubc9C/SUMO1C conformation affects the stability of the RanBP2
complex. (A) Ribbon structure of the Ubc9C/SUMO1C interface within the RanBP2 complex
(PDB: 1Z5S). Ubc9 is shown in plum, SUMO1 in purple, IR1 in black (background) and the C-
terminal domain of RanGAP1 in orange (upper right corner). Mutated residues at the interface are
colored: Ubc9 L114 and G115 in grey, Ubc9 E118 and E122 in red and SUMO1 R63 in blue. The
potentially SENP1-sensitive isopeptide bond between SUMO1 glycine 97 and RanGAP1 lysine 524
is shown in cyan. (B) Isopeptidase protection assays with BD34 complex variants mutated at the
Ubc9C/SUMO1C interface. BD34 complex variants and free RanGAP1*SUMO1 wt (50 nM each)
were incubated with 150 nM SENP1 (SENP1 419-644 = catalytic fragment) as indicated. Samples
were analyzed by αRanGAP1 immunoblot. S1 = SUMO1.
A BD34 complex built with the Ubc9C/SUMO1C open mutants, which destabilize
the folded-back conformation, displayed a much stronger degree of RanGAP1*SUMO1
deSUMOylation than the wild-type complex. Importantly, even after 3h deSUMOy-
lation was not complete and thus much less efficient than for free RanGAP1*SUMO1
or a RanBP2 complex forced to form on IR2 [Werner et al., 2012]. These findings
suggest that the Ubc9C/SUMO1C open mutation is indeed able to subtly loosen
the structure of the BD34 complex (possibly by opening it at the Ubc9C/SUMO1C
interface) without compromising its structure entirely.
In contrast, a BD34 complex built with the Ubc9C/SUMO1C closed mutants
was less susceptible to RanGAP1*SUMO1 deSUMOylation than the wild-type com-
plex. This observation is in line with a subtle stabilization. In both BD34 complex
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variants the Ubc9C/SUMO1C mutants appeared to have changed the kinetics of
complex formation/de-formation, since they showed a proportional increase of Ran-
GAP1*SUMO1 deSUMOylation over time, while deSUMOylation in the wild-type
complex remained largely constant after 2 min. Next, I tested these BD34 com-
plex variants in binding and activity assays. Interestingly, the BD34 complex with
the Ubc9C/SUMO1C open mutants supported co-migration of the thioester mimic
to a slightly higher degree than the wild-type complex, while the situation was
reversed for the BD34 complex variant with the Ubc9C/SUMO1C closed mutants
(Figure 37A). In vitro SUMOylation assays revealed a higher E3 ligase activity for
the BD34 complex with the the Ubc9C/SUMO1C open mutation compared to the
wild-type, while the activity of the BD34 complex with the Ubc9C/SUMO1C closed
mutants was comparable to the wild-type (Figure 37B).
For the BD34 complex with the Ubc9C/SUMO1C closed mutants, the results from
the binding assay are in line with the model where thioester binding is facilitated
by an opening at the Ubc9C/SUMO1C interface within the complex. This effect did
however not translate to activity assays, as the mutant complex showed comparable
rather than reduced activity compared to the wild-type complex.
Corresponding data for the complex with the Ubc9C/SUMO1C open mutants
support the model, as their destabilizing effect resulted in stronger binding of the
thioester mimic and higher E3 ligase activity. In sum the mutational analysis sup-
ported the idea of a partial opening of the RanBP2 complex upon thioester binding.
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Figure 37: The relative position of Ubc9C and SUMO1C in the RanBP2 complex affects
binding of the thioester mimic and catalytic activity. (A) Gel filtration binding assays
were performed with BD34 complex variants and the thioester mimic (2 µM each) as indicated.
Pre-incubated proteins were run over Superdex200 5/150 GL gel filtration column. Samples were
collected at 0.42 CV and analyzed by Colloidal Coomassie-stained SDS-PAGE gel. (B) A time
course of in vitro SUMOylation reactions of YFP-Sp100 (500 nM) was performed with the SUMO
E1 enzyme (100 nM), Ubc9 (50 nM), SUMO1 (10 µM) and BD34 complex variants (25 nM each)
as indicated. Samples were analyzed by αGFP (top) and αRanBP2 immunoblot (bottom). S1 =
SUMO1; GAP*S1 = RanGAP1*SUMO1.
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However, I needed to rule out one alternative explanation for the striking gain of
activity: the destabilizing effect of the Ubc9C/SUMO1C open mutants may expose
the IR1 sequence, which is more active than the proper RanBP2 complex (see Sec-
tion 2.1.4). I reasoned that if this were the case, then the gain-of-function effects
in binding and activity assay would depend on IR1 and conversely not on IR2 (as
is the case for the proper BD34 complex). I thus reconstituted a BD34 complex
variant with the Ubc9C/SUMO1C open mutants and BD34 mIR2, which was shown
to be defective in binding the mimic and E3 ligase activity (see Section 2.1.4).
Binding assays showed that the mIR2 mutation in BD34 complex had a similarly
negative effect on thioester mimic binding regardless whether the BD34 complex had
been reconstituted with wild-type Ubc9C and SUMO1C or with the Ubc9C/SUMO1C
open mutants (Figure 38A). Essentially the same result was observed for the E3
ligase activity of the BD34 complex in auto-SUMOylation (Figure 38B). These find-
ings hence suggest a dependency of mimic binding and E3 ligase activity on IR2
despite the complex-opening Ubc9C/SUMO1C open mutants. Admittedly, the neg-
ative effect of the mIR2 mutation in both assays was slightly more pronounced in the
wild-type background than in the complex with the Ubc9C/SUMO1C open mutants.
However, given the antagonizing effects of the BD34 mIR2 mutation on the one hand
and the Ubc9C/SUMO1C open mutants on the other, this was to be expected.
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Figure 38: In a RanBP2 complex built with the complex-opening mutants, binding of
the thioester and catalysis depend on IR2. (A) Gel filtration binding assays were performed
with BD34 complex variants and the thioester mimic (2 µM each) as indicated. Pre-incubated
proteins were run over Superdex200 5/150 GL gel filtration column. Samples were collected at
0.42 CV and analyzed by Colloidal Coomassie-stained SDS-PAGE gel. (B) A time course of
RanBP2 auto-SUMOylation was performed with the SUMO E1 enzyme (100 nM), Ubc9 (50 nM),
SUMO1 (10 µM) and BD34 complex variants (25 nM each) as indicated. Samples were analyzed
by αRanBP2 immunoblot. S1 = SUMO1; GAP*S1 = RanGAP1*SUMO1; BD34*xS1 = multiply
SUMOylated BD34.
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2.1.7 A backside interaction between Ubc9T and SUMO1C
Having given evidence for an opening of the RanBP2 complex at the Ubc9C/SUMO1C
interface during thioester binding, I next wanted to address the potential backside
interaction between the SUMO1C and the Ubc9T as a result of this opening. For
the Ubc9/SUMO1 backside interactions, prototypic mutants in Ubc9 (H20D) and
SUMO1 (E67R) have been described, which are able to abolish this interaction be-
tween the isolated proteins [Knipscheer et al., 2007].
With these mutants, I reconstituted a thioester mimic and a BD34 complex,
respectively. When compared to wild-type proteins in binding assays, the BD34
complex with SUMO1 E67R displayed a defect in thioester binding. Similarly, the
thioester mimic with Ubc9 H20D showed decreased binding to the BD34 complex
(Figure 39A).
In vitro SUMOylation reactions under single turnover conditions showed compara-
ble levels of E3 ligase activity in substrate SUMOylation between the BD34 complex
built with the SUMO1 E67R variant and the wild-type complex (Figure 39B). A
clear defect in substrate SUMOylation was however observed when the Ubc9 H20D
variant was used for thioester formation instead of the wild-type. Thioester loading
with the Ubc9 H20D variants did not seem to be affected.
Both mutants, SUMO1 E67R and Ubc9 H20D, were designed to prevent the same
interaction, yet only the Ubc9 H20D mutant showed an effect in activity assays. I
hence wanted to verify its catalytic capability as a SUMO E2 enzyme. I tested the
mutant and the wild-type in E3 ligase-independent SUMOylation reactions under
multiple turnover conditions (Figure 39C). Here, YFP-Sp100 SUMOylation medi-
ated by the Ubc9 H20D variant was decreased, which suggested a general catalytic
defect of the E2 mutant. A similar defect of this mutant was observed in FRET
experiments (data not shown).
This was particularly surprising, as the Ubc9 H20D mutant had been described
to be as active as the wild-type in Sp100 in vitro SUMOylation [Knipscheer et al.,
2007]. However, the SUMOylation reactions performed in the published study used
almost exclusively SUMO2 for SUMOylation, which might have been less affected
by the H20D mutation. This puts the use of the Ubc9 H20D mutant to assess a
possible backside interaction between the RanBP2 complex and the Ubc9∼SUMO1
thioester during catalysis into question.
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Figure 39: Analysis of backside interaction-deficient Ubc9 and SUMO1 mutants in
RanBP2 complex-mediated catalysis. (A) Mutations in Ubc9T and SUMO1C , which prevent
a backside interaction, abolish an interaction between the RanBP2 complex and the thioester
mimic. Gel filtration binding assays were performed with the BD34 complex variants and thioester
mimic variants (2 µM each) as indicated. Pre-incubated proteins were run over Superdex200
5/150 GL gel filtration column. Samples were collected at 0.42 CV and analyzed by Colloidal
Coomassie-stained SDS-PAGE gel. (B)Amutation in the catalytically active Ubc9, which prevents
a Ubc9/SUMO-backside interaction, abolishes RanBP2 complex-dependent SUMOylation. A time
course of in vitro SUMOylation reactions of YFP-Sp100 under single turnover conditions was
performed. First, Ubc9∼SUMO1 thioester variants were pre-formed with 1.6 µM E1 enzyme, 8 µM
Ubc9 variants and 24 µM SUMO1 variants as indicated. Pre-forming reactions were quenched by
EDTA and analyzed by alphaUbc9 immunoblot (right). Pre-forming reactions were diluted 1:16
into SUMOylation reactions containing 1 µM YFP-Sp100 and 25 nM BD34 complex variants.
SUMOylation reactions were analyzed by αGFP (left) immunoblot. (C) The Ubc9 H20D variant
shows a catalytic defect in E3 ligase-independent SUMOylation. A time course of E3 ligase-
independent in vitro SUMOylation reactions of YFP-Sp100 (1 µM) was performed with the SUMO
E1 enzyme (150 nM), Ubc9 variants (500 nM) and SUMO1 (2 µM) as indicated. Samples were
analyzed by αGFP. S1 = SUMO1; Ubc9∼S1 = Ubc9∼SUMO1 thioester.
In summary, I presented data that support a model in which the RanBP2 com-
plex samples the folded-back Ubc9∼SUMO1 thioester conformation and in that
way catalyzes discharge of SUMO1 from the E2. The binding of the thioester dur-
ing catalysis appears to be mediated by the SIM-like interaction and a canonical
Ubc9-binding sites within IR2 on the one hand and a backside interaction between
SUMO1C and Ubc9T on the other. This additional interaction requires a structural
rearrangement within the RanBP2 complex. While I could demonstrate an involve-
ment of this backside interaction for thioester binding, unequivocal evidence for its
role in catalysis is still at large.
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2.2 The RanBP2 complex as a specific
disassembly platform for Crm1-dependent
export complexes
Under teh common theme of characterizing RanBP2 complex interactions, I also
aimed to address possible binding with nuclear transport receptors. As a molec-
ular entity, the RanBP2 complex not only incorporates the capability to mediate
SUMOylation (as an E3 ligase), but also to regulate the Ran GTPase cycle (by Ran-
GAP1*SUMO1 and RanBDs). The literature has provided several links between the
RanBP2 complex and nuclear transport receptors, but information on the molecular
level is scarce. With the reconstituted BD34 complex, which contains RanGAP1,
RanBDs and FG-repeat patches (see Figure 12), I set out to systematically study
the interaction of physiologically relevant transport receptor complexes with the
RanBP2 complex, the capability of the latter to disassemble the former and to ad-
dress a potential role of the SUMO E3 ligase function in this context.
2.2.1 A stable and direct interaction between RanBP2 and
the export receptor Crm1 in vitro
In an unbiased approach, I tested a selection of transport receptors (2 µM each) for
their interaction with the BD34 complex (1 µM) in the presence of the GTP-loaded,
hydrolysis-deficient Q69L mutant of Ran (= RanQL) in gel filtration binding as-
says (Figure 40A). In this setting, neither the import receptor transportin 1, NTF2
(import receptor of Ran-GDP), nor CAS (the export receptor of importin α) co-
migrated with the BD34 complex. While importin β and importin 13 did co-eluted,
the export receptor Crm1 displayed the strongest degree of co-migration.
In order to assess to what extend these interactions were mediated by RanQL,
particularly in light of the fact that Crm1 and Ran-GTP do not strongly interact in
the absence of an NES-cargo, I repeated the experiment in the absence of RanQL.
Here, co-migration of import receptors with the BD34 complex ceased, which sup-
ports the view of a Ran-GTP/RanBD-mediated interaction [Yaseen and Blobel,
1999]. Crm1 co-migration persisted, although to a lesser degree (Figure 40). Of
note, small amounts of importin 13 were found in the peak fraction of the BD34
complex, but analysis of all fractions revealed that the elution peaks of the complex
and free importin 13 merely overlap (Figure 41). This finding advocates a stable
and specific between Crm1 and the BD34 complex.
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Figure 40: Interaction of various transport receptors with the BD34 complex. (A) In
the presence of RanQL, Crm1, importin β and importin 13 stably interact with the BD34 complex.
Gel filtration binding assays were performed with the BD34 complex (1 µM), different transport
receptors (2 µM each) and RanQL (5 µM) as indicated. Pre-incubated proteins were run over
Superdex200 5/150 GL gel filtration column. Samples of the input (10%) and of fractions collected
at 0.42 CV were analyzed by Colloidal Coomassie-stained SDS-PAGE gel. (B) Crm1, but not other
transport receptors interacts with the BD34 complex stably and directly. Gel filtration binding
assays were performed as in (A) without RanQL. S1 = SUMO1; * ovalbumin from buffer.
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Fraction (CV) 0.42 0.580.560.500.46
BD34 complex + Crm1
Fig. S1 Due to the early elution volumn of the BD34 complex, gel filtra-
tion-based binding assesy can be performed.
(a) Gel filtration profiles of the BD34 complex (1 µM), Crm1 (2 µM) and a 
binding reaction of BD34 complex + Crm1 (1 and 2 µM, respectively) on 
Superdex200 5/150 GL gel filtration column were recorded at 280 nm. The 
grey box indicates the 60 µl peak fraction of the BD34 complex, which is 
typically collected for gel filtration binding assays.
(b) Crm1 co-migrates with the BD34 complex in gel filtration, while the elu-
tion peak of Importin 13 overlaps in part with that of the BD34 complex. Gel 
filtration binding assays were performed as described in Fig.1b with the 
BD34 complex (1 µM), Crm1 (left) and Importin 13 (right) (2 µM each). 
Pre-incubated proteins were run over Superdex200 5/150 GL gel filtration 
column. Fractions collected at 0.42-0.50 CV were analyzed by Colloidal 
Coomassie-stained SDS-PAGE gel.
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Figure 41: Crm1, but not importin 13 co-migrates with the BD34 complex on gel
filtration. Gel filtration binding assays were performed with the BD34 complex (1 µM), Crm1
(left) and importin 13 (right) (2 µM each) as in Figure 40. Pre-incubated proteins were run over
Superdex200 5/150 GL gel filtration column. Fractions collected at 0.42 - 0.50 CV were analyzed
by Colloidal Coomassie-stained SDS-PAGE gel. S1 = SUMO1; Imp 13 = importin 13.
2.2.2 IR-flanking FG-rep at patches are required for the
Crm1/RanBP2 interaction
Given the presence of two FG-repeat patches flanking the IR region of RanBP2,
I asked whether they act as binding sites for Crm1. For this, I created BD34
complex variants, in which the FG-repeat patches were rendered non-functional by
phenylalanine-to-serine mutations [Frey et al., 2006] (Figure 42A).
Interestingly, obliteration of either of the two patches (as well as of both) resulted
in a complete loss of Crm1 co-migration (Figure 42B), suggesting that both are
involved in Crm1 binding. I repeated these experiments in the presence of RanQL
and observed that the amount of co-migrating Crm1 increased, as suggested in the
previous section. Importantly, Crm1 co-migration was not detectable for the BD34
mFG12 complex variant in the absence and presence of RanQL; this suggested that
in both cases Crm1 binding depended on the FG-repeat patches and that the pres-
ence of RanQL cooperatively strengthened this interaction. Of note, when only one
of the two FG-patches was mutated, Crm1-binding was detectable in the presence
of RanQL. Crm1 binding seemed to be less pronounced for the BD34 complex vari-
ant in which the C-terminal FG-repeat patch had been mutated, which suggests a
stronger contribution of this patch to Crm1 binding.
72 RESULTS CHAPTER 2
B
Crm1 +
BD34 complex wt mF
G1
mF
G2
mF
G1
2
A
mFG1 = 6 F to S mutations mFG2 = 5 F to S mutations
mFG12 = 11 F to S mutations
RanBD3 RanBD4IR1 IR2
130 kDa
70 kDa
25 kDa
15 kDa
40 kDa
wt mF
G1
mF
G2
mF
G1
2
BD34
GAP1*S1
Ubc9
Crm1
RanQL
RanQL
Figure 42: The interaction between Crm1 and the BD34 complex is mediated by two
FG-repeat patches. (A) Depiction of BD34 variants used in (B), in which the two FG-repeat
patches flanking the IR-region were rendered non-functional by F to S mutation [Frey et al., 2006]
of each patch. (B) Gel filtration binding assays were performed with BD34 complex variants built
from the FG mutants described in (a): BD34 complex variants (1 µM each) were incubated with
Crm1 (2 µM) and RanQL (5 µM) as indicated. Pre-incubated proteins were run over Superdex200
5/150 GL gel filtration column. Samples were collected at 0.42 CV and analyzed by Colloidal
Coomassie-stained SDS-PAGE gel. For clarity reasons, input samples for gel filtration binding
assays are not shown anymore from this point on. GAP*S1 = RanGAP1*SUMO1.
In order to quantify the interaction of Crm1 with FG-repeat patches of the BD34
fragment, I performed microscale thermophoresis experiments with Cy3-labeled Crm1
(Figure 42C). The measurements revealed an apparent KD of about 230 nM, which is
unusually strong for transport receptor/FG-nucleoporin interaction [Macara, 2001,
Stewart, 2007, Stewart et al., 2001]. In these experiments, I was able to recapitulate
the change in apparent affinity of Crm1 in the presence of RanQL and quantified it
to a roughly 6-fold increase.
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Figure 43: Dissociation constants of the Crm1/BD34 interaction determined by mi-
croscale thermophoresis. Recombinant Crm1 was labeled with Cy3-NHS-ester monoreactive
dye. Binding reactions were set up containing Crm1-Cy3 (20 nM), RanQL (30 µM) and BD34
variants (from 0.3 nM to 10 µM) in SAB+ as indicated. Measurements were conducted on a
Monolith NT.115 with a laser power of 70% and an LED power of 20%; the “laser on time” was set
to 20 sec and the “final laser off time” to 5 sec. Shown is a summary of microscale thermophoresis
experiments with values normalized to fraction of bound Crm1-Cy3. Error bars reflect the S.E.M.
from at least five measurements for each experiment. The thermophoresis equipment as kindly
provided by the group of Felix Wieland (BZH, Heidelberg).
Mitosis-specific, phosphomimetic variants of Crm1 and RanGAP1 do not
influence the FG-mediated interaction between Crm1 and BD34 in vitro
The RanBP2 complex does not only exist at the NPC during interphase, but also
enriches at the kinetochore and mitotic spindle during mitosis [Joseph, 2002]. It
was shown to be recruited to the kinetochore via Crm1-dependent export complex
formation [Arnaoutov et al., 2005] where it is involved in ensuring proper kineto-
chore/MT attachment [Joseph et al., 2004].
During mitosis, the phosphorylation status of many proteins changes, among
which are Crm1 (phosphorylation at serine 391 [Wu et al., 2013]) as well as the
RanBP2 complex components RanBP2 (phosphorylation at threonine 19 and 2450
as well as serine 21 and 2454 [Nousiainen et al., 2006]) and RanGAP1 (phosphoryla-
tion at threonine 409, serine 428 and 442 [Swaminathan et al., 2004]). Interestingly,
phosphorylation of Crm1 at serine 391 was reported to enhance the interaction with
the RanBP2 complex in a Ran-GTP-dependent manner in HeLa cells.
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Figure 44: Phospho-mimetic mutations in Crm1 do not influence binding of Crm1 to
the BD34 complex. (A) Gel filtration binding assays were performed with the BD34 complex
(1.5 µM), Crm1 variants (3 µM each) and RanQL (6 µM) as indicated. Pre-incubated proteins
were run over Superdex200 5/150 GL gel filtration column. Samples were collected at 0.42 CV,
analyzed by Colloidal Coomassie-stained SDS-PAGE gel. (B) Gel filtration binding assays were
performed as in (A) with BD34 complex variants (1 µM each), Crm1 (2 µM) and RanQL GTP
(5 µM) as indicated. S1 = SUMO1; RanGAP1 tm = RanGAP1 T409E/S428D/S442D.
I wanted to test whether this enhanced interaction could be recapitulated in vitro
in the context of the FG-repeat-mediated interaction near the IR region of RanBP2.
I created phospho-mimetic and phospho-deficient Crm1 mutants and compared their
binding capability to the BD34 complex in gel filtration binding assays (Figure 44A).
The mutants behaved like the wild-type in direct binding to the BD34 complex, but
also in the presence of RanQL. It is unlikely that in the in vitro setting the mutants
did not work as phospho-mimetic and phospho-deficient variants respectively, since
the same mutants showed effects in cells [Wu et al., 2013]. However, it seems that
the enhanced interaction of phosphorylated Crm1 with the RanBP2 complex either
depends on other regions of RanBP2 or is an indirect effect that depends on addi-
tional factors or dynamics, which are not recapitulated by the in vitro system.
In contrast to the phosphorylation of Crm1, functional consequences of the mod-
ification of RanBP2 and RanGAP1 during mitosis are less well understood. The
reported phosphorylation site of RanBP2 are not in direct proximity to the IR re-
gion and were thus not further analyzed here. However, RanGAP1 binds to the IR
region and is quantitatively phosphorylated at its C-terminal domain at the onset
of mitosis [Swaminathan et al., 2004]. Therefore, I also tested whether these modi-
fications had an effect on the binding of Crm1 to the RanBP2 complex.
Using the phospho-mimetic RanGAP1 T409E/S428D/S442D mutant (= Ran-
GAP1 tm - “tm” for “triple mutant”) to reconstitute a BD34 complex, I conducted
gel filtration binding assays (Figure 44B). Crm1 co-migration with the BD34 Ran-
GAP1 tm complex was comparable to the complex built with wild-type RanGAP1.
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This result is in accord with previous findings in this work that mainly RanBP2
and not RanGAP1 is involved in Crm1-binding (Figure 42). It also fits data from
the Melchior group, which showed that in mitotic cells the Crm1-dependent lo-
calization of the RanBP2 complex to kinetochores does not depend on RanGAP1
phosphorylation (PhD thesis by Dr. Annette Flotho).
2.2.3 Relevance of the FG-mediated Crm1/RanBP2
interaction in cells
As the experiments so far were conducted in an in vitro setting, I next tested
whether the FG-mediated binding of Crm1 near IR region of RanBP2 can also be
recapitulated in cells. For this, I made use of a full-length, HA-tagged RanBP2
transfection construct [Wälde et al., 2011], in which I introduced the mFG12 muta-
tions that render the FG-repeat patches flanking the E3 ligase region incompetent
for Crm1-binding (see Section 2.2.2).
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Figure 45: The IR-adjacent FG-repeat patches of RanBP2 contribute to binding of
Crm1 in mitotic cells. (A) Schematic depiction of co-IP experiment. In HEK293T cells,
endogenous RanBP2 was knocked-down via a double siRNA treatment. Cells were transfected
with siRNA resistant, full-length, HA-tagged RanBP2 constructs: wild type (wt) or a variant
lacking the E3 ligase-adjacent FG-repeats (mFG12). After nocodazole arrest, cells were lyzed
and αHA IP was performed. The amount of co-immunoprecipitated Crm1 was analyzed using
immunoblot. (B) Representative αHA (top) and αCrm1 (bottom) immunoblots from αHA IP as
described in (A). The IPs were performed either in the absence and presence of 250 µM GTPγS
as indicated. As a control, αHA IP was performed with cells which were not transfected with a
full-length, HA-tagged RanBP2 construct and treated with non-targeting (n.t.) siRNA (right most
lane). (C) Quantification of Crm1 signals normalized to the HA-RanBP2 signals as shown in (B)
from n=3 experiments. Error bars reflect the S.E.M.
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After transfection into HEK293T cells, I addressed a Crm1/RanBP2 interac-
tion via co-immunoprecipitation (IP). In order for RanBP2 to be accessible for IP,
cells were arrested with the MT-destabilizing drug nocodazole in mitosis, where the
RanBP2 complex becomes largely soluble [Swaminathan et al., 2004] and has been
shown to co-immunoprecipitate Crm1 (PhD thesis by Dr. Annette Flotho in the
Melchior group).
During interphase, RanBP2 makes up the cytoplasmic filaments of the NPC [?]
and electron microscopy analyses of the NPC showed that there are commonly 8 fil-
aments to one NPC [Jarnik and Aebi, 1991]. A recent compositional analysis of the
NPC implied that there are about 32 copies of RanBP2 per NPC [Ori et al., 2013],
which suggested that the electron microscopy-visible cytoplasmic filaments consist of
RanBP2 tetramers, i.e. that the protein generally tends to from mulitmers and po-
tentially also does so during mitosis. In order to avoid a potential co-precipitation
of endogenous RanBP2 with the transfected HA-tagged RanBP2 variants, I also
knocked-down the endogenous RanBP2 via siRNA in parallel to transfection of the
(siRNA-resistant) HA-RanBP2 construct (Figure 45A).
An αHA IP of the transfected, full-length, wild-type RanBP2 showed Crm1 co-
immunoprecipitating (Figure 45B). Importantly, αHA IP of mutant mFG12 RanBP2
co-immunoprecipitated significantly less Crm1 (Figure 45B and C). This suggests
that the two E3 ligase-adjacent FG-repeat patches indeed contribute considerably
to the interaction between RanBP2 and Crm1 in cells.
That the mFG12 mutation did not completely abolish the interaction with Crm1
was not surprising. Residual Crm1 co-immunoprecipitating with the mFG12 RanBP2
mutant is likely due to several other Crm1-binding sites within the RanBP2 molecule.
These are the N-terminal zinc finger cluster domain of RanBP2, which has been im-
plicated in specific Crm1-binding [Singh et al., 1999], and additional FG-repeats,
which might all serve as potential binding sites.
In order to address the strengthening-effect of Ran-GTP observed in vitro (see
Section 2.2.2), I repeated the IP in the presence of 250 mM GTPγS, a chemical
analog to GTP, which is much more stable towards Ran-mediated hydrolysis. The
presence of GTPγS led to a mild increase of co-immunoprecipitated Crm1 both for
wild-type and mutant RanBP2 (Figure 45C).
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2.2.4 Towards structural characterization of the
Crm1/RanBP2 interaction
Gel filtration analysis
In a next step, I wanted to gain structural insight into the Crm1/RanBP2 interac-
tion. Particularly interesting was the behavior of the BD34 complex on gel filtration.
The BD34 fragment is largely unfolded, which is in line with a large Stokes radius
[Pichler et al., 2004, Reverter and Lima, 2005]. The Stokes radius of a Crm1-bound
BD34 complex showed no difference to its free counterpart on Superdex200 gel fil-
tration column despite a considerable increase in the molecular weight (compare
Figure 64).
In order to get a better resolution in the high Stokes radius range, I switched to
a Superose6 gel filtration column. Also on this column the binding of Crm1 did not
alter the Stokes radius of the BD34 complex considerably (Figure 46). This effect
persisted over an extended separation range of the column given that the BD34
fragment alone and a complex built with only the SUMOylated GAPtail (= BD34
GAPtail complex) showed a similar behavior upon Crm1 binding (Figure 45A). This
effect was even more pronounced in the presence of RanQL (slight decrease in Stokes
radius vs. doubling of molecular weight assuming binding of two RanQL molecules
per BD34 complex molecule - Figure 46B).
I hypothesized that this behavior of the Stokes radius was caused by molecu-
lar compaction of the flexible BD34 fragment as it wraps around the curved Crm1
molecule due to the double FG-binding at the outer surface of the Crm1 molecule
[Koyama et al., 2014, Monecke et al., 2014] (Figure 46C).
Electron microscopy and single particle analysis
With the results from gel filtration analyses, I sought to obtain a more com-
prehensive structural model of the Crm1/RanBP2 interaction. Given the fact that
crystal structures of most individual proteins and domains involved are available, an
obvious idea was to use electron microscopy, single particle analysis and molecular
replacement to obtain a low-resolution structural model.
Pilot experiments to test the suitability of the BD34 complex bound to Crm1 ac-
cessible for electron microscopy, were performed by me and will be discussed below.
Detailed electron microscopy work resulting in meaningful structural models was
however beyond the scope of my work.
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Figure 46: The BD34 complex assumes a more compacted structure upon binding
to Crm1 (A) Binding of Crm1 to BD34 and BD34 complex variants has no major effect on
Stokes radii despite a significant increases in molecular weight. Gel filtration binding assays were
performed with BD34, BD34 complex variants (1 µM each) and Crm1 (1.5 µM) as indicated. Pre-
incubated proteins were run over Superose6 PC 3.2/300 GL gel filtration column. Shown are the gel
filtration profiles recorded at 280 nm. The insets shows peak fractions collected at 0.57, 0.61 and
0.65 CV, respectively, and analyzed by Colloidal Coomassie-stained SDS-PAGE gel. (B) Binding
of Crm1 and RanQL to the BD34 complex does not increase Stokes radii despite a significant
increases in molecular weight. Gel filtration binding assays were performed as in (A) with RanQL
(3 µM). Peak fractions were collected at 0.57 CV. S1 = SUMO1; G = RanGAP1; Gt = GAPtail.
(C)Possible model for the binding of the flexible BD34 molecule with its two FG-repeat patches
bound to the surface of Crm1.
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The project was hence continued and is currently brought to fruition by Hrishikesh
Das, a PhD student shared by the Melchior group and the group of Rasmus Schröder
(BioQuant, Heidelberg), who collaborated in this endeavor. His results are also
shown here to provide structural insights in addition to my biochemical analyses.
Due to the stable binding of Crm1 to the BD34 complex in the presence of RanQL,
I incubated the BD34 complex with an excess of Crm1 and RanQL, which was then
separated from unbound proteins by anion exchange chromatography and gel filtra-
tion. Spreading the purified complex on electron microscopy girds at a concentration
of about 400 nM followed by negative staining with 3% uranyl acetate yielded images
of separated particles (Figure 47A). However, many of these particles were reminis-
cent in shape (ring-like) and dimension (approximately 8 nM) of the structure of
the Crm1 protein alone [Monecke et al., 2012]. It hence stood to reason that on the
grids, Crm1 and the BD34 complex dissociated either due to the staining procedure
and/or spontaneously due to the given concentrations.
To circumvent this problem, I sought to chemically stabilize the BD34 com-
plex/Crm1 interaction by cross-linking with glutaraldehyde, a bifunctional cross-
linker specific for primary amines, which is commonly used in electron microscopy
sample preparation [Migneault et al., 2004, Prentø, 1995]. In a test experiment, I
tried to assess the specificity of the cross-link by titrating glutaraldehyde into a bind-
ing reaction between the BD34 complex, Crm1 and RanQL; as a negative control
served the BD34 mFG12 complex, which cannot bind Crm1, and RanQ69L loaded
with GDP, which has an approximately 1,000-fold lower affinity for the RanBDs of
RanBP2 than the GTP-bound form [Kuhlmann et al., 1997, Villa Braslavsky et al.,
2000].
Immunoblot analysis of the cross-linking reactions showed with increasing glu-
taraldehyde concentrations a decrease in signal of free Crm1, RanQL-GTP and the
BD34 complex (judged by its Ubc9 signal - Figure 47B). At the same time, a rather
discrete high-molecular-weight band (αRanGAP1 signal) appeared, which reflects
a cross-linked BD34 complex. In the negative control, a drop in signal of the free
proteins was observed as well, which in part may have been caused by intra-protein
cross-links that affect the running behavior in SDS-PAGE. Importantly however, in
the negative control the signal of the free Crm1 and RanQ69L-GDP persisted over
a much wider concentration range of glutaraldehyde and the high-molecular-weight
signal appeared as a broad smear rather than a discrete band.
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Figure 47: A cross-linked BD34 complex bound to Crm1 and RanQL. (A) Electron
micrograph of a BD34 complex bound to Crm1 and RanQL (400 nM), purified (without cross-
link) and negatively stained (3% uranyl acetate). Red arrows indicate possible free Crm1 particles.
(B) Bound Crm1 and RanQL can be cross-linked to the BD34 complex with glutaraldehyde.
Cross-linking experiments were performed by incubating BD34 complex variants (400 µM each),
Crm1, RanQ69L loaded with GTP and GDP (320 µM each) with increasing concentrations of
glutaraldehyde (0, 50, 75, 125, 250 and 500 mM) as indicated. Quenched cross-linking reactions
(20 µl each) were analyzed for cross-linked adducts by αRanGAP1 immunoblot (top), for free
Crm1 by aαCrm1 (second from the top), for free Ran by aαRan (third from the top) and for free
BD34 complex by aαUbc9 immunoblot (bottom). Xlink = cross-link. (C) Cross-linking does not
change the Stokes radius of the BD34 complex/Crm1/RanQL ensemble. Gel filtration profiles of
a purified BD34 complex/Crm1/RanQL ensemble cross-linked with 250 nM glutaraldehyde and
non-cross-linked (400 nM each) on a Superdex200 5/150 GL gel filtration column, recorded at 280
nm.
From this, I concluded that glutaraldehyde was able to yield links between stable
binding partners in this setting rather than between any two proteins in solution. For
further experiments, the lowest glutaraldehyde concentration was chosen at which
no considerable signal of the free proteins was detected, i.e. 250 mM.
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In order to check, whether cross-linking did not lead to a multimerization of the
cross-linked complex, a gel filtration analysis of the a cross-linked and a mock-treated
BD34 complex bound to Crm1 and RanQL was performed (Figure 47C). It revealed
identical elution volumes in both cases, which suggested that the cross-link in fact
yielded monomers. A careful analysis of the gel filtration profile of the cross-liked
supercomplex revealed a small peak at the void volume, which in fact increased in
intensity under higher glutaraldehyde concentrations (data not shown) and likely
reflects cross-linked multimers. Importantly, at the chosen glutaraldehyde concen-
tration of 250 mM this peak was negligibly small and was separable.
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Figure 48: Molecular compaction in the BD34 complex upon binding of Crm1 and
RanQL. (A) The BD34 complex bound to Crm1 and RanQL (350 kDa - top panel) yields defined
and much bigger particles than the free BD34 complex (180 kDa - bottom panel). Electron micro-
graphs of cross-linked, uranyl acetate (3%) stained particles imaged at 120 keV (Sesam). (B) The
BD34 complex bound to Crm1 and RanQL (350 kDa - top rows)) is comparable in size to Crm1
(124 kDa - bottom rows) alone. Micrographs were obtained as in (A). Scale bar corresponds to 10
nm. Left panel: individual particles. Right panel: 2D class averages obtained by processing with
standard programs (Eman, Relion). (C) the structure of Crm1 fits neatly into the structure of
the BD34 complex bound to Crm1 and RanQL. Left: low-resolution 3D reconstruction the BD34
complex bound to Crm1 and RanQL (yellow). Right: superimposition the structure as on the
left with a 3D reconstruction of Crm1 (green). Protein preparation, grid preparation, micrograph
acquisition, particle analysis and modeling was performed by Hrishikesh Das and Götz Hofhaus.
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With this established and validated protocol for sample preparation, electron
micrographs of cross-linked species were recorded and single particle analysis was
conducted by Hrishikesh Das. Micrographs of the cross-linked BD34 complex bound
to Crm1 and RanQL showed homogeneous particles, which were considerably big-
ger than those of the BD34 complex alone (Figure 48A). Particles of cross-linked
Crm1 were comparable in size to the BD34 complex bound to Crm1 and RanQL
(Figure 48B). Importantly, a low-resolution structural reconstruction of these par-
ticles revealed that Crm1 can be fitted into the model of the BD34/Crm1/RanQL
complex indicating that BD34 an Crm1 are engaged in a close molecular embrace
(Figure 48C). This data is compatible with the results from the gel filtration analysis
and supports the notion that the flexible BD34 molecule wraps around the curved
Crm1 molecule in the context of the FG-mediated binding.
2.2.5 Binding of a Crm1-dependent export complex to
RanBP2 in vitro
A typical scenario, in which Crm1 and RanBP2 encounter each other during in-
terphase is at the NPC with Crm1 in an export complex coming from the nucleus.
I therefore wanted to test whether the IR-adjacent FG-repeat patches in RanBP2
also support the binding of Crm1 in an export complex.
For this, I first incubated Crm1, RanQL and the NES-model cargo SNP1 (Snur-
portin1; [Paraskeva et al., 1999]) and assessed the formation of an export complex
(Figure 49). As expected, Crm1, SNP1 and RanQL co-migrated over the gel filtra-
tion column, while no co-migration between Crm1 and RanQL was detectable in the
absence of SNP1. In the absence of RanQL, SNP1 co-migrated to a lesser extend
with Crm1 than in the presence of RanQL; however, it was readily detectable. This
is not surprising given the much higher affinity of SNP1 for Crm1 than that of other
NES-cargoes [Paraskeva et al., 1999].
To assess the specificity of export complex formation in the presence of all three
components, Crm1 was pre-treated with the Leptomycin B-analog Ratjadone A, a
small molecule that also specifically and irreversibly modifies the cargo binding-site
of Crm1 resulting in its inability to form an export complex [Köster et al., 2003].
Ratjadone A-treated Crm1 was not able to support co-migration of RanQL and
co-migration of SNP1 was hardly detectable. The residual amounts of co-migrating
SNP1 might stem from incomplete Crm1 inhibition by Ratjadone A and/or be me-
diated at the given concentrations by the NES-independent, hydrophilic interaction
surface in the C-terminal part of SNP1 [Monecke et al., 2009, Paraskeva et al., 1999].
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To test binding to the BD34 complex, I used the pre-formed export complex
directly without further purification. Importantly, export complex formation was
performed with an excess of RanQL (5 µM), which was large enough to assure export
complex formation and saturation of the RanBDs in the BD34 complex (1 µM BD34
complex, i.e. 2 µM RanBDs). I reasoned that the saturation of the RanBDs would
neutralize them in promoting possible cargo dissociation ([Koyama and Matsuura,
2010, Maurer et al., 2001] - see also Section 2.2.6).
All components of the export complex displayed co-migration with the BD34
complex (Figure 50A). This effect was mediated by the FG-repeat patches of the
BD34 complex, as the corresponding mFG12 complex variant did neither support
Crm1 nor SNP1 co-migration.
To ensure that the co-migration of SNP1 was mediated by an export complex,
the assay was repeated using Ratjadone A-treated Crm1. Ratjadone A-treatment
of Crm1 resulted in a complete loss of SNP1 co-migration with the BD34 complex.
In line with this observation, SNP1 co-migration was also lost, when either Crm1
or RanQL was absent in the binding assays. The co-migration of export complex
components did not depend on the RanBDs, since a RanBP2 complex lacking the
RanBDs (= ∆BD34 complex) also supported SNP1 co-migration. Of note, up to
three RanQL molecules may co-migrate with the BD34 complex (to via its RanBDs
and one via the export complex), but only one with the ∆BD34 complex, the one
that is part of the export complex. In sum, this suggested that SNP1 co-migration
with the BD34 complex was mediated by the binding of a Crm1-dependent export
complex. It implies that binding of Crm1 to BD34 and the formation of an export
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complex with SNP1 are compatible with each other.
Intriguingly, when comparing binding of free Crm1 and of Crm1 in an export
complex, I observed a higher degree of Crm1 co-migration in latter case (Figure 50B).
The BD34 complex contains RanBDs and RanGAP1, which 8 have an influence on
export complex binding. However, the effect of a higher degree of Crm1 co-migration
persisted in the absence of RanBDs and the catalytic domain of RanGAP1. This
suggests an inherently higher affinity of Crm1 to the BD34 complex in an export
complex versus in the free form.
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Figure 50: The BD34 complex binds a Crm1 export complex with high affinity. (A)The
BD34 complex accommodates a Crm1/Ran/SNP1 export complex in an FG-dependent fashion.
Gel filtration binding assays were performed with BD34 complex variants as well as the ∆BD34
complex (1 µM each), Ratjadone A or mock treated Crm1 (2 µM each), SNP1 (4 µM) and RanQL
(5 µM) as indicated. Pre-incubated proteins were run over Superdex200 5/150 GL gel filtration
column. Samples were collected at 0.42 CV for the BD34 complex and at 0.46 CV for the ∆BD34
complex and analyzed by Colloidal Coomassie-stained SDS-PAGE gel. Crm1, SNP1 and RanQL
(= export complex) were pre-incubated for 20 min on ice before addition of the RanBP2 complex
variants. (B) The BD34 complex binds a Crm1/Ran/SP1 export complex with higher affinity than
free Crm1. Gel filtration assays were performed as in (A) with the BD34 complex, the ∆BD34
complex and the BD34 GAPtail complex as indicated. S1 = SUMO1.
2.2.6 RanBP2 can displace cargo in Crm1-dependent export
complexes
The finding that the BD34 complex cannot only bind Crm1, but also a Crm1-
dependent export complex prompted the question whether the RanBP2 complex
can disassemble the bound export complex. Canonical export complex disassem-
bly starts with the binding of a RanBP1-like RanBD to Ran-GTP within the ex-
port complex. This results in the dissociation of NES-cargo by the formation of a
Crm1/Ran/RanBD complex and allosteric changes in Crm1 [Koyama and Matsuura,
2010, Maurer et al., 2001]. Although the isolated RanBDs of RanBP2 have already
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been tested positively concerning their ability to promote NES-cargo dissociation
from an export complex [Koyama and Matsuura, 2010], these experiments lacked
the context of the RanBP2 complex.
To assess cargo dissociation by the BD34 complex, I pre-formed export complexes
with either 5 µMRanQL (to neutralize the RanBDs) or 1 µMRanQL (to prevent this
neutralization) and performed binding assays with the BD34 complex (Figure 51).
While SNP1 co-migrated, as shown before, with the BD34 complex in the presence
of an excess of RanQL, co-migration was lost in the presence of limiting amounts
of RanQL. Importantly, the ∆BD34 complex variant, which lacked RanBDs, did
support SNP1 co-migration even in the presence of limiting amounts of RanQL.
SNP1 co-migration was altogether abolished in the additional presence of an excess
of GST-RanBP1 (10 µM) as an external source of RanBDs. Taken together, these
observations suggest that the RanBDs in the BD34 complex are competent to pro-
mote NES-cargo dissociation from a Crm1-dependent export complex.
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Figure 51: The RanBDs of the BD34 complex can displace cargo from a Crm1 export
complex. Gel filtration binding assays were performed with the BD34 and the ∆BD34 complex
(1 µM each), Crm1 (2 µM), SNP1 (4 µM), GST-RanBP1 (10 µM) and RanQL at different concen-
trations (1 and 5 µM) as indicated. Pre-incubated proteins were run over Superdex200 5/150 GL
gel filtration column. Samples were collected at 0.42 CV and analyzed by Colloidal Coomassie-
stained SDS-PAGE gel. Crm1, SNP1 and RanQL (= export complex) were pre-incubated for
20 min on ice before addition of the RanBP2 complex variants and GST-RanBP1. GAP*S1 =
RanGAP1*SUMO1.
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The RanBDs of the BD34 complex can interact in cis with Crm1 and Ran
As a next step, I asked whether cargo dissociation could indeed happen in cis,
i.e. whether cargo dissociation in a given export complex is accomplished by the
RanBDs of the same BD34 complex to which the export complex is bound.
In gel filtration binding assays, I observed that, upon incubation of the BD34
complex with a Crm1-dependent export complex pre-formed with limiting amounts
of RanQL, a complex species is purified that contains only Crm1 and RanQL (see
Figure 51). It resembles in its composition and Stokes radius the complex species
that is purified when the BD34 complex was directly incubated Crm1 and RanQL
(see e.g. Figure 40A). The increased affinity between Crm1 and BD34, which was
measured for this species (see Figure 43), is easiest explained by the formation of a
Crm1/RanQL/RanBD sub-complex within the BD34 complex (i.e. a twofold bind-
ing of Crm1 to the BD3 complex fashion: on the one hand by the two FG-repeat
patches and on the other by a RanBD-tethered RanQL). Crm1/RanQL/RanBD
sub-complex formation is expected, if the RanBDs of BD34 act in cis to dissociate
NES-cargo from a bound export complex [Koyama and Matsuura, 2010]. I hence
used this affinity increase of Crm1 as a marker and reasoned that if the formation
of a Crm1/RanQL/RanBD sub-complex within the BD34 complex was responsible
for the increase in affinity, it must depend on a RanBD/RanQL interaction as well
as on a direct Crm1/RanQL interaction.
To test this, I compared the binding of Crm1 to the BD34 complex and to ∆BD34
complex (Figure 52B). In the presence of RanQL, the binding of Crm1 to the BD34
complex was stronger than to the ∆BD34 complex. For the latter, Crm1 binding
was comparable to the BD34 complex in the absence of RanQL, which shows the
clear dependency of the affinity increase on the RanBDs and RanQL. In these exper-
iments, complex variants were used, which instead of full-length RanGAP1*SUMO1
contained only the SUMOylated C-terminal GAPtail domain, in order to avoid any
possible interactions with the N-terminal, catalytic domain of RanGAP1 (see Sec-
tion 2.2.7 and [Seewald et al., 2002]).
To test for the contribution of a direct Crm1/Ran interaction, I together with
Iker Valle Aramburu (rotation studnet in the Melchior group in 2012) designed
and purified a Crm1 mutant, which carries mutations in residues critical for its
interaction with Ran in an export complex as well as in the Crm1/Ran/RanBD
complex (Crm1 E364A/E371A/D932A/T933A = Crm1 qm - “qm” for “quadruple
mutant”) [Koyama and Matsuura, 2010, Monecke et al., 2009]. Correspondingly,
Crm1-dependent export complex formation in gel filtration binding assays marked
by RanQL co-migration with Crm1 was not detectable with the Crm1 qm variant
(Figure 52C).
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Figure 52: The formation of a Crm1/RanQL/RanBD sub-complex increases the affin-
ity of Crm1 for the BD34 complex in the presence of RanQL. (A) In the presence of
RanQL, the amount of Crm1 co-migration with the BD34 complex increases. Gel filtration bind-
ing assays were performed with the BD34 complex (1 µM), Crm1 (2 µM) and RanQL (5 µM)
as indicated. Pre-incubated proteins were run over Superdex200 5/150 GL gel filtration column.
Samples were collected at 0.42 CV and analyzed by Colloidal Coomassie-stained SDS-PAGE gel.
(B) The RanBDs of the BD34 complex are required for increased Crm1 co-migration in the pres-
ence of RanQL. Gel filtration binding assays were performed as in (A) with the BD34 and the
∆BD34 complex (1 µM each), Crm1 (2 µM) and RanQL (5 µM) as indicated. (C) The Crm1 qm
variant is deficient in RanQL-interaction within an export complex. Gel filtration binding assays
were performed as in (A) with Crm1 variants (2 µM each), SNP1 (1.5 µM) and RanQL (5 µM)
as indicated. (D) A direct Crm1/Ran interaction is required for increased Crm1 co-migration to
the BD34 complex in the presence of RanQL. Gel filtration binding assays were performed as in
(A) with different BD34 complex variants (1 µM each), different Crm1 variants (2 µM each) and
RanQL (5 µM) as indicated. S1 = SUMO1; * contamination from Crm1 purification.
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To assess RanQL’s effect on the ability of the Crm1 qm variant to interact with
RanBP2 complexes, we turned to the BD34 mFG1 and mFG2 complex variants de-
scribed in Section 2.2.2. Their affinity for Crm1 was low enough to strictly depend
on RanQL in gel filtration binding assays. Indeed, RanQL was not able to induce
interaction of Crm1 qm with these complexes (Figure 52D). Taken together, these
data indicate the recapitulation of a Crm1/RanQL/RanBD sub-complex in the con-
text of the BD34 complex.
A possible action of the RanBDs of BD34 in trans to dissociate NES-cargo from a
bound export complex would imply the formation dimer complex species. However,
these were not observed in gel filtration binding assays judging by Stokes radii.
Both RanBDs of the BD34 complex can engage in a Crm1/Ran/RanBD
sub-complex
To investigate formation of the Crm1/RanQL/RanBD sub-complex within the
BD34 complex by an alternative assay, I took advantage of the fact that RanQL
bound to the BD34 complex can be in vitro SUMOylated at lysine 130, 132 and
134, while the presence of transport receptors prevents this (observation by [Sakin
et al., 2015, in revision]).
The crystal structure of Xpo1 (yeast Crm1) in complex with hydrolysis-deficient
Gsp1p (yeast Ran) and the RanBD of Yrb1p (yeast RanBP1) reveals that the export
receptor in part occludes the substrate lysines (Figure 53A - PDB: 3M1I, [Koyama
and Matsuura, 2010]). Thus, I here used SUMOylation of Ran as a measure of the
steric accessibility of its SUMOylation sites.
In vitro SUMOylation assays showed extensive SUMOylation of RanQL by the
BD34 GAPtail complex (in these experiments, complex variants lacking the N-
terminal catalytic domain of RanGAP1 were used to avoid any additional inter-
actions of RanQL with this domain - see Section 2.2.7 and [Seewald et al., 2002]).
Ran SUMOylation depended on its binding to the complex, as the ∆BD34 GAP-
tail complex, which cannot bind RanQL, did not show RanQL SUMOylation (Fig-
ure 53B). Interestingly, RanQL SUMOylation by the BD34 GAPtail complex was
drastically reduced in the presence of Crm1. In light of my findings, the inhibition
of Ran SUMOylation by Crm1 is likely due to Crm1/RanQL/RanBD sub-complex
formation and steric inhibition. This idea is in line with the observation that no
clear reduction in RanQL SUMOylation was observed in the presence of Crm1 with
the BD34 mFG12 GAPtail complex, which cannot bind Crm1.
The presence of two RanBDs in the BD34 fragment prompts the questions whether
the Crm1/RanQL/RanBD sub-complex has an intrinsic preference to form with ei-
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ther RanBD3 or RanBD4. To assess this question, I performed SUMOylation assays
with complex variants that contained either RanBD3 (= ∆BD4) or RanBD4 (=
∆BD3). Both complex variants supported SUMOylation of RanQL in the absence
of Crm1, while inclusion of the export receptor led to a drastic inhibition of SUMOy-
lation in both cases (Figure 53B). This indicates that both RanBDs in the BD34
complex are sterically capable of engaging in a Crm1/RanQL/RanBD interaction.
Of note, I observed that RanQL SUMOylation in the absence of Crm1 was more
efficient with the ∆BD3 GAPtail complex than with the ∆BD4 GAPtail complex.
This finding may reflect different levels of steric accessibility of the SUMO machin-
ery to the two complex variants, but more importantly does not affect the inhibitory
effect of Crm1 on each variant.
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Figure 53: In the context of the BD34 GAPtail complex, SUMOylation of RanQL is
inhibited by Crm1. textbf(A) The interaction between Crm1 and Ran in the Crm1/Ran/RanBD
complex occludes in vitro SUMOylation sites in Ran. Left: Surface structure of a complex of
Gsp1pQ71L-GTP (yeast RanQL - in maroon) binding simultaneously to the RanBD of Yrb1p
(yeast RanBP1 - light brown) and Xpo1 (yeast Crm1 - turquoise) - PDB: 3M1I. Residues K130 (in
yeast Ran K129), K132 and K134 are shown in blue, which were identified as in vitro SUMOylations
sites [Sakin et al., 2015, in revision]. Right: Structure as on the left without Crm1. In (B) In vitro
SUMOylation reactions of RanQL (1 µM) were performed with the SUMO E1 enzyme (50 nM),
Ubc9 (50 nM) and SUMO1 (20 µM). RanBP2 GAPtail complex variants with and without RanBDs
(500 nM each) and Crm1 (1 µM) were added as indicated. Samples were incubated at 30◦C for
60 min and analyzed by αRan immunoblot. S1 = SUMO1
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It should also be noted that SUMOylation of RanQL in the presence of Crm1 was
not completely abolished. In the case of the BD34 GAPtail complex, which contains
two RanBDs, each of which may carry a RanQL molecule, this finding may reflect
simply that only one of the RanBD-tethered RanQL molecules can engage in the
interaction with Crm1 leaving the other exposed for the SUMOmachinery. However,
even in the case of the ∆BD3 and ∆BD4 GAPtail complex, RanQL SUMOylation
was not entirely inhibited in the presence of Crm1. This observation may be due to
a rather incomplete shielding of RanQL by Crm1 from the SUMO machinery during
the course of the experiment (see Figure 53A). Despite this incomplete inhibition
of RanQL SUMOylation however, this assays allowed qualitative conclusions about
the binding status of RanQL within the complex variants.
2.2.7 Ran-GTP hydrolysis by the RanBP2 complex
Lastly, I wanted to recapitulate Ran-GTP hydrolysis by the RanBP2 complex in
gel filtration binding assays. Therefore, I used GTP-loaded Ran wild-type instead
of the hydrolysis-deficient Q69L mutant for export complex formation (Figure 54).
I tested export complex co-migration with RanBP2 complex variants in which the
important regulators of export complex disassembly were missing.
As expected, the∆BD34 GAPtail complex, which lacks both RanBDs and the cat-
alytic domain of RanGAP1, supported stable binding of an export complex marked
by the co-migration of SNP1 and Ran. I interpreted this species as the first step in
export complex disassembly at the RanBP2 complex.
For the BD34 GAPtail complex, cargo co-migration was lost, as observed in Fig-
ure 51, while Ran co-migration was preserved. Together with the data shown in
Section 2.2.6, I interpreted this species as an intermediate step in export complex
disassembly marked by the formation of the Crm1/Ran/RanBD sub-complex.
Conversely, for the ∆BD34 complex co-migration of SNP1 and Ran was observed,
which underlined the protection of Ran-GTP from RanGAP activity in the context
of an export complex (and in the absence of RanBDs). The extend of Ran and
SNP1 co-migration was lower compared to the ∆BD34 GAPtail complex despite
the absence of RanBDs. This was attributed to the prolonged incubation of pro-
teins during the gel filtration run (approximately 15 min) and the comparably high
RanGAP1 concentrations with regard to conventional assays [Maurer et al., 2001].
Importantly, the BD34 complex, which contained RanBDs and RanGAP1, dis-
played a lack of Ran and SNP1 co-migration, which is compatible with rapid and
complete cargo dissociation and Ran-GTP hydrolysis. I construed this species as
the last step of disassembly, which notably and in line with my first experiments
still featured considerable amounts of Crm1 co-migration.
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Figure 54: The RanBP2 complex can disassemble a Crm1 export complex. (A) The
RanBDs and RanGAP1*SUMO1 in the BD34 complex bring about export complex disassembly.
Gel filtration assays were performed with RanBP2 complex variants built with either BD34 or
∆BD34 and RanGAP1*SUMO1 or GAPtail*SUMO1 (1 µM each), Crm1 (2 µM), SNP1 (4 µM) and
Ran wt loaded with GTP (1 µM) as indicated. Crm1, SNP1 and Ran-GTP (= export complex) were
pre-incubated for 20 min on ice; RanBP2 complex variants were added directly before gel filtration
runs. S1 = SUMO1; GAP*S1 = RanGAP1*SUMO1. (B) Models of the three reconstituted stages
of Crm1-dependent export complex disassembly at the RanBP2 complex. Left: the export complex
binds with high affinity to IR-adjacent FG-repeat patches in the C-terminus of RanBP2. Middle:
one of the RanBDs of RanBP2 engages the export complex resulting in cargo ejection and the
formation of a Crm1/Ran/RanBD sub-complex. Right: Following its deprotection in the export
complex by RanBD, Ran is engaged by the catalytic domain of RanGAP1, hydrolysis is induced
and Ran GDP diffuses away leaving a moderately stably bound Crm1.
RanGAP1 can interact with Ran within the RanBP2 complex
Similar to the previous section, here the question presented itself whether activa-
tion of Ran’s GTPase function by RanGAP1 could sterically occur in cis, i.e. within
one RanBP2 complex. Again, I reasoned that an in cis GTPase activation would
be marked by the formation of a stable sub-complex between the catalytic domain
of RanGAP1, RanQL and a RanBD within the same BD34 complex.
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Indications for the formation of such a sub-complex came from gel filtration anal-
yses: here, the BD34 complex displayed the same Stokes radius in the absence and
presence of RanQL (despite an increase in molecular weight from 179 kDa to 229 kDa
assuming a binding of two RanQL molecules per BD34 complex - Figure 55A). How-
ever, the BD34 GAPtail complex as well as free BD34 showed reproducible increases
in their Stokes radii upon binding of RanQL.
These observations are compatible with the formation of a RanGAP1/Ran/RanBD
sub-complex within the BD34 complex, which would spatially restrain one flexible
end of the BD34 protein and thus counteract the increase in Stokes radius caused by
the increase in molecular weight after binding of RanQL (Figure 55B). This is not
possible for the BD34 GAPtail complex and free BD34, as both lack the catalytic
domain of RanGAP1 to engage in this interaction.
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Figure 55: Binding of RanQL leads to molecular compaction of the BD34, but not
of the BD34 GAPtail complex and the BD34 fragment. (A) Gel filtration binding as-
says were performed with the BD34 complex, the BD34 GAPtail complex, the BD34 fragment
(1 µM each) and RanQL (6 µM) as indicated. Pre-incubated proteins were run over Superose6
PC 3.2/300 GL gel filtration column. Shown are the gel filtration profiles recorded at 280 nm.
The insets shows peak fractions collected at 0.587, 0.61 and 0.65 CV, respectively, and analyzed
by Colloidal Coomassie-stained SDS-PAGE gel. Molecular weight indications assume the binding
of two molecules of RanQL per BD34 molecule. G*S1 = RanGAP1*SUMO1; Gt*S1 = GAP-
tail*SUMO1. (B) Model for an interaction between RanBD-tehtered RanQL and the catalytic
domain of RanGAP1 restricting the flexibility of the BD34 complex. Left: flexible BD34 complex
without RanQL. Right: BD34 complex with two RanQL molecules bound to its RanBDs and one
engaging in an interaction with RanGAP1.
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For further evidence of a RanGAP1/Ran/RanBD sub-complex formation in cis,
I turned to in vitro SUMOylation assays of RanQL (see also Section 2.2.6 and Fig-
ure 53). The catalytic domain of RanGAP1 and Crm1 bind to a similar surface
in Ran. Hence, in a RanGAP1/Ran/RanBD sub-complex, the in vitro SUMOyla-
tion sites of RanQL are partly occluded as well, as the structure of the catalytic
domain of Rna1 (yeast RanGAP1) in complex with Ran-GMPPNP and the RanBD
of RanBP1 shows (Figure 56A - PDB: 1K5D, [Seewald et al., 2002]).
As shown before, in vitro SUMOylation assays showed SUMOylation of RanQL by
the BD34 GAPtail complex, which lacks the catalytic domain of RanGAP1, but no
SUMOylation by the ∆BD34 GAPtail complex, which cannot bind RanQL. RanQL
SUMOylation levels were also clearly diminished for the BD34 complex, which con-
tains full-length RanGAP1 (Figure 56B). This speaks in favor of the formation of a
RanGAP1/RanQL/RanBD sub-complex within the BD34 complex and hence sug-
gest that GTPase activation in the RanBP2 complex can happen in cis.
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Figure 56: The presence of the catalytic domain of RanGAP1 in the BD34 complex
inhibits SUMOylation of RanQL. (A) The interaction between the catalytic domain of Ran-
GAP1 and Ran in the RanGAP1/Ran/RanBD complex occludes in vitro SUMOylation sites in
Ran. Left: Surface structure of a complex of non-hydrolyzable Ran-GMPPNP (maroon), the
RanBD of RanBP1 (light brown) and the N-terminal, catalytic domain of Rna1 (yeast RanGAP1
-orange) (PDB: 1K5D). Residues K130, K132 and K134 of Ran are shown in blue, which were
identified as in vitro SUMOylations sites [Sakin et al., 2015, in revision]. Right: Structure as on
the left without Rna1. In (B) In vitro SUMOylation reactions of RanQL (1 µM) were performed
with the SUMO E1 enzyme (50 nM), Ubc9 (50 nM) and SUMO1 (20 µM). RanBP2 complex vari-
ants with and without RanBDs (500 nM each) were added as indicated. Samples were incubated
at 30◦C for 60 min and analyzed by αRan immunoblot. S1 = SUMO1
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Again, the symmetry of the BD34 fragment concerning its two RanBDs motivates
the questions whether the RanGAP1/RanQL/RanBD sub-complex has an intrinsic
preference to form with either RanBD3 or RanBD4. To address this question, I
made use of complex variants lacking either of the two RanBDs. Reactions con-
taining the ∆BD3 and the ∆BD4 complex variants displayed drastically diminished
levels of RanQL SUMOylation in comparison to reaction featuring the the ∆BD3
GAPtail and the ∆BD4 GAPtail complex, respectively (Figure 56B). This indicates
that both RanBDs in the BD34 complex are sterically capable of engaging in a
RanGAP1/RanQL/RanBD interaction.
2.2.8 A Crm1-bound RanBP2 complex is active as a SUMO
E3 ligase
Due to the close proximity of the regulators of export complex disassembly (Crm1-
interacting FG-repeats, RanBD3 and 4 and RanGAP1*SUMO1) and the SUMO E3
ligase activity within the RanBP2 complex, I wondered whether these two activities
would influence each other. Having given evidence for a close molecular embrace
between Crm1 and BD34, which potentially involves the catalytic center of the E3
ligase (namely the IR2 region), I particularly was interested whether Crm1 binding
is compatible with SUMOylation activity of the RanBP2 complex.
For this, I first reconstituted the three intermediate stages of export complex disas-
sembly at the RanBP2 complex: (1) BD34 complex bound to a Crm1/RanQL/SNP1
export complex, (2) BD34 complex bound to Crm1 and RanQL and (3) BD34 com-
plex bound to Crm1 alone (see also Figure 55B). I then tested the efficiency of
SUMOylation of the model substrate YFP-Sp100 as well as auto-SUMOylation of
the RanBP2 fragment itself in in vitro SUMOylation assays. Here, I compared the
activity of the BD34 complex in all three stages with that of the BD34 mFG12
complex, which cannot bind Crm1.
Interestingly, the activities for substrate and auto-SUMOylation were very com-
parable in all cases and clearly due to the presence of the BD34 complex, since
a reaction without E3 ligase resulted in hardly any SUMOylation (Figure 57). A
SUMOylation reaction with the BD34 complex in the absence of an export complex
yielded comparable SUMOylation.
In the activity assays, the BD34 E3 ligase complex is present at a concentration
of 25 nM. To ensure that at this concentration the complex is nearly saturated by
its respective binding partners, Crm1, RanQL and SNP1 were added in a 100-fold
excess (given a KD of about 230 nM for the Crm1/BD34 interaction, about 92% of
the BD34 complex should be bound to Crm1 under the given conditions). To ensure
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that SUMOylation is indeed mediated by the BD34 complex in the three disassem-
bly stages and not by the remaining fraction of free, unbound complex, a control
SUMOylation reaction was set up with 10% (free) BD34 complex in the absence of
export complex components. Importantly, this reaction showed much less activity
when compared to the other reactions. In sum, these results suggest that interaction
of the BD3 complex with export complex disassembly intermediates is compatible
with SUMOylation activity in vitro.
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Figure 57: The interaction with Crm1 is compatible with SUMO E3 ligase activity
of the RanBP2 complex. A time course of in vitro SUMOylation reactions of the YFP-Sp100
(500 nM) was performed with the SUMO E1 enzyme (100 nM), Ubc9 (50 nM), SUMO1 (10 µM),
the BD34 complex variants (25 nM each), Crm1, RanQL and SNP1 (2.5 µM each) as indicated.
The reaction in the ninth lane was performed with 10% of the BD34 wt complex (2.5 nM) to
control for the effect of potentially unbound complex in the other reactions. Of note, this reaction
showed no detectable RanBP2 signal most likely due to lower signal intensity (10% of the other
lanes) and extensive auto-SUMOylation. Crm1, SNP1 and RanQL (= export complex) were pre-
incubated for 20 min on ice before addition of the BD34 complex. S1 = SUMO1; BD34*xS1 =
multiply SUMOylated BD34. (A) Substrate SUMOylation was analyzed by αGFP immunoblot.
(B) Auto-SUMOylation of RanBP2 was analyzed by αRanBP2 immunoblot. S1 = SUMO1.
The components of a Crm1 export complex are poor SUMO substrates
Having shown the compatibility of Crm1-interaction and E3 ligase activity of the
BD34 complex, I next asked whether the increased residence time of Crm1 and
a Crm1-dependent export complex (particularly when using RanQL) would allow
SUMOylation of these binding partners. I performed in vitro SUMOylation assays
with Crm1, RanQL, SNP1 and an export complex formed by them. In order to
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achieve a large degree of binding to the E3 ligases, the BD34 complex was used not
in enzymatic, but in near-stoichiometric concentrations with regard to the potential
substrates (500 nM E3 vs. 1 µM Crm1, RanQL GTP and SNP1).
Despite the very high E3 ligase concentrations, SUMOylation levels of export com-
plex components were very poor. Crm1 (either alone or in the context of an export
complex) showed a small degree of double SUMOylation. As already shown and
discussed before (see Figure 53 and 56), RanQL was only SUMOylated when being
bound the BD34 complex alone. In the presence of Crm1 or an export complex,
RanQL SUMOylation was effectively inhibited by the additional binding of Crm1
(and the catalytic domain of RanGAP1). SNP1 as a model NES-cargo showed only
a very faint band at the edge of detection limit, which is compatible with a SUMOy-
lated form of the protein.
Given these results, it stands to reason that the poor SUMOylation levels in vitro
might not translate into a significant role in cells where a much lower residence time
of Ran wild-type (and not RanQL) at the RanBP2 complex is expected.
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Figure 58: The components of a Crm1/Ran/SPN1 export complex are poorly SUMOy-
lated by the BD34 complex. A time course of in vitro SUMOylation reactions was performed
containing the SUMO E1 enzyme (100 nM), Ubc9 (50 nM), SUMO1 (10 µM), the BD34 complex
(500 nM), Crm1, RanQL and SNP1 (1 µM each) as indicated. Samples were analyzed by αCrm1
(top), αSNP1 (middle) and αRan immunoblot (bottom). Crm1, SNP1 and RanQL (= export com-
plex) were pre-incubated for 20 min on ice before addition of the BD34 complex. S1 = SUMO1;
Ran*xS1 = multiply SUMOyalted Ran; * unspecific band caused by SNP1.
Chapter 3
Discussion
The RanBP2 complex is a fascinating molecular entity because it has functions
throughout the cell cycle and combines (at least) two key enzymatic activities: on
the one hand the activity to regulate the Ran GTPase system via RanGAP1 and
RanBDs and on the other an E3 ligase activity to regulate SUMOylation. In this
work, I set out to perform a detailed biochemical characterization of the RanBP2
complex with regard to both of these activities.
In the first part, I addressed the catalytic mechanism of the RanBP2 complex
(and the free RanBP2) as a SUMO E3 ligase, i.e. how the enzyme accommodates
the Ubc9∼SUMO thioester to accelerate SUMOylation. Key to this endeavor was
the creation of thioester mimics, which are stable in the presence of the E3 ligase
and hence could be used for binding assays. Inspired by a biochemical strategy
published by Plechnovova and colleagues [Plechanovová et al., 2012] as well as a
chemical strategy pioneered by the group of Henning Mootz [Weikart and Mootz,
2010], we could create and characterize an isopeptide- and a triazole-linked thioester
mimic.
With these biochemical tools, I outlined the catalytic route that the RanBP2 com-
plex takes in mediating catalysis, particularly in comparison to the free RanBP2.
Essentially, I gave evidence to support the hypothesis that a complex component,
i.e. SUMO1C provides an additional binding site for the Ubc9∼SUMO thioester.
Interestingly, in order for this binding site to be accessible, the RanBP2 complex
has to undergo a subtle structural rearrangement at its Ubc9/SUMO1 interface.
In the second part of the work presented here, I addressed the potential of the
RanBP2 complex to interact with transport receptor complexes coming from the nu-
cleus during interphase. I could show an unusually strong interaction with a Crm1-
dependent export complex. This interaction is largely mediated by Crm1 and the
two FG-repeat patches in RanBP2 that flank the binding site of RanGAP1*SUMO1
and which in turn are flanked by two RanBDs. Given the close proximity of these
two important Ran GTPase regulators, I could provide evidence that the RanBP2
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complex can act on a bound Crm1-dependent export complex to disassemble it. In
the following sections I will discuss a selection of important topics arising from the
presented results in more detail.
3.1 Ubc9-SUMO1 conjugates as stable thioester
mimics
As described in the Results Section, we have now two different Ubc9∼SUMO
thioester mimics available: a triazole-linked conjugate obtained by bio-orthogonal
CuCAA methodology and an isopeptide-linked adduct obtained by enzymatic con-
jugation with the SUMO E1 activating enzyme.
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Figure 59: Overview of native and non-native Ubc9-SUMO linkages. (A) Native
Ubc9∼SUMO thioester formed by the E1 activating enzyme between Ubc9 wild-type and SUMO
wild-type. (B) Triazole-linke Ubc9-SUMO conjugate formed by Cu(I)-catalyzed azide-alkyne cy-
cloaddition between a Ubc9 Cys93AzPhe mutant and SUMO(∆G)-Pa. (C) Isopeptide-linked
Ubc9-SUMO adduct formed by the E1 activating enzyme at high pH between a Ubc9 Cys93Lys
mutant and SUMO wild-type. pAzPhe = p-azidophenylalanine; TBTA = Tris(benzyltriazolyl-
methyl)amine; TCEP: Tris(2-carboxyethyl)phosphine; PA = propargylamine. Figure adapted from
[Sommer et al., 2015].
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Both linkages differ from the thioester bond with regard to length and pattern of
freely rotatable and conformationally restricted bonds (Figure 59). However, mech-
anistic analyses of E3 ligase in general [Metzger et al., 2013] as well as the work
presented here on RanBP2 and the RanBP2 complex suggested that binding of the
thioester is mediated by distinct binding sites within the E2 and the modifier rather
than by recognition of the link between them. In addition, the crystal structure
of the complex of the ubiquitin RING E3 ligase RNF4 and an isopeptide-linked
UbcH5A-ubiquitin adduct showed that the isopeptide (instead of a thioester bond)
can in principle be accommodated in a E3/E2 complex [Plechanovová et al., 2012].
I performed a biochemical analysis for both conjugates regarding their binding
properties to the RanBP2 E3 ligase complex (see Section 2.1.1), in which both be-
haved as expected for the endogenous thioester. However, an inherent problem of
these binding assays is the lack of the proper positive control, i.e. the endogenous
thioester due to its instability in the presence of E3 ligases. For instance, the experi-
ments do not conclusively show that the conjugates bind as strongly to the RanBP2
complex as the endogenous thioester.
Nevertheless, the binding experiments presented here showed that general charac-
teristics expected of the binding of the thioester are recapitulated by the conjugates
(i.e. stronger binding than its separate components and mimicking of catalytic de-
fects of mutants). This suggests that, even if the absolute binding strength of the
thioester is not mirrored by the conjugates, relative comparisons of binding, for ex-
ample between the wild-type and a mutant conjugate, are valid and transferable.
In sum, these observations justify the use of the triazole- and the isopeptide-linked
conjugates as Ubc9∼SUMO thioester mimics.
Although oxyester-linked E2-ubiquitin adducts have been used as thioester mim-
ics numerous times [Eddins et al., 2006, Hamilton et al., 2001, Kamadurai et al.,
2009, Sakata et al., 2010, Serniwka and Shaw, 2009], this is, to my knowledge, the
first time that Ubc9∼SUMO thioester mimics have been described. Although in
this work I only made use of one of them for a very specific purpose, I envision a
set of distinct, yet complementary applications for both mimics in the SUMO field.
The isopeptidase-stable triazole-linked conjugate is recommended to identify, for
instance, unknown E3 ligases or other components that interact with SUMO-loaded
Ubc9 from cell lysates, which inevitably contain isopepitdase activity. The isopep-
tidase-linked adduct on the other hand can be easily obtained in large quantities
and is hence a prudent choice for in vitro and particularly structural experiments
as shown in this work.
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3.2 The folded-back thioester conformation
Work in the ubiquitin field revealed that E2∼ubiquitin thioesters are flexible
molecular entities in solution with regard to the relative position of ubi-quitin to-
wards its E2 enzyme [Levin et al., 2010, Miura et al., 1999, Pruneda et al., 2011].
However, it is a particular conformation that appears to prime the modifier for the
nucleophilic attack by a substrate lysine and hence for discharge from the E2 enzyme.
In this conformation the modifier is folded back onto the E2 enzyme contacting its
α2-helix.
There has also been structural evidence that suggested an equally central role
of a folded-back Ubc9∼SUMO thioester conformation for SUMOylation [Reverter
and Lima, 2005, Yunus and Lima, 2009]. However, in these studies no Ubc9∼SUMO
thioester mimics have not been used. In this work, I could show that the use of Ubc9
and SUMO1 mutants that disrupt the folded-back thioester conformation reduces
SUMOylation of the model substrate YFP-SP100 in E3-independent and -dependent
reactions. In reaction with mutants that reverted this disruption, the SUMOylation
defect was reverted as well (see Sections 2.1.2, 2.1.3 and 2.1.4.
X-ray scattering experiments demonstrated that the thioesters of different ubiqui-
tin E2 enzymes populate the folded-back conformation to different degrees [Pruneda
et al., 2011], which correlates with their ability to perform E3-independent ubiquitin
transfer.
Since Ubc9 can be used for E3-independent SUMOylation as well, it is fair to
assume that in solution the equilibrium of the Ubc9∼SUMO thioester occupies at
least to some degree the folded-back conformation. However, a direct and possibly
quantitative comparison between Ubc9 and other E2 enzymes regarding their ability
to populate the fold-back conformation would be of interest.
3.3 The RanBP2 complex forms a multifaceted
interaction surface for the Ubc9∼SUMO
thioester
The Melchior group has proposed that the RanBP2 complex constitutes a mul-
tisubunit SUMO E3 ligase, i.e. that it is not just RanBP2 itself but also other
components of the complex that vitally contribute to catalysis [Werner et al., 2012].
They base this idea on the fact that IR2, which on its own possesses hardly any E3
ligase activity, becomes central for catalysis after complex formation.
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The work presented here supports the idea of a multisubunit E3 ligase complex.
NMR and mutational analyses suggest an interaction of Ubc9T with a component
of the RanBP2 complex, namely with SUMO1C . My binding assays suggested that
interaction between the RanBP2 complex and the Ubc9∼SUMO1 thioester is me-
diated in a threefold manner: (1) SUMO1/SIM-like binding (2) canonical Ubc9-
binding and (3) a Ubc9T/SUMO1C backside interaction (Figure 60A and D; (1) and
(2) are discussed in more detail in Section 3.4). While I could show a clear contri-
bution of the first two interactions to catalysis in activity assays, no clear evidence
for an involvement of the backside interaction in catalysis could be obtained so far.
This was in part due to the use of the Ubc9 H20D mutant, which in literature
has been described as the prototoypic mutant to specifically inhibit the backside-
interaction [Knipscheer et al., 2007], but which in my hands proved to have general
SUMOylation defects. Additionally, a RanBP2 complex with the backside-defective
SUMO1 E67R mutant had no obvious catalytic defect in single-turnover reactions.
It is possibly that also this mutation is not suitable for this analysis.
In light of the fact that binding of the thioester does not solely depend on the
backside interaction, it is conceivable that, in the context of the RanBP2 complex,
the SUMO1 E67R mutation affects the off-rate of the backside interaction rather
than its on-rate. In gel filtration binding assays, the formation of an interaction
between the RanBP2 complex and the thioester mimic is given ample time (incu-
bation over night), so that co-migration is basically determined by the off-rates of
the interaction. If this off-rate is still below the rate of SUMOylation, it is quite
possible that a binding defect is observed in gel filtration assays, yet no catalytic
defect would be apparent in activity assays.
In sum, the experiments presented here only address one set of mutants and thus
do not exclude the involvement of a backside interaction in catalysis. They rather
warrant the testing of a different set of backside interaction-defective SUMO1 (and
possibly also Ubc9) mutants, which due to time restriction could not be included in
this work. The following paragraph will hence describe an experimental outlook for
a more thorough analysis of a backside interaction within the RanBP2 complex.
Although NMR measurements are highly suggestive of a backside interaction in-
volving SUMO1C , they cannot offer conclusive prove. While previous studies have
focused on a backside interaction between isolated Ubc9 and SUMO, the proteins
are here embedded in a network of interactions. Hence, mutations have an effect
in the former setting may not suffice in the latter case. Indeed, glutamate 67 of
SUMO1 and histidine 20 of Ubc9 only mediate a fraction of the interactions at the
backside surface (see supplements of [Knipscheer et al., 2007]). One idea is to repeat
activity assays with Ubc9T H20D and SUMO1C E67R using the BD34 mIR2 com-
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plex variants, in which catalysis should depend more on the backside interaction.
Alternatively, the use of more disruptive mutations in Ubc9T and SUMO1C seems
warranted. I will test Ubc9 and SUMO1 mutants, that abolish the central salt
bridges of the backside interaction (Ubc9 R13E/R17E and SUMO1 E83R/D86R -
[Knipscheer et al., 2007]). The advantage of these mutants will be that charge swap
experiments are possible, which have the potential to unequivocally prove a back-
side interaction. Of note, mutating argenine 13 and 17 of Ubc9 has been shown to
drastically interfere with E1-dependent thioester formation [Capili and Lima, 2007].
While corresponding mutants can be used in binding assays, their use for activity
assays is doubtful. I therefore additionally want to test another Ubc9 mutation,
which has been reported as a backside-interaction-defective variant with no defects
in thioester formation: the F22A/G23Q/Y25S mutation in yeast Ubc9 (F22A/G23Q
in human Ubc9) [Bencsath et al., 2002, Duda et al., 2007]. I will also test a BD34
complex containing the harsh SUMO1 V87E mutation, i.e. in that residue which
showed the severest CSPs in NMR measurements (see Figure 34B).
3.3.1 A small conformational change in the RanBP2 complex
contributes to its catalytic activity
Vital to considerations of a Ubc9T/SUMO1C backside interaction during RanBP2
complex-mediated catalysis is the fact that given a rigid structure, SUMO1C is
somewhat blocked by Ubc9C and thus not available for a backside interaction with
another Ubc9. However, NMR experiments suggested clear changes at the inter-
face of SUMO1C and Ubc9C upon binding of the thioester mimic. They suggest an
opening of the RanBP2 complex at this interface, which could potentially liberate
the SUMO1C for a backside interaction (Figure 60B and C).
The lack of changes at the GAPtail/Ubc9 interface within the RanBP2 complex
during NMR experiments suggest that the relative orientation of Ubc9 and Ran-
GAP1 does not change. The potential complex opening at the Ubc9/SUMO1 inter-
face implies that IR1, which holds the two proteins in place, also has to undergo a
conformational rearrangement. In particular, one would expect the αC-helix of IR1
to rearrange and allow more conformational flexibility for Ubc9C and SUMO1C .
If this is the case, then a RanBP2 complex mutant in which the αC-helix of IR1
cannot form (BD34 K2645P complex) should increase catalytic efficiency or at least
support catalysis. While I was able to purify this complex, it showed strongly dimin-
ished stability in isopeptidase protection assays (data not shown). Hence, it is not
guaranteed that this complex variant retains its integrity and it cannot be excluded
that during catalysis the highly active IR1 may become available.
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Figure 60: Model for the binding of the thioester to the RanBP2 complex. (A)
Schematic depiction of the RanBP2 complex in the closed conformation before binding the
Ubc9∼SUMO1 thioester (left) and in an opened-up conformation after binding the thioester
(right). This openend-up conformation makes SUMO1C accessible for the thioester so that the
Ubc9T /SUMO1C backside interaction can engage (red star). (B) Ribbon Structure of the RanBP2
complex in the closed conformation (PDB: 1Z5S). Ubc9C (plum) and SUMO1C (purple) assume
the folded-back conformation stabilized by SIM1 (grey), the αC-helix (red) and the canonical and
backside Ubc9-binding site of IR1 (grey). The C-terminal domain of RanGAP1 (orange) contacts
the C-terminus of Ubc9 and is covalently linked (blue line) to the C-terminus of SUMO1C . (C)
Structural model the RanBP2 complex in a opened-up conformation (derived from PDB: 1Z5S).
While the Ubc9C/RanGAP1 conformation is preserved, SUMO1C bound to SIM1 folds back (pur-
ple arrow) and opens the Ubc9C/SUMO1C interface. This possibly involves an unfolding of the
αC-helix (red line). The strcutre is shown in the same orientation as in (B) aligned at Ubc9C
and RanGAP1. (D) Structural model of the RanBP2 complex in the opened-up conformation
as (C) having bound a Ubc9∼SUMO1 thioester. Ubc9T (light green) and SUMO1T (olive) are
shown in the folded-back conformation (from PDB: 1Z5S); the catalytic cysteine of Ubc9T and the
C-terminus of SUMO1T are shown in yellow. Bound to the thioester is the modeled putative SIM2
and canonical Ubc9-binding site of IR2 (black). The straight grey line represents the M-region, the
straight red line the possibly unfolded αC-helix of IR1. Top: representation in the same orientation
as in (B) and (C). Bottom: structure turned be 180◦ along the z-axis.
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While a conformational change on the side of IR1 thus still awaits conclusive
proof, a mutational analysis with RanBP2 complex variants, in which the stability
of the Ubc9C/SUMO1C interface was tweaked directly, showed that an opening of
this interface has a positive effect on thioester mimic binding as well as catalytic
activity. Importantly, isopeptidase protections assays with these variants could rule
out that the mutations compromised the stability of RanBP2 complex and thus
would have liberated the catalytically active IR1 region.
These findings are highly surprising, since they suggest that a structural non-
destructive rearrangement of the RanBP2 complex has a gain-of-function effect on
thioester mimic-binding and catalysis. They thus reshape our view of the RanBP2
complex from a static unit towards a flexible, yet still biochemically stable entity.
Partial opening of the RanBP2 would make the interaction between SUMO1C and
UbcT possible.
A common denominator of many biochemical experiments involving the RanBP2
complex (in contrast to free RanBP2) is the observation that effects of mutants were
generally quite subtle and hardly ever all-or-nothing. This observations might be
disconcerting at first glance, however support the model of the RanBP2 complex as
a multisubunit E3 ligase, where interactions are multifaceted and hence not easily
abolished by single mutations.
3.4 A comparison of different E3 ligase
mechanisms
3.4.1 Binding of the E2∼modifier thioester by the E3 ligase
A mechanistic key feature of (SP-)RING-type E3 ligases is the promotion of the
folded-back E2∼modifier thioester conformation. With a mutational analysis that
is based on and complements previous structural work [Reverter and Lima, 2005], I
here showed that free RanBP2 as well as the RanBP2 complex mechanistically also
rely on the folded-back thioester conformation. The fact that RanBP2 exploits a
similar mechanism given no evolutionary nor structural similarities between it and
the (SP-)RING-type E3 ligases is a beautiful example of convergent evolution.
A crucial feature in promoting the folded-back thioester conformation is the bind-
ing of the E3 ligase at a canonical surface of the E2 enzyme (namely the α1-helix,
loop 1 and loop 2), in which (SP-)RING-type E3 ligases, RanBP2 and the RanBP2
complex engage. However, several supporting ways how ubiquitin E3 ligases pro-
mote this folded-back thioester conformation have been discovered.
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Binding of the modifier by the E3 ligase
While the canonical interaction surface on the E2 is largely conserved among E3
ligases, most of them also provide a binding site for the modifier. Interestingly, the
binding surface on the modifier strongly varies between different E3 ligases. Homod-
imeric RING-type E3 ligases for instance were found to contact ubiquitin via both
RING domains at a surface between the α1-helix and the β3-strand [Dou et al.,
2012, Plechanovová et al., 2012]. In contrast, the SP-RING-type E3 ligase Siz1
binds SUMO via a basic patch in the N-terminal region of SUMO [Yunus and Lima,
2009]. While Siz1 and other SP-RING-type E3 ligases commonly also feature a SIM
C-terminally of their SP-RING domain, this SIM is generally not essential for the
catalytic activity [Kotaja et al., 2002, Reindle et al., 2006, Takahashi and Kikuchi,
2005, Yunus and Lima, 2009].
The Melchior group previously reported that a SIM-like interaction with the mod-
ifying SUMO is important for catalysis mediated by the RanBP2 complex [Werner
et al., 2012]. However, mutating the hydrophobic residues of the putative SIM2 had
no effect on substrate SUMOylation [Werner et al., 2012]. In my hands, these exper-
iments showed a slight, yet reproducible defect, which may lie in the margin of error
between different experimentators. My experiments also showed that the catalytic
defect is much more pronounced in auto-SUMOylation, which had not been previ-
ously addressed and is a more direct measure of E3 ligase activity. I thus concluded
that the putative SIM2 contributes to RanBP2 complex-mediated SUMOylation.
An in silico modeling approach validated by a mutational analysis suggested
that not only the hydrophobic residues of the putative SIM2 contribute to SUMO-
binding, but also the C-terminal residues, which are by definition not part of the
classical SIMr motif (see Figure 25). The relevance of tryptophan 2714 and a salt
bridge formed by lysine 2716 was experimentally verified. These findings are in
line with the fact that those C-terminal residues are strictly conserved in IR2 se-
quences throughout vertebrates. Compatible with the relevance of the additional
salt bridge in the putative SIM2, which is absent in SIM1, Tatham and colleagues
showed a higher affinity of SIM2-containing RanBP2 fragments for SUMO1 over
SIM1-containing fragments [Tatham et al., 2005].
The in silico model suggested that the N-terminal acidic patch of the putative
SIM2, which is part of the classical SIMr motif, does not partake in β-augmentation
of SUMO1. Intriguingly, one of the residues of this acidic patch is a lysine, which
is strictly conserved in IR2 sequences throughout vertebrates. The lysine residue
clearly breaks with the classical definition of a SIMr motif. Taken together, these
observations suggest that the putative SIM2 in the RanBP2 complex may constitute
a novel extended SIM-type.
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Of note, SIM1 of IR1 seems to employ a similar mode of binding (see Figure
25A). Yet, the contribution of the C-terminal residues does not appear to be as pro-
nounced as in the putative SIM2 due to the lack of the [SUMO1]E33-[SIM2]K2716
salt bridge. Another difference between SIM1 and the putative SIM2 is that the
former does fit the definition of a consensus SIMr motif. However, as alluded to
above, the contribution of the N-terminal acidic patch to binding cannot be judged
based upon available data. Hence, it is conceivable that SIM1, like the putative
SIM2, belongs to the novel extended SIM-type and not to the classical SIMr-type.
One striking observations in the mutational analysis of the putative SIM2 and
canonical Ubc9-binding site in IR2 in the BD34 complex was that their ablation
had a much more pronounced effect on auto- than on substrate SUMOylation. Ad-
ditional factors, like substrate binding, contribute to the latter, which may account
for this difference. Another so far unexplored possibility is that there are mecha-
nistic differences between auto- and substrate SUMOylation. In that sense, auto-
SUMOylation would strictly require the IR2-mediated interaction with the thioester,
while substrate SUMOylation, which involves transient interaction, does not.
An additional binding site for the E2 enzyme
In addition to the canonical E2-binding site, many E3 ligases were found to bind
the E2 enzyme via a second binding site (see details below). Importantly, the oblit-
eration of this additional binding site in these examples decreases the affinity of the
thioester for the E3 ligase [Buetow et al., 2015]. The data I presented here suggests
a similar concept for the RanBP2 complex, which appears to offer backside interac-
tion for Ubc9 with SUMO1C .
The exploitation of a backside E2-binding by ubiquitin E3 ligases is not unprece-
dented. The effects of this type of interaction vary: for instance, the backside E2-
binding region, G2BR (Ube2g2 binding region), of the RING-type E3 ligase gp78
(glycoprotein 78) binds its cognate E2 enzyme Ube2g2 (ubiquitin E2 G2) with high
affinity and induces an allosteric change in the latter, which increases its affinity
for the canonical E2-binding site within the RING domain [Das et al., 2013, Li
et al., 2009]. After ubiquitin-discharge, the RING domain in turn allosterically in-
fluences the E2 enzyme to loosen the interaction to G2BR thus ensuring efficient
turnover. Conversely, the backside binding region, R6BD (Rad6 binding domain),
of the RING-type E3 ligase Rad18 (radiation) binds to the E2 enzyme Rad6 and
thereby limits its inherent ubiquitin chain-forming activity [Hibbert et al., 2011].
Ranaweera and Yang reported that ubiquitin auto-modification of the RING-
type E3 ligase MDM2 (mouse double minute 2 homolog) serves to recruit additional
E2∼ubiquitin thioesters via an E2/ubiquitin backside interaction and thus increase
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their local concentration for more efficient substrate modification [Ranaweera and
Yang, 2013]. Very recently, Buetow and colleagues published an extensive bio-
chemical study, in which they demonstrated that an UbcH5B/ubiquitin backside
interaction allosterically enhances the affinity of the E2∼ubiquitin thioester for the
RING-type E3 ligase RNF38 and thus improves the catalytic efficiency of ubiquitin
transfer [Buetow et al., 2015]. They showed that the source of backside interacting
ubiquitin can be the cellular pool of free ubiquitin as well as ubiquitin attached to
a substrate (by previous modification) or the E3 ligase (by auto-modification).
Their picture of an E3-ubiquitin/UbcH5b∼ubiquitin complex resembles concep-
tually very much my model of a Ubc9∼SUMO1 thioester-bound RanBP2 complex.
The question whether an alloesteric effect similar to the one described by Buetow
and colleagues also applies to the RanBP2 complex remains to be determined. How-
ever, given that the connection between SUMO1C and IR2 is flexible, the model
described above does not thoroughly explain how the three interactions surfaces
within the RanBP2 complex are fixed with respect to each other so that preferen-
tially the folded-back thioester conformation is bound. Hence, an allosteric effect of
the Ubc9T/SUMO1C interaction to promote the folded-back thioester conformation
is conceivable.
Allosteric influences on the E2 enzyme
Another way by which RING-type ubiquitin E3 ligases were shown to promote the
folded-back thioester conformation is a direct allosteric effect of the RING domain
on the E2 enzyme. This effect hinges on subtle structural changes in an aspartate
residue near the active site (aspartate 87 in UbcH5A), as for example already the
slightly longer glutamate at this position had negative effects on catalysis [Pruneda
et al., 2012, Wenzel et al., 2011]. Interestingly, the corresponding residue in Ubc9 is
serine 95, which is similar in length to aspartate.
Crucial to this allosteric effect of RING-type E3 ligases is a hydrogen bond involv-
ing a region of the E2 enzyme upstream of the aspartate and a conserved arginine (or
lysine) in the RING domain [Pruneda et al., 2012]. Unfortunately, a corresponding
analysis has not yet been extended to SP-RING domains, where a polar residue,
capable of forming a hydrogen bond (glutamine, asparagine, aspartate or serine), is
conserved at this spatial position. Judging from the structure of the trapped prod-
uct complex of IR1, Ubc9 and RanGAP1*SUMO1, neither RanBP2 (with IR1) nor
the RanBP2 complex (with IR2) feature a residue that spatially corresponds to the
conserved argenine/lysine of the ubiquitin RING-type E3 ligases.
This however does not exclude the elicitation of a similar alloesteric effect in Ubc9
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by RanBP2 or the RanBP2 complex. In future experiments, I want to assess the
principle existence of such an effect in Ubc9. For this, I want to test the activity of
a Ubc9 S95E mutant as an E2 enzyme particularly in RanBP2 complex-mediated
SUMOylation reactions to see if a mutation at this position has a similar effect as
in ubiquitin E2 enzymes.
Complementary, I plan an IVL-labeling approach of the Ubc9∼SUMO1 thioester
mimic and NMR measurements in the absence and presence of 2H,15N-labeled Ran-
BP2 complex. However, due to the propensity of the isopeptide-linked thioester
mimic to form backside interaction-mediated multimers at concentrations needed
for NMR measurements, I was concerned not to be able to separate effects elicited
by mulitmer formation from those caused by E3 ligase interaction. Using a backside
interaction-defective E2 mutant to form the mimic, as done by Plechanovovoa and
colleagues [Plechanovová et al., 2012], does not seem a feasible idea due to the po-
tential involvement of a backside interaction in RanBP2 complex/thioester mimic
binding. Instead, I want to use a backside interaction-deficient SUMO1 mutant for
mimic formation to perform this experiment.
3.4.2 Natively unfolded E3 ligases
Free RanBP2 and the RanBP2 complex as natively unfolded E3 ligases
The distinctive feature of the E3 ligase region of RanBP2 with respect to (SP-)
RING-type E3 ligases is its natively unfolded character, which greatly contributes to
its enzymatic activity. The globular (SP-)RING domain is thought to interact with
an E2∼modifier thioester in a comparably rigid way. Conversely, evidence from this
work and others [Pichler et al., 2004, Reverter and Lima, 2005, Tatham et al., 2005]
has supported a model where the SIM and Ubc9-binding sites of IR1 act largely
independently of each other and as linear (natively unfolded) motives [Dyson and
Wright, 2005] to bind the Ubc9∼SUMO thioester. This model predicts that IR1
can sample a variety of conformations of the thioester from its conformational equi-
librium in solution. In contrast, RING-type E3 ligases (and the RanBP2 complex)
appear to invoke a preference in sampling the folded-back thioester conformation
from the equilibrium.
In line with this model is my finding, that IR1 binds the Ubc9∼SUMO1 thioester
mimic quite strongly and that mutations, which tweak the propensity of the mimic
to form the folded-back conformation, have no influence on IR1 binding. In contrast,
these same mimic mutants do have an effect on binding to the RanBP2 complex.
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While the folded-back thioester conformation does not seem to play a signifi-
cant role in binding to IR1, its eventual formation does play a role in catalysis.
This finding suggests that binding of the thioester and promotion of its folded-
back conformation are separate steps in IR1-mediated SUMOylation. Conversely,
in RING- and RanBP2 complex-mediated catalysis both steps are much more inti-
mately linked.
For IR1, I hypothesized that the link between thioester-binding and catalysis
hinges on formation of a helix in IR1 termed the αC-helix. This helix is strategi-
cally positioned between SIM1 and the Ubc9-binding sites. If formed, as shown in
PDB: 1Z5S, it fixes Ubc9 and SUMO1 with respect to each other in the folded-back
conformation. If unfolded however it should allow the SUMO1/SIM1 and Ubc9/IR1
interactions to take place with much more flexibility towards each other.
In line with this view, the formation of the αC-helix (but not necessarily its se-
quence) proved to be crucial for IR1-mediated catalysis, while not affecting binding
of the thioester mimic. These observations combined with the fact that none of the
residues of the αC-helix actually contact Ubc9 or SUMO1, suggest that the driving
force in promoting the folded-back thioester conformation by IR1 is the formation
of this helix.
While a potential αC-helix of IR2 in the RanBP2 complex appeared to be in-
volved in catalysis as well, its effects were much less pronounced compared to IR1.
Also, its inability to form affected binding of the thioester mimic. These findings
are in line with a view that the RanBP2 complex in its E3 ligases mechanism is
situated somewhere between the globular and rigid (SP-)RING-type E3 ligases and
the completely natively unfolded IR1 of free RanBP2. While several characteristics
of the flexible IR1 region are conserved within IR2, the sampling of the folded-back
thioester conformation from the equilibrium in solution by a set of spatially coor-
dinated binding sites (the putative SIM2, the canonical Ubc9-binding site and the
complex-SUMO) is more reminiscent of the action of (SP-)RING-type E3 ligases.
It was shown that the RanBP2 complex and not free RanBP2 is the endogenously
relevant SUMO E3 ligase, as RanGAP1*SUMO1 and Ubc9 stably occupy virtually
all RanBP2 molecules in the cell [Werner et al., 2012]. This indicates that under
normal conditions RanBP2 is limiting. However, it is imaginable that under condi-
tions where RanGAP1 levels are reduced, e.g. during the differentiation of coronary
artery smooth muscle cells [Vorpahl et al., 2014], free RanBP2, i.e. IR1, becomes
endogenously relevant as an E3 ligase.
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Other potential natively unfolded E3 ligases
While IR1 and IR2 share no sequence similarity to (SP-)RING-type or HECT
E3 ligases, homology was identified for an N-terminal sequence of the transcription
factor E4F1. Interestingly, this sequence was demonstrated to possess ubiquitin E3
ligase activity [Le Cam et al., 2006]. E4F1 is a p53-associated protein, which is
able to mediate oligo-ubiquitination on lysine residues at the hinge region of p53.
Their ubiquitiylation is mutually exclusive with modification by the acetyltrans-
ferase PCAF and evokes a p53-dependent transcriptional cell cycle arrest program.
Despite the fact that E4F1 is able to mediate ubiquitination at enzymatic concen-
trations, peculiarly, auto-modification, a hallmark of E3 ligases, was not observed
for it [Le Cam et al., 2006]. Unfortunately, mechanistic data on E4F1 remain scarce.
While the IR-related, N-terminal region of E4F1 has not been subjected to a bio-
physical analysis, the sequence is predicted to have a similar degree of disorder as
the IR regions (prediction by ELM), which points to a natively unfolded region.
Critical residues for E2-binding in IR1 (canonical and backside) are conserved. This
finding is particularly intriguing, since the IR regions interact specifically with the
SUMO E2 enzyme Ubc9, while ubiquitination assays for E4F1 were conducted with
the ubiquitin E2 enzyme UbcH5B. Biochemical and structural studies to address
the catalytic mechanism of this atypical E3 ligase and how it discriminates between
the SUMO and the ubiquitin enzymes are eagerly anticipated.
A recent study postulated SUMO E3 ligase activity for the Fanconi anemia protein
SLX4 (synthetic lethal of unknown function 4), which is unrelated to SP-RING-type
proteins or RanBP2 [Guervilly et al., 2015]. SLX4 contains three SIM, which by
nature are natively unfolded, and which were responsible for the SUMO E3 ligase
activity of SLX4 by interacting with SUMO in a Ubc9∼SUMO thioester. Addition-
ally, acidic residues in SLX4, which intersperse the SIMs, are believed to bind to a
basic patch in Ubc9 formed by lysine 65, 74 and 76. The data provided by this study
suggests a model of a natively unfolded E3 ligase that, similarly to IR1, wraps itself
around the Ubc9∼SUMO thioester for catalysis and uses a surface on Ubc9 that is
located far away from the canonical E3 ligase interaction. However, while the role
of SLX4 as a SUMO-binding protein is uncontested [Ouyang et al., 2015], its action
as an E3 ligase enzyme is put into question by the observation that relatively long
incubation (1 h) of recombinant SLX4 with a pre-formed Ubc9∼SUMO2 thioester
resulted only in a very poor SUMOylation in vitro.
In sum, the recent years have shown that E3 ligase activity does not neces-
sarily have to depend on globular protein fold, but that the crucial folded-back
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E2∼modifier thioester conformation can be promoted also by natively unfolded pro-
teins as a new class of E3 ligases. Particularly, further mechanistic and undoubtedly
challenging structural work is required to better understand these enzymes.
3.4.3 IR2 - an incomplete SUMO E3 ligase
My biochemical analysis of the free BD34 fragment showed that, while IR1 is
an efficient E3 ligase and IR2 shows very little activity, both regions appear to be
able to bind the thioester mimic equally well. Pull-down assays with IR1 and IR2
showed a higher affinity of Ubc9 for IR1 [Pichler et al., 2004, Tatham et al., 2005],
while IR2 (or rather SIM2) has a higher affinity for SUMO1 [Tatham et al., 2005].
These observations prompt the hypothesis that in the interaction between IR2 and
the thioester mimic, the Ubc9-mediated interaction is weaker in comparison to IR1,
but the SUMO1-mediated interaction is stronger resulting in no considerable net
change in overall affinity. However, the differences in E3 ligase activity between IR1
and IR2 suggest that not (only) the affinity, but rather the mode of interaction with
the Ubc9∼SUMO thioester is crucial for catalysis.
A closer look at IR1 and IR2 may indicate an explanation for the different Ubc9
affinities. While the canonical Ubc9-binding site is perfectly conserved between IR1
and IR2, the backside binding site is somewhat degenerated: only three of the eleven
backside-binding amino acids of IR1 are conserved in IR2 and the spacing between
the canonical and backside Ubc9-binding sites in IR1 and IR2 is different (see Figure
6C). Mutation of glutamate 2675, aspartate 2676, phenylalanine 2677 or tyrosine
2689 in the backside Ubc9-binding site of IR1 decreased its catalytic efficiency mod-
erately [Pichler et al., 2004]. This observation seems to indicate a relevant, yet not
crucial role of the backside Ubc9-binding site in IR1-mediated catalysis, a role that
however IR2 alone with its degenerated C-terminal sequence cannot fulfill. In the
future, I want to test this hypothesis by creating and biochemically characterizing
mutants of IR2 that in their backside Ubc9-binding site resemble IR1 (e.g. N2747E,
N2749E, Q2764L and K2765Y); these mutants or their combinations should increase
the E3 ligase activity of IR2 alone.
In the case of free RanBP2, the backside interaction surface on Ubc9T is effec-
tively blocked during catalysis by IR1-binding [Reverter and Lima, 2005, Tatham
et al., 2005]. My NMR and mutational analysis provided evidence that in the case
of RanBP2 complex, this surface on Ubc9T is engaged by SUMO1C . These findings
prompt a model in which IR2 is an “incomplete” E3 ligase due to its inefficient bind-
ing to Ubc9’s backside. In the RanBP2 complex, where IR2 becomes the catalytic
center, this missing binding site is complemented by a component of the complex
(SUMO1C), thus restoring a binding pattern on Ubc9 similar to IR1.
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The “incompleteness” of IR2 and composite character of the RanBP2 complex may
be biologically meaningful for turnover during a SUMOylation reaction. In IR1, the
canonical and the backside Ubc9-binding site are directly connected and the connect-
ing sequence overlaps with the Ubc9-binding site of the SUMO E1 enzyme [Wang
et al., 2010]. In the RanBP2 complex, the C-terminal IR2 sequence does not appear
to bind to the backside of Ubc9, which would make the E1-binding site readily avail-
able for another round of SUMO-loading. Additionally, while the RanBP2 complex
presumably can bind the thioester in a threefold manner (i.e. SUMO/SIM, canon-
cial and backside Ubc9-binding), the SUMO/SIM interaction breaks away with the
discharge of SUMO during catalysis. Also, the backside Ubc9-binding is only made
possible by an opening of the RanBP2 complex, which most likely is a reversible
process. In sum, this suggests that Ubc9 in the context of the thioester can bind
to the RanBP2 complex efficiently, but then efficiently dissociates from it after dis-
charge of SUMO to allow repeated rounds of modification. In the ubiquitin field,
several instances of an increased affinity of the E3 ligase for the thioester and a de-
creased affinity for the E2 alone are documented: while one of these examples shows
phosphorylation to be mechanistically responsible [Ryan et al., 2010], two others
intriguingly indicate an allosteric mechanism involving an E2-backside interaction
[Buetow et al., 2015, Das et al., 2013]. Future experiments will have to determine if
the RanBP2 complex acts in a similar way.
3.5 A specific, high-affinity interaction between
the export receptor Crm1 and RanBP2
In order to address potential interactions of the RanBP2 complex with compo-
nents of the Ran GTPase system, I tested binding via gel filtration between a re-
constituted version of the RanBP2 complex to a selection of recombinant transport
receptors, which had been implicated with the complex by literature. None of the
tested transport receptors with the exception of Crm1 bound in sufficient strength
to the RanBP2 complex directly; this is not surprising as literature evidence for a
contribution of the RanBP2 complex in their respective transport pathways came
mainly from cell biological studies, that did not address direct interaction. In con-
trast, I could recapitulate in my experimental setting a stable interaction between
the reconstituted RanBP2 complex and an importin β/RanQL complex, which had
been biochemically demonstrated before and which thus served as a positive control
[Yaseen and Blobel, 1999]. A similar interaction, although to my knowledge not
specifically demonstrated in the literature, could be shown for the import receptor
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importin 13. Although a contribution of other regions of the RanBP2 complex to
these interactions cannot be excluded, they were highly dependent on the presence
of RanQL. Thus an indirect interactions between the RanBDs of the RanBP2 com-
plex and theses transport receptors via Ran seems to play a crucial role here.
The clear exception in the tested transport receptors was the export receptor
Crm1, which bound stably to the RanBP2 complex in the absence and presence of
RanQL. Although a direct interaction between Crm1 and RanBP2 has been sug-
gested before [Singh et al., 1999], it involved the N-terminal zinc finger motives of
the latter. In contrast, I could demonstrate that the stable interaction observed here
was mediated by both of the IR region-adjacent FG-repeat patches in the C-terminus
of RanBP2 and hence constitutes a novel binding site for Crm1. Interestingly, while
low-affinity docking of transport receptors to the many FG-repeats in RanBP2 has
been assumed [Hutten and Kehlenbach, 2007], this interaction has a KD in the nM-
range and appears to be Crm1-specific.
In a meta-study, Tetenbaum-Novatt and colleagues have reported that the affin-
ity of transport receptor/FG-nucleoporin interactions is generally overestimated in
in vitro assays with an average measured KD of 270 nM [Tetenbaum-Novatt et al.,
2012]. However, most of the studies they investigated measured transport receptor-
binding to immobilized FG-nucleoporins, which represent a high local concentration.
In my assays, a 1:1 stoichiometry of binding in solution was observed. Even if the
affinity of of the Crm1/RanBP2 interaction had been overestimated in vitro, it is
still of a higher affinity than those between RanBP2 and the other tested transport
receptors. Particularly, the lack of a corresponding interaction with the structurally
related export receptor CAS speaks in favor of a specific interaction between the
RanBP2 complex and Crm1.
3.5.1 A structural view on the novel Crm1/RanBP2
interaction
Almost as surprising as the stable interaction between the IR-adjacent FG-repeats
of RanBP2 and Crm1, was the fact that RanBP2 is able to bind a Crm1-dependent
export complex (formed with the model NES-cargo SNP1) with a seemingly higher
affinity than the free Crm1. Importantly, the interaction with the export complex
was still entirely dependent on the FG-repeats in RanBP2 and thus seems to be
mediated by Crm1 alone (without contributions of Ran or the cargo). This in turn
suggests that the affinity increase from free Crm1 to Crm1 in an export complex is
intrinsic.
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Figure 61: FG-binding sites on Crm1. (A) Surface structure of a complex of Xpo1, Gsp1p-
GTP and Yrb2p. Xpo1 (yeast Crm1 in turquoise) in the closed conformation bound to Gsp1pQ71L-
GTP (yeast RanQL in maroon) and Yrb2p (yeast RanBP3 in light brown) (PDB: 3WYF). The
RanBD of Yrb2p is visible in the crystal structure (right) as well as two FG-repeat patches (left),
which bind to the N- and C-terminus of Xpo1 (yellow). (B) Surface structure of Chaetomium ther-
mophilum (= C.t.) Crm1 in the free, extended conformation with FG-binding sites corresponding
to (A) marked in yellow.
During the preparation of this manuscript, Koyama and colleagues published a
crystal structure of Xpo1 (yeast Crm1) in complex with Gsp1pQ71L-GTP (yeast
RanQL) and the FG-repeat protein Yrb2p (yeast RanBP3), an auxiliary factor in
the formation of Crm1-dependent export complexes [Koyama et al., 2014] (see also
Section 3.5.2). The two FG-repeat patches of Yrb2p, which are otherwise natively
unfolded, were visible in this structure and bound via three specific phenyalainine
sidechains each to the outer surface of the N- and C-terminus of Xpo1 (Figure 61A).
The relevance of both patches for Xpo1-binding was confirmed biochemically. Pull-
down assays showed that FG/Crm1-binding is sufficient for an interaction between
Yrb2p and the export receptor, but it is enhanced by the presence of Gsp1p-GTP. In
sum, these results are very reminiscent of the findings presented in this work. They
prompt the idea that the binding sites in the N- and C-terminus of Xpo1, which are
largely conserved in human Crm1, are a blue print for specific FG/Crm1 interaction
that may be relevant for the interaction with the IR-adjacent FG-repeats RanBP2 as
well. I hope to test this idea by employing bona fide FG-binding-defective mutants
of human Crm1 (based on the mutants from Koyama and colleagues) in binding
assays with the RanBP2 complex.
While the free Crm1 largely assumes an extended conformation, in which N- and
C-terminus are roughly 24 Å apart [Monecke et al., 2012] (Figure 61B), the Crm1
structure in the export complex is rather compacted with its N- and C-terminus in
close contact [Monecke et al., 2009] (Figure 61A). It is tempting to speculate that
the increased distance between Crm1’s N- and C-terminus, which might act at FG-
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binding sites, is the molecular explanation for the affinity decrease for Crm1 from
free to export complex form when binding to the RanBP2 complex.
A structurally interesting feature of the novel Crm1/RanBP2 interaction is the
fact that it requires two FG-repeat patches in RanBP2 and that the region between
them is largely unfolded [Pichler et al., 2004]. As interactions between importin
β-related transport receptors and FG-nucleoporin are thought to occur on the outer
surface of the receptors [Bayliss et al., 2000, Koyama et al., 2014, Liu and Stewart,
2005], my findings prompted a model in which the flexible RanBP2 wraps around
Crm1. Gel filtration analyses of the Stokes radii of the RanBP2 complex alone
and bound to Crm1 are compatible with this structural model. Also, EM negative
staining experiments seem to indicate a much more defined structure of the RanBP2
complex when bound to Crm1.
Having made the RanBP2 complex accessible for EM experiments, I hope that
attempts to obtain a high-resolution structures (possibly by cryo-EM) can be made.
Of particular interest here would be the structure of a RanBP2 complex (possibly
without RanBDs, i.e. BD∆34 complex) bound to Crm1 alone and bound to a Crm1-
dependent export complex. These structures should give much needed insight into
the FG-binding surface on Crm1 as well as the relative spatial position of RanGAP1
and IR2 towards Crm1 and its cargo. They might also, as alluded to above, give
hints towards understanding the affinity increase to RanBP2 between free Crm1 and
a Crm1-dependent export complex.
3.5.2 The RanBP2 complex as a functional unit to
disassemble Crm1-dependent export complexes
In this work, I have given biochemical evidence that the RanBP2 complex can
not only bind a Crm1-dependent export complex, but also that the directly adjacent
RanBDs can bind the Ran molecule in the export complex and expel the NES-cargo
via the allosteric mechanism described by Koyama and Matsuura [Koyama and
Matsuura, 2010]. I have also shown that the resident RanGAP1 in the RanBP2
complex can bring about GTP hydrolysis on Ran after RanBD binding. In short,
this data suggests that the RanBP2 complex can act autonomously to disassemble
Crm1-dependent export complexes in a three-stepped process: (1) binding, (2) cargo
expulsion and (3) Ran-GTP hydrolysis (Figure 62A). This view is supported by my
finding that the export complex has a higher affinity for the RanBP2 complex than
free Crm1, which would provide directionality to the process.
Of note, my data does not exclude that after binding of the export complex the
other two steps are performed by the RanBDs/RanGAP1 of another RanBP2 com-
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plex, i.e. in trans or that in the cell they can be executed by soluble RanBP1 and
RanGAP1. Indeed, in gel filtration binding assays I observed efficient export com-
plex disassembly not only by the RanBP2 complex, but also by soluble RanGAP1
and GST-RanBP1 (data not shown). However while a number of studies have
alluded to a role of the RanBP2 complex as an autonomous platform for export
complex disassembly, this work, to my knowledge, for the first time biochemically
addresses this model [Bernad et al., 2004, Engelsma et al., 2004]. It seems rea-
sonable to assume that tethering RanGAP1 to RanBDs and combining this with a
high-affinity binding site for an export complex would increase the efficiency of dis-
assembly, particularly because it would simplify disassembly from three-component
to a two-component reaction. However, if and to what extend the RanBP2 complex
is more effective than soluble RanGAP1 and RanBP1 still awaits a detailed kinetic
analysis by cargo dissociation assays [Koyama and Matsuura, 2010] and Ran-GTP
hydrolysis assays [Maurer et al., 2001].
How in detail the presence of a functional unit to bind and disassemble export
complex at the NPC affects Crm1-dependent export in cells also remains to be in-
vestigated. Earlier studies have reported the nucleoporin Nup214, which forms the
base of the cytoplasmic filaments of the NPC and the anchorage site for RanBP2,
as a principle docking site for Crm1-dependent export complexes [Fornerod et al.,
1997]. This interaction is also mediated by FG-repeats [Askjaer et al., 1999]. It will
be interesting to see if and how Nup214 and the RanBP2 complex can complement
each other in export complex binding and disassembly.
The fact that several studies did not observe a drastic export defect in the ab-
sence for example of RanBP2, seems to indicate that the RanBP2 complex is not
essential or respectively that soluble RanBP1 and RanGAP1 are sufficient for trans-
port processes under normal conditions [Bernad et al., 2006, Hamada et al., 2011,
Hutten and Kehlenbach, 2006]. This is compatible with the fact that yeast lacks
RanBP2 altogether. Of note, studies in the vertebrate system have been exclusively
conducted in rapidly dividing tissue culture cells that have high levels of soluble
RanGAP1 and RanBP1 and are relatively small in size. The RanBP2 complex may
be especially relevant for export complex disassembly in differentiated cells with
extended dimensions such as neurons or in cells with low levels of soluble RanGAP1
or RanBP1. Significant reduction of RanGAP1 levels has been observed in human
coronary artery smooth muscle cells for instance [Vorpahl et al., 2014]. It also seems
conceivable that the role of the RanBP2 complex may become more critical under
(yet to be identified) stress conditions, where nuclear export or rather turn-over
during export becomes rate-limiting. In that sense, Bernad and colleagues showed
that the effects of actinomycin D, a drug that induces nuclear export, were partly
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inhibited by RanBP2 knock-down [Bernad et al., 2004].
Hamada and colleagues speak in favor of a supportive role of RanBP2 com-
plex during transport, but also showed that all transport defects in the absence of
RanBP2 were rescued by expression of an N-terminal fragment of RanBP2 [Hamada
et al., 2011]. They affirmed that it is the C-terminal half of RanBP2 with IR-flaking
FG-repeat patches [Hamada et al., 2011], which mediates Crm1 localization at NPC
[Bernad et al., 2004, Engelsma et al., 2004, Hutten and Kehlenbach, 2006]. This
finding prompts the idea that the RanBP2 complex with its position at the NPC
may become critical where diffusion of transport factors away from the nucleus be-
comes kinetically relevant to transport, e.g. in cell types with large volumes and/or
diameters. Hence, the remaining affinity of Free Crm1 for RanBP2 may be inter-
preted as a way to prevent Crm1’s dissociation into the cytoplasm and to destine
it for efficient re-import to the nucleus. Future experiments will have to address
whether the RanBP2 complex increases transport efficiency by making export com-
plex disassembly or the re-import of Crm1 more effective.
Expanding the disassembly capabilities of the RanBP2 complex: RanBP3
RanBP3 aids in Crm1-dependent export complex formation in the nucleus by
capturing Ran-GTP with its RanBD on the one hand and recruiting it to Crm1
by an FG-mediated interaction on the other [Koyama et al., 2014]. Thus, it puts
a molecular frame on the the otherwise non-stable interaction between Crm1 and
Ran-GTP (Figure 61A and 62A)). In turn, this RanBP3-facilitated interaction be-
tween Crm1 and Ran-GTP induces a conformational change in the export receptor,
which increases its affinity for NES-cargo [Englmeier et al., 2001, Koyama et al.,
2014, Lindsay et al., 2001]. A key intermediate in this export complex formation
mechanism is the tetrameric Crm1/Ran-GTP/RanBP3/NES-cargo complex [Lind-
say et al., 2001]. While the binding of RanBP3 to Ran-GTP in this tetramer appears
to be severed by binding of the NES-cargo to Crm1 [Koyama et al., 2014], the direct,
FG-mediated Crm1/RanBP3 interaction may persist, so that the tetramer (instead
of the trimeric export complex) is exported [Lindsay et al., 2001].
For the yeast system, Koyama and colleagues showed that FG-nucleoporins from
the central channel of the NPC like Nup116p and Nsp1p (nucleoskeletal-like protein
1 protein) can compete with Yrb2p (yeast RanBP3) for the binding to Xpo1 (yeast
Crm1) in a tetrameric export complex [Koyama et al., 2014]. They interpret this
passive competition as a mechanism to release Yrb2p from the tetrameric export
complex; Yrb2p can then be re-imported on account of its N-terminal NLS.
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Figure 62: Proposed model for Crm1 export complex formation and disassembly.
(A) Mechanism of Crm1-dependent export complex formation [Lindsay et al., 2001] [Koyama
et al., 2014]. In the nucleus, RanBP3 recruits Ran-GTP (via its RanBD) to Crm1 (via its FG-
repeat patches signified by triple black lines). The binding of Ran-GTP to Crm1 increases the
affinity of the latter for an NES-cargo (signified by red star). Binding of an NES-cargo severs
the Ran-GTP/RanBP3 interaction and either leads to the dissociation of RanBP3, which leaves
the trimerc export complex, or to the formation of a tetrameric export complex. Both types
of export complexes reach the cytoplasm. (B) Mechanism of Crm1-dependent export complex
disassembly by the RanBP2 complex. In the cytoplasm, both types of export complexes bind via
Crm1 to the IR-adjacent FG-repeat patches of the RanBP2 complex at the filaments of the NPC.
In the tetrameric export complex, this displaces RanBP3, which is re-imported via its NLS. In
the bound trimeric export complex, a RanBD of the RanBP2 complex binds to Ran-GTP thereby
allosterically expelling the NES-cargo. The resident RanGAP1 induces GTP hydrolysis on Ran
thereby achieving the dissociation of the latter. Crm1 still interacts, albeit weaker with RanBP2
and can be re-imported.
The human RanBP3 seems to behave functionally in a similar way as the Yrb2p,
although the FG-repeat patch region is only poorly conserved (instead of two FG-
repeat patches there are only two FG-repeats in RanBP3) [Koyama et al., 2014]. If
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the FG-binding sites on Crm1 for RanBP3 and RanBP2 are indeed overlapping (see
Section 3.5.1), it is tempting to speculate that the RanBP2 complex in vertebrate
cells, which does not have a homolog in yeast, plays a role not only in the disas-
sembly of trimeric, but also of the tetrameric Crm1/Ran-GTP/RanBP3/NES-cargo
export complexes. In this model, the RanBP2 complex offers specific FG-meditaed
binding site to displace RanBP3 from the exported tetramer and simultaneously
bind the remaining trimer (Figure 62B). In consecutive steps, the RanBP2 complex
could then expel the NES-cargo by virtue of its RanBDs and finally bring about
GTP hydrolysis on Ran. However, it remains to be determined in the vertebrate
system, but also in yeast to what extend disassembly of tetrameric Crm1 export
complexes by nucleoporins is of functional relevance.
3.5.3 A Crm1/RanBP2 interaction during mitosis
The role of the FG-mediated Crm1/RanBP2 interaction has thus far been dis-
cussed in the context of nucleocytoplasmic transport, i.e. during interphase. As
I could show in this work that the interaction also takes place in cells arrested
by nocodazole, it may also serve important functions during mitosis. Here, the
RanBP2 complex is loaded onto kinetochores in dependence of a Crm1-dependent
export complex after the initial MT/kinetochore attachment and is crucial in sta-
bilizing MT/kinetochore interaction and proper progression through mitosis [Ar-
naoutov et al., 2005, Joseph et al., 2004].
This recruitment implies a bipartite interaction of Crm1: on the one hand with the
RanBP2 complex and on the other with a kinetochore component. It is appealing to
speculate that the interaction with the RanBP2 complex is the FG-mediated binding
described in this work, while export complex formation ties Crm1 to the kinetochore
(either directly via an NES-kinetochore protein or indirectly via an NES-cargo that
interact with a kinetochore component).
While the transfectable full-length RanBP2 mFG12 variants has the potential to
test this model, I was unfortunately so far unable to reproduce the kinetochore lo-
calization of the RanBP2 complex in HeLa cells. A study by Roscioli and colleagues
speak in favor of this model by finding that over-expression of the FG-interacting
fragments of importin β prevented the kinetochore localization of the RanBP2 com-
plex, while concomitant over-expression of Crm1 or RanBP2 fragments reversed
this effect [Roscioli et al., 2012]. This suggests an involvement of an FG-mediated
Crm1/RanBP2 interaction in the kinetochore recruitment.
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Figure 63: Proposed model for the role of the RanBP2 complex at kinetochores. See
next page for Figure legend.
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Figure 63: Proposed model for the role of the RanBP2 complex at kinetochores (see
previous page). (A) Situation during early prometaphase. The mitotic chromosomes have con-
densed and have kinetochores formed (left). I suggest the existence of two Crm1 populations
at the kinetochore: a large resident Crm1 population (dark green), which is associated with the
kinetochore in an export complex-independent way [Arnaoutov et al., 2005], and a small Crm1
population (turquoise) bound by export complex formation with an NES-cargo that is either a
kinetochore component or binds a kinetochore component. Export complex formation is made
possible by Ran-GTP locally produced by the chromatin associated RCC1. MTs, which have not
yet attached to the kinetochore, presumably carry the RanBP2 complex (right) [Joseph et al., 2004].
(B) After MT/kinetochore attachment during prometaphase, the RanBP2 complex is loaded onto
kinetochores by binding to Crm1-dependent export complexes [Arnaoutov et al., 2005]. At the
kinetochore, the RanBP2 complex may fulfill one or more (non-exclusive) effector functions im-
portant for progression through mitosis. (1) By its E3 ligase activity, it may SUMOylate the
NES-cargo of the export complex it bound to or a kinetochore protein in close proximity. (2) The
complex may locally decrease the concentration of Ran-GTP by stimulation of GTP hydrolysis
on Ran. (C) The RanBP2 complex disassembles the export complex it is bound to. Afterwards,
it will either dissociate from kinetochores (left) or stay bound via the resident pool of Crm1 (right).
RCC1 remains chromatin-associated during mitosis, which keeps the Ran-GTP
concentration high around chromosomes [Kalab et al., 2002, Moore et al., 2002]
and would make the formation of a Crm1-dependent export complex at the kineto-
chore possible. Crm1 localizes to kinetochores at the end of prophase and remains
associated until late anaphase/telophase. Its kinetochore localization cannot be sig-
nificantly prevented by inhibition of export complex formation via Lepotmycin B
[Arnaoutov et al., 2005]. Where this suggests that the bulk of kinetochore-associated
Crm1 is not bound in an export complex fashion, it does not exclude the binding of
a small Crm1 population in this way.
This finding reveals a general conundrum of the Crm1-dependent loading model:
while export complex formation is needed for the recruitment of the RanBP2 com-
plex, its presence would counteract this process by its export complex disassembly
activity. There are a number of mutually non-exclusive ideas, which can help re-
solve this dilemma. (A) The disassembly activity of the RanBP2 complex may be
somewhat inhibited during mitosis; several mitosis-specific phosphorylations may
work in favor of this idea (phosphorylation of RanBP2 [Nousiainen et al., 2006]),
RanGAP1 [Swaminathan et al., 2004]) and/or Crm1 [Wu et al., 2013]). This idea is
supported by the finding of Dr. Annette Flotho in the Melchior group and myself
that during lengthy immunoprecipitation experiments (several hours), Crm1 and
Ran co-immunoprecipitate in almost stoichiometric amount with RanBP2.
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(B) The recruitment of the RanBP2 complex may be two-stepped process: in a
first ‘capture’ step, the RanBP2 complex binds with high affinity and high on-rate
respectively to an export complex at kinetochores. During the disassembly of the
latter, the RanBP2 complex binds with a lower on-rate to another kinetochore com-
ponent in a second step. My finding of a two-faceted binding of Crm1 to RanBP2
(strong binding in the export complex; less strong binding in the free form) allows
the speculation that during both recruitment steps RanBP2 interacts with Crm1
via its IR-adjacent FG-repeats: in the first step, with a small Crm1 population in-
volved in an export complex with a kinetochore component (or a protein that binds
to kinetochore component) and in the second step, with the resident Crm1 popula-
tion, which is Leptomycin B-insensitively associated with the kinetochore (as seen
in [Arnaoutov et al., 2005]).
3.5.4 A Crm1/RanBP2 interaction to couple the Ran
GTPase system with SUMOylation
The fact that a small portion of RanBP2 not only contains enzymatic activities
to regulate the Ran GTPase system and SUMOylation, but also the FG-mediated
Crm1-binding site allows to conceptually speculate about this Crm1/RanBP2 in-
teraction as a functional link between the Ran GTPase cycle and SUMOylation.
In this work, I showed that Crm1-interaction and SUMO E3 ligase activity of the
RanBP2 complex are at least in vitro compatible. Several mutually non-exclusive
ways how such a link may look like are discussed below; their existence is rather
speculative than based on specific experimental results.
Model I: SUMOylation affecting the Ran GTPase system
One scenario is imaginable where SUMOylation interferes with the Ran G T P a s e
system. There is precedence in the literature for such an influence of the SUMO
system: defective SUMO modification and de-modification impairs importin β-
dependent import [Stade, 2002]; SUMOylation of the import receptor Kap114 is
required for its proper function [Rothenbusch et al., 2012]. However, this evidence
is so far restricted to yeast where RanBP2 is absent. Work by the Melchior group
and others has shown that Ran can be SUMOylated and that the relevant lysines
are located on a surface that is involved in the binding of RanGAP1 and transport
receptor [Tammsalu et al., 2014] and [Sakin et al., 2015, submitted]. While this
finding allows exciting speculations about a possible regulatory mechanism, RanQL
and Crm1 are only very poorly SUMOylated by the RanBP2 complex in vitro, when
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they are in an export complex, i.e. the form in which they most likely encounter the
RanBP2 complex during interphase (shown by Sakin et al., 2015, submitted and in
this work). Also, there is evidence that the relevant species for Ran SUMOylation
is Ran-GDP and not Ran-GTP [Sakin et al., 2015, submitted]. Of note, if SUMOy-
lation were to efficiently interfere with the Ran GTPase system via the RanBP2
complex, the modification reaction would kinetically have to clearly precede the ac-
tion of the RanBDs or RanGAP1. However, the current kinetic knowledge seems to
indicate that RanGAP1-induced hydrolysis is fast (in the order of seconds), while
SUMOylation has a rather slow kinetic (in the range of minutes [Bossis and Mel-
chior, 2006]).
Model II: the Ran GTPase system affecting SUMOylation
Crm1, as the principle export receptor, interacts in the context of export com-
plexes with the plethora of proteins containing an NES. It is plausible that a fraction
of these proteins can get SUMOylated, as they are recruited to the E3 ligase region
of the RanBP2 complex (see Section 3.6 for details); a mechanism which could prin-
cipally apply to both interphase and mitosis. Of note, this does not imply that all
NES-cargoes of Crm1 become SUMO substrates in that way, as I could show in this
work e.g. for SNP1, but that the steric orientation of substrate lysines in cargo and
possibly SUMO consensus sites matter in this respect.
Nevertheless, the kinetic argument mentioned above is valid here as well. Given
the prolonged binding of Crm1 (and Ran) to RanBP2 in cells, as detected by im-
munoprecipitation experiments in the Melchior group, it is however not unlikely
that SUMOylation (of a sterically optimal substrate and/or possibly with the help
of additional so far unknown factors) can happen in similar time frame as export
complex disassembly. In any case, a detailed kinetic comparison of Crm1-dependent
export complex disassembly and SUMOylation will be as essential in this context
as it will be challenging.
Instead of substrate recruitment, the Crm1/RanBP2 interaction may be used by
the cell to recruit the E3 ligase to a specific site where SUMO substrates or a spe-
cific population of substrates are located. This scenario can be integrated into the
Crm1-dependent recruitment of the RanBP2 complex to kinetochores during mitosis
(see Section 3.5.3). Here, the SUMO E3 ligase activity may represent the effector
function of the RanBP2 complex, for which it needs to be localized to kinetochores
and which eventually ensures normal progression through mitosis (Figure 63).
While specific SUMO substrates and their downstream functional role in this
context are currently not known, the fact that the only two identified endogenous
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RanBP2 substrates (Topoisomerase IIα [Dawlaty et al., 2008] and Borealin [Klein
et al., 2009]) have functions during mitosis, is an indicator for the E3 ligases activ-
ity as a mitotic effector function of the RanBP2 complex. Hamada and colleagues
support this view, as they showed that over-expression of a RanBP2 fragment con-
taining the IR region in conjunction with an N-terminal RanBP2 fragment can
correct chromosome segregation errors during mitosis in the absence of endogenous
RanBP2 [Hamada et al., 2011]. Despite the fact that this fragment did not include
the IR-flanking FG-repeat patches, over-expression may have dissolved the require-
ment for a targeted recruitment of the E3 ligase activity in their experiments.
A circumstance which makes the interpretation of Hamada and colleagues debat-
able in hindsight however is the fact that they used mutations in IR1 (L2651A/
L2653A): while this mutation abolishes the SUMO E3 ligase activity of naked
RanBP2 in vitro, it prevents formation of the stable RanBP2 complex in cells and
thus the association of RanGAP1*SUMO1 [Werner et al., 2012]. This may imply
that (not SUMOylation, but) the local decrease of Ran-GTP by the RanBDs and
RanGAP1*SUMO1 is the relevant mitotic effector function of the RanBP2 complex
at kinetochores (Figure 63). This possibility was deemed unlikely, as depletion of
RCC1, which generally decreases Ran-GTP concentrations, had a negative effect
on mitosis progression [Arnaoutov et al., 2005, Arnaoutov and Dasso, 2005]. Addi-
tionally, it has been shown that a significant Ran-GTP gradient by local action of
RanGAP1 can only exist in large volumes (across a diameter of about about 30 µm)
[Görlich et al., 2003].
In sum, these findings demonstrate that only with our detailed knowledge of the
architecture of the RanBP2 complex, a meaningful and unequivocal dissection of
the effects of its different activities is possible. In the future, structure-function ex-
periments will be possible that systematically compromise each biochemical activity
contained within the RanBP2 complex (i.e. RanBDs, RanGAP1, E3 ligase activity,
Crm1-binding site).
3.6 Parallels between the RanBP2 SUMO E3
ligase and SCF E3 ligases
The main characteristic of an E3 ligase is the promotion of modification at enzy-
matic concentrations, which is achieved via two complementary molecular strategies:
(1) activation of the E2∼modifier for efficient discharge after nucelophilic attack by
the substrate lysine and (2) spatially coordinating the consolidation of the thioester
and the specific substrate [Hua and Vierstra, 2011]. In CRL ubiquitin E3 ligases
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(see Section 1.1.4) in general and in SCF CRLs specifically, a division of labor has
been observed by the subunits of the enzymes, which synergistically work in favor
of these two molecular strategies.
Although they are evolutionary unrelated, one cannot help but notice certain par-
allels between CRL ubiquitin E3 ligases and the RanBP2 SUMO E3 ligase complex.
Both constitute multisubunit E3 ligases. While the RING domain protein RBX1
tightly binds Cullin1 in SCF CRLs to form a catalytic core unit, which interacts
and activates the E2∼ubiquitin thioester, the IR region of RanBP2 plays a concep-
tually corresponding role in the RanBP2 complex for the Ubc9∼SUMO thioester.
Here, I have given evidence that the SUMO1C provides an additional binding sur-
face for Ubc9T . Intriguingly, it was shown for the SCFCdc4 (cell division cycle) E3
ligase, which works in concert with the ubiquitin E2 enzyme Cdc34, that not only
RBX1 interacts with the Cdc34∼ubiquitin thioester, but that Cullin1 provides an
additional binding site for the E2 enzyme mediated by its C-terminal, acidic tail
[Kleiger et al., 2009].
In SCF CRLs, Cullin1, SKP1 and the F-box proteins together are believed to cor-
rectly positions the substrate next to the thioester to bring the substrate lysine close
to the activated ubiquitin. A striking feature in this context is the ability of F-box
proteins to interact with a multitude of different substrates via short specific motives
called degrons [Wang et al., 2014]. This greatly expands the substrate repertoire
of these E3 ligases. With the evidence of a specific Crm1/RanBP2 complex inter-
action and the compatibility of this interaction with SUMO E3 ligase activity, it is
tempting to speculate that Crm1 can function as a substrate adaptor for SUMOy-
lation. This principle has not been documented in the SUMO field and would help
to explain the stunning discrepancy between the huge number of SUMO proteins
and the relatively small number of identified SUMO E3 ligases. Particularly fasci-
nating about this is the fact that, while ubiquitin substrate adaptors are proteins
that seem to have evolved for this specific purpose, Crm1 is a protein with a distinct
set of functions in interphase and mitosis, which are independent of SUMOylation.
Potential substrate adaption could be construed as a kind of molecular hijacking of
these functions by the SUMO machinery to expand substrate specificity.
One of the so far limited arguments that supports this model is that fact that a
minimal catalytic fragment of RanBP2 lacks distinct substrate specificity in vitro
[Pichler et al., 2004]. This suggests that in vivo additional mechanisms are required
to specify its substrate range, particularly in light of that fact that RanBP2 at the
NPC is located at a gateway of protein trafficking.
Conversely, I have shown that while the RanBP2 complex is still active when
bound to Crm1-dependent export complexes, Crm1 and Ran seem to have evolved
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in a way that largely prevents them from unspecific SUMOylation in the proximity
of the RanBP2 complex. Of note, the inability of the BD34 complex to SUMOy-
late the cargo SNP1 does not preclude other NES-cargoes recruited to the RanBP2
complex to act as SUMO substrates in that way. This finding demonstrates that
the correct geometric orientation of proteins is vital for them becoming SUMO sub-
strates. Interesting in this context will be a medium- to high-resolution structural
characterization of the RanBP2 complex bound to a Crm1-export complex in or-
der to elucidate a possible spatial and functional connection between the E3 ligase
region of tee RanBP2 complex and the Crm1-bound cargo. At the end however,
validation of the substrate adaptor model essentially requires the identification of
Crm1 cargoes, which can be specifically SUMOylated in dependence of RanBP2 and
importantly the cell biological relevance of this SUMOylation.
Chapter 4
Materials & Methods
4.1 Materials
4.1.1 Technical equipment
Table 5: Technical equipment
Equipment Manufacturer
AVANCE III 600, 700 and 800 MHz HD NMR Spectrom-
eter
Burker
Bacterial Incubator ISF-1-x Kühner
Balance PC4400 Mettler
Cell culture Hood Hera Safe Thermo Scientific
Cell culture Incubator Hera Cell 150 Thermo Scientific
Centrifuge Allegra X-22R Beckman Coulter
Centrifuge Heraeus Multifuge 1S Thermo Scientific
Centrifuge RC 3BP+ Sorvall
Centrifuges 5417R Eppendorf
Chromatography system Äktapurifier and Äktamicro GE Healthcare
Douncer (50 ml) Satorius
Electron microscope Zeiss 910 Zeiss
Electrophoresis and blotting chambers Workshops at MPI, Martinsried
Biochemistry I, Göttingen and
ZMBH, Heidelberg
Electrophoresis power supply EPS300/301 Pharmacia Biotech
Electrophoresis power supply Power Pac HC Bio-rad
EmulsiFlex-C5 Avestin
Freezers, Refrigerators Liebherr
Gelfiltration columns: GE Healthcare
HiLoad 26/60 Superdex 200 prep grade
HiLoad 26/60 Superdex 75 prep grade
MonoQ 5/50 GL
Superdex Peptide PC 3.2/30
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Equipment Manufacturer
Superdex200 10/300 GL
Superdex200 5/150 GL
Superdex75 10/300 GL
Superose 6 PC 3.2/300 GL
Heating blocks Störk-Tronic
HeraFreeze Thermo Scientific
Icemachine Scotsman
Immunoblot documentation sytem Odyssey CLx LI-COR Biotechnology
Incubation water bath 1008 GFL
Gel documentation system LAS-4000 Fujifilm
Magnetic stirrer MR Hei-Mix L Heidolph
Micro balance CP 60-OCE Sartorius
Microplate reader Appliskan Thermo Scientific
Microwave R-93ST-A Sharp
Monolith NT.115 Red/Green NanoTemper Technologies
NanoDrop 2000c Thermo Scientific
Neubauer counting chamber Brand
pH-meter 720 WTW
Pipettes Gilson, Eppendorf
Precision balance TE601, Mettler PC4400, Sartorius
Rotors: FiberLite F13-14x50cy, F9-4x1000y, F10-6x500y Piramoon Technologies Inc.
Rotors: TLA45, Type45Ti, Type70.1Ti Beckman Coulter
Shaker DRS-12 Neolab
Thermocycler T3000 and Tprofessional Biometra
Thermomixer Compact Eppendorf, Hamburg
UV-table UVT-20L Herolab
Ultracentrifuge Discovery 90SE, M120 SE Thermo Scientific
Ultrasonic bath Sonorex RK 100 Bandelin
UV-transilluminator Peqlab Biotechnologie GmbH
UV/Visible SpectroPhotometer Ultraspec 3100 pro Amersham Biosciences
Vortex 7-2020 Neolab
Water purification system MembraPure MembraPure GmbH
4.1.2 Consumables
Table 6: Consumables
Item Manufacturer
Cannulae, syringes (different sizes) Braun, Mediware
Cell culture consumables Sarstedt, TPP
Centrifugal filter units Millipore, Vivaspin
Dialysis tubing Spectra-Por Roth
continued on next page
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Item Manufacturer
Disposable plastic columns Bio-Spin, Poly-Prep, Econo-Pac Bio-Rad
Electron microscopy 300 mesh copper grids Plano Gmbh
Filter paper Whatman
Fraction collection 96well plates Roth
FRET 383well plates Greiner
Glass slides, coverslips Roth
Glassware Schott
Gloves (Rotiprotect-LATEX, -NITRIL, Peha-soft) Roth, Hartmann
MO-K002 Monolith NT.115 Standard Treated Capillaries NanoTemper Technologies
PCR tubes Sarstedt
Pipette tips (combi tips, filter tips) Sarstedt, Eppendorf, Nerbe,
Plus, Biozym, Ratiolab
Plastic pasteur pipettes Roth
Protein low binding reaction tubes Sarstedt, Eppendorf
PROTRAN Nitrocellulose Schleicher & Schuell
Reaction tubes Sarstedt, Eppendorf
Scalpels Lance Paragon LTD
Sterile filters and membranes (0.22-0.45 µm) Millipore, Pall, Sartorius
4.1.3 Software
Table 7: Software
Software Source
ApE 2.0.38 Jean-Claude wippler (equi4 software)
CTFFind3 Software [Mindell and Grigorieff, 2003]
ELM (web-based) [Dinkel et al., 2014]
EM-Menu 4.0 TVIPS
EMAN2.1 [Tang et al., 2007]
Image Studio Software 2.1.12 LI-COR Biotechnology
ImageJ 1.48h Rasband, W.S., ImageJ, U. S. National Institutes of
Health, Bethesda, Maryland
LAS-400 2.1 Fujifilm
Microsoft Excel 2008 for Mac 12.3.6 Microsoft Corporation
MO-S002 Monolith NT.Analysis NanoTemper Technologies
Prism v5.0c GraphPad Software Inc.
ProtParam (web-based) Gasteiger et al., Protein Identification and Analysis
Tools on the ExPASy Server in John M. Walker’s The
Proteomics Protocols Handbook, Humana Press (2005).
pp. 571-607
RELION [Scheres, 2015]
Serial Cloner 2.6.1 Franck Perez (SerialBasics)
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Software Source
SkanIT RE for Appliskan 2.3 Thermo Scientific
SWISS-Model (web-based) Swiss Institute of Bioinformatics, Biozentrum, Univer-
sity of Basel
Texmaker 4.0.2 Pascal Brachet
UCSF chimera 1.8 [Pettersen et al., 2004]
4.1.4 Chemicals, reagents and kits
Common chemicals were obtained from AppliChem, ROTH, Merck, Serva, and
Sigma-Aldrich. Some selected Chemicals, reagents and kits are listed below.
Table 8: Chemicals, reagents and kits
Chemical, reagent or kit Manufacturer
α-Ketobutyric acid, sodium salt (methyl-13C,
99%; 3,3-D2, 98%)
Cambridge Isotope Laboratories
α-Ketovaleric acid, sodium salt (3-methyl-13C,
99%; 3,4,4,4-D4, 98%)
Cambridge Isotope Laboratories
Acrylamide solution (30%, 37.5:1 AA:bisAA) AppliChem, Roth
Ammonium chloride (15N, 99%) Cambridge Isotope Laboratories
Antarctic Phosphatase (+ buffer) New England Biolabs
Aprotinin Biomol
ATP, disodium salt Sigma
BSA, fraction V AppliChem
Cy3 Mono-Reactive Dye Pack Amersham, GE Healthcare
D-Glucose (U-◦13C6, 99%) Cambridge Isotope Laboratories
DEAE-Sepharose Sigma
Deuterium oxide (D, 99.85%) Cambridge Isotope Laboratories
Digitonin Calbiochem
DMEM PAA
DNA ladder Fermentas
DNAse I AppliChem
dNTPs Fermentas
DpnI restriction enzyme (+ buffer) New England Biolabs
DraIII restriction enzyme (+ buffer) New England Biolabs
Factor Xa Qiagen
Fetal bovine serum, FBS Gibco
Fluorescent mounting medium DakoCytomation
Glutathione Agarose 4B Macherey & Nagel
Glycerol (D8, 99%) Cambridge Isotope Laboratories
GTP and GDP, sodium salt Sigma
HA-Agarose Sigma
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Chemical, reagent or kit Manufacturer
Hoechst 33258 Sigma
IPTG Fermentas
L-glutamine (cell culture grade) Gibco
Leupeptin Biomol
Lipofectamine RNAiMAX Invitrogen
Ni-NTA Agarose Qiagen, Macherey & Nagel
Nocodazole AppliChem
NucleoBond PC20, PC100, PC500 Macherey & Nagel
NucleoSpin Extract II Kit Macherey & Nagel
OptiMEM Invitrogen
Ovalbumine Sigma
PageRuler Prestained Protein Ladder Thermo Scientific
Pefa bloc Roth, Sigma
Pepstatin Biomol
Pfu DNA Polymerase (+ buffer) Promega
Pfu Ultra (+ buffer) Agilent
PMSF Sigma
Q-Sepharose Fast Flow Sigma
QuikChange Multi Site-Directed Agilent
Mutagenesis Kit
Ratjadone A Synthesized and kindly provided by Markus
Kalesse, OCI, University of Hannover
SexAI restriction enzyme (+ buffer) New England Biolabs
SP-Sepharose Sigma
Xa Removal Resin Qiagen
4.1.5 Buffers, media and standard solutions
Table 9: Buffers, media and standard solutions
Solution Composition
100x Trace elements 21.5 mM FeSO4 · 7H2O, 5.8 mM MnCl22 · 4H2O, 4.0 mM
CoCl2 · 6H2O, 2.4 mM ZnSO4 · 7H2O, 1.8 mM CuCl2 · 2H2O,
323 µM H3BO3, 215 µM (NH4)6Mo7O24 · 4H2O in H2O or
2H2O
2x SDS sample buffer 100 mM Tris/HCl pH 6.8, 4% w/v SDS, 0.2% w/v bromophe-
nol blue, 20% v/v glycerol and 200 mM DTT in H2O
4x SDS sample buffer 200 mM Tris/HCl pH 6.8, 8% w/v SDS, 0.4% w/v bromophe-
nol blue, 40% v/v glycerol and 400 mM DTT in H2O
6x DNA loading dye 0.2% w/v bromphenol blue, 0.2% w/v xylene cyanol FF,
60% w/v glycerol, 60 mM EDTA in H2O
Blocking buffer PBST supplemented with 5% w/v skim milk
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Solution Composition
Blot buffer 25 mM Tris-HCl, 193 mM glycine, 20% v/v methanol
and 0.036% w/v SDS in H2O; prepared from a 10x stock;
methanol was added to the solution directly prior to use
Colloidal Coomassie solution 0.08% w/v Coomassie G-250, 1.6% w/v ortho-phosphoric
acid, 8% w/v (NH4)2SO4 and 20% v/v methanol in H2O
Coomassie fixing solution 40% v/v ethanol and 10% v/v acetic acid in H2O
Crm1 standard buffer 50 mM HEPES pH 8.0, 500 mM NaCl, 1 mM DTT and
1 mg/ml of each aprotinin, leupeptin, and pepstatin in H2O
Crm1 buffer I Crm1 standard buffer supplemented with 10 mM imidazole
pH 8.0
Crm1 buffer II Crm1 standard buffer supplemented with 20 mM imidazole
pH 8.0
Crm1 buffer III Crm1 standard buffer supplemented with 300 mM imidazole
pH 8.0
Cross-link buffer TB with pH adjusted to 8.0 and supplemented with 1 mM
DTT
Factor Xa buffer 50 mM Tris pH 8.0, 100 mM NaCl, 5 mM CaCl2 in H2O;
prepared from a 10x stock solution
GST buffer I 50 mM Tris-HCl pH 8.0, 300 mM NaCl, 1 mM EDTA, 1 mM
EGTA, 1 mMDTT and 1 µg/mL of each aprotinin, leupeptin,
pepstatin in H2O
GST buffer II GST buffer I supplemented with 20 mM glutathione
LB medium 1% w/v bacto-tryptone, 0.5% w/v yeast extract, 1% w/v
NaCl, pH 7.0 in H2O or 2H2O
M9 minimal medium 25.3 mM Na2HPO4 · 7H2O, 22 mM KH2PO4, 8.5 mM NaCl,
30 mg/l thiamin-HCl, 100 µM CaCl22, 2 mM MgSO4 and
1% 100x Trace elements in H2O or 2H2O; prepared from a 5x
stock solution
Mimic buffer 50 mM Tris-HCl pH 10.0, 150 mM NaCl, 5 mM MgCl2, 1 mM
DTT and 1 µg/mL of each aprotinin, leupeptin, pepstatin in
H2O
MonoQ buffer A I 50 mM Tris-HCl pH 7.5, 50 mM NaCl, 2 mM DTT and
1 µg/mL of each aprotinin, leupeptin, pepstatin in H2O
MonoQ buffer A II MonoQ buffer A I supplemented with 1 M NaCl in H2O
MonoQ buffer B I 50 mM Tris-HCl pH 8.0, 1 mM MgCl2, 1 mM DTT and
1µg/mL of each aprotinin, leupeptin, pepstatin in H2O
MonoQ buffer B II MonoQ buffer B I supplemented with 1 M NaCl
MonoQ buffer C I 50 mM Tris-HCl pH 8.0, 1 mM DTT and 1 µg/mL of each
aprotinin, leupeptin, pepstatin in H2O
MonoQ buffer C II MonoQ buffer C I supplemented with 1 M NaCl
Ni-NTA standard buffer 50 mM sodium phosphate pH 8.0, 300 mM NaCl, 1 mM DTT
and 1 mg/ml of each aprotinin, leupeptin, and pepstatin in
H2O
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Solution Composition
Ni-NTA buffer I Ni-NTA standard buffer supplemented with 10 mM imidazole
pH 8.0
Ni-NTA buffer II Ni-NTA standard buffer supplemented with 20 mM imidazole
pH 8.0
Ni-NTA buffer III Ni-NTA standard buffer supplemented with 250 mM imida-
zole pH 8.0
NMR buffer I 50mM sodium phosphate pH 6.5, 100 mM NaCl, 2.5 mM
DTT in H2O
NMR buffer II 50mM potassium phosphate pH 7.3, 25 mM KCl, 2.5 mM
DTT in 2H2O
Non-reducing sample buffer 50 mM Tris pH 6.8, 4 M urea, 10% v/v glycerol and 2% w/v
SDS in H2O
PBS 140 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.5 mM
KH2PO4, pH 7.5 in H2O; prepared from 10x stock solution
PBST PBS supplemented with 0.2% v/v Tween 20
Peptide buffer 30% acetonitrile and 0.1% trifluoroacetic acid in H2O
PIPES buffer 20 mM PIPES pH 6.8, 150 mM NaCl, 1 mg/ml ovalbumin,
0.05% Tween 20, 1 mM DTT and 1 mg/ml of each aprotinin,
leupeptin, and pepstatin in H2O
Protease buffer 50 mM Tris-HCl pH 7.5, 150 mM NaCl and 1 mM DTT in
H2O
Ran lysis buffer 50 mM Tris-HCl pH 8.0, 75 mM NaCl, 1 mM MgCl2, 1 mM
DTT and 1 µg/mL of each aprotinin, leupeptin, pepstatin in
H2O
RanGAP1 standard buffer 50 mM Tris-HCl pH 7.4, 1 mM DTT and 1 µg/mL of each
aprotinin, leupeptin, pepstatin in H2O
RanGAP1 buffer I 50 mM Tris-HCl pH 8.0, 100 mM NaCl, 1 mM EDTA, 1 mM
DTT and 1 µg/mL of each aprotinin, leupeptin, pepstatin in
H2O
RanGAP1 buffer II 50 mM Tris-HCl pH 8.0, 1% v/v TritonX100, 1 mM DTT
and 1 µg/mL of each aprotinin, leupeptin, pepstatin in H2O
RanGAP1 buffer III RanGAP1 standard buffer supplemented with 2 M urea
RanGAP1 buffer IV RanGAP1 standard buffer supplemented with 8 M urea
RanGAP1 buffer V RanGAP1 standard buffer supplemented with 150 mM NaCl
RanGAP1 buffer VI RanGAP1 standard buffer supplemented with 300 mM NaCl
RanGAP1 buffer VII RanGAP1 standard buffer supplemented with 1 M NaCl
SAB- TB+++ supplemented with 0.05% v/v Tween 20
SAB+ TB+++ supplemented with 0.2 mg/ml ovalbumine,
0.05% v/v Tween 20
SDS running buffer 25 mM Tris, 192 mM glycine and 0.05 w/v SDS in H2O;
prepared from 10x stock solution
Single turnover buffer SAB+ supplemented with 0.1 mM DTT (instead of 1 mM)
and 10 mM EDTA pH 7.3
continued on next page
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Solution Composition
SOC medium 2% w/v tryptone, 0.5% w/v yeast extract, 10 mM NaCl,
2.5 mM KCl, 10 mM MgCl2, 10 mM MgSO4, 20 mM glu-
cose, pH 7.0 in H2O
TAE buffer 40 mM Tris-HCl pH 7.7, 1 mM EDTA, 0.1% v/v acetic acid
in H2O; prepared from 10x stock solution
TB 20 mM HEPES-KOH pH 7.3, 110 mM KAcO, 2 mM
Mg(AcO)2 and 1 mM EGTA in H2O; prepared from 10x stock
solution
TB+++ TB supplemented with 1 mM DTT and 1 mg/ml of each
aprotinin, leupeptin, and pepstatin
Ubc9 buffer II Ubc9 buffer I supplemented with 300 mM NaCl
4.1.6 Antibodies
Table 10: Antibodies
Antibody Host Species Dilution Source
Primary Antibodies
αBorealin mouse 1 : 1,000 MBL
αCrm1 goat 1 : 1,000 affinity purified by Dr. Volkan Sakin
of the Melchior group
αGFP (YFP) rabbit 1 : 1,000 Santa Cruz
αGMP1 (SUMO1) mouse 1 : 5 Developmental studies Hybridoma
Bank Uni. of Iowa [Matunis et al.,
1996]
αHA clone HA.11 mouse 1 : 500 Covance
αRan mouse 1 : 2,000 BD Transduction Laboratories
αRanBP2 goat 1 : 1,000 [Hutten et al., 2008]
αRanGAP1 goat 1 : 1,000 [Pichler et al., 2002]
αSNP1 (N-20) goat 1 : 1,000 Santa Cruz
αUbc9 rabbit 1 : 1,000 Santa Cruz
Secondary Antibodies
αmouse-IRDye 800CW donkey 1 : 10,000 LI-COR Biotechnology
αrabbit-IRDye 800CW donkey 1 : 10,000 LI-COR Biotechnology
αrabbit-IRDye 680RD donkey 1 : 10,000 LI-COR Biotechnology
αgoat-IRDye 680RD donkey 1 : 10,000 LI-COR Biotechnology
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4.1.8 Plasmids
All Plasmids contain the coding sequence of human proteins, except for Ubc9-
containing plasmids, which carry the coding sequence from mouse (on the protein
level human and moue Ubc9 are identical).
Table 12: Previously avbailable plasmids
Plasmid # Features Source
Plasmids for bacterial expression
pET11a-RanGAP1 tm 1182 full-length sequence, untagged with
mutations T409E/S428D/S442D
[Werner et al.,
2012]
pET11a-RanGAP1 wt 1180 full-length sequence, untagged [Werner et al.,
2012]
pET11a-SUMO1∆C4 wt 90 sequence covering amino acid 1-97,
untagged
[Pichler et al.,
2002]
pET11a-SUMO1∆C4 E67R 1317 sequence covering amino acid 1-97,
untagged with indicated mutation
[Knipscheer
et al., 2007]
pET11a-SUMO1∆C4 F36L 1458 sequence covering amino acid 1-97,
untagged with indicated mutation
[Werner et al.,
2012]
pET11a-SUMO2∆C11 134 sequence covering amino acid 1-92,
untagged
[Meulmeester
et al., 2008]
pET11d-Ran Q69L 248 full-length sequence, untagged with
indicated mutation
Prof. Dr. Ralph
Kehlenbach∗
pET11d-Ran wt 1 full-length sequence [Melchior et al.,
1993]
pET11d-Uba2 74 full-length sequence, untagged [Pichler et al.,
2002]
pET23a-GAPtail 1142 sequence covering amino acid 398-587
of RanGAP1 with N-terminal His6-
tag
Dr. Andreas
Werner‡
pET23a-RanBP2-BD34
mIR2
1131 sequence covering amino acid 2304-
3062 with C-terminal His6-tag with
mutations L2729A/L2731A/F2736A
[Werner et al.,
2012]
pET23a-RanBP2-BD34
mSIM1
1128 sequence covering amino acid 2304-
3062 with C-terminal His6-tag with
mutations IV2634/35AA
[Werner et al.,
2012]
pET23a-RanBP2-BD34
mSIM1/mIR1
1132 sequence covering amino acid 2304-
3062 with C-terminal His6-tag with
mutations I2634A/V2635A/L2651A/
L2653A/F2658A
[Werner et al.,
2012]
pET23a-RanBP2-BD34
mSIM2
1130 sequence covering amino acid 2304-
3062 with C-terminal His6-tag with
mutations II2711/12AA
[Werner et al.,
2012]
continued on next page
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Plasmid # Features Source
pET23a-RanBP2-BD34 wt 1127 sequence covering amino acid 2304-
3062 with C-terminal His6-tag
[Werner et al.,
2012]
pET23a-Ubc9 wt 72 full-length sequence, untagged [Pichler et al.,
2002]
pET23a-Ubc9 C93A 1205 full-length sequence, untagged with
indicated mutation
Dr. Annette
Flotho‡
pET23a-Ubc9 H20D 1163 full-length sequence, untagged with
indicated mutation
[Knipscheer
et al., 2007]
pET23a-Ubc9-HA 824 full-length sequence with C-terminal
HA-tag
Dr. Nicolas
Stankovic‡
pET28a-Aos1 73 full-length sequence with N-terminal
His6-tag
[Pichler et al.,
2002]
pGEX-3X-RanBP2 ∆FG 124 sequence covering amino acid 2553-
2838 with N-terminal, TEV-cleavable
GST-tag
[Pichler et al.,
2002]
pQE60-Crm1 29 full-length sequence with C-terminal
His6-tag
Prof. Dr. Ralph
Kehlenbach∗
Plasmids for mammalian expression
pEF-HA-RanBP2 1698 full-length sequence with N-terminal
HA-tag
Dr. Sarah
Wälde and Prof.
Dr. Ralph
Kehlenbach∗
[Wälde et al.,
2011]
# refers to number under which this plasmid can be found in the plasmid stock of the Melchior
group. The amino acid numbering relates to the sequence of the full-length, wild-type proteins. ‡
refers to current or former members of the Melchior group. ∗ University of Göttingen.
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4.1.9 Recombinant proteins
Table 14: Recombinant proteins
Protein Source
∆FG kindly purified by Gerry Meese‡ using plasmid 124
Aos1/Uba2 (SUMO E1 enzyme) purified in this work using plasmid 73 and 74
BD34 K2645P purified in this work using plasmid 1673
BD34 K2645P/K2723P purified in this work using plasmid 1674
BD34 K2716A purified in this work using plasmid 1676
BD34 K2723P purified in this work using plasmid 1675
BD34 mFG1 purified in this work using plasmid 1677
BD34 mFG12 purified in this work using plasmid 1678
BD34 mFG2 purified in this work using plasmid 1679
BD34 mIR1 purified in this work using plasmid 1132
BD34 mIR1/mIR2 purified in this work using plasmid 1680
BD34 mIR2 purified in this work using plasmid 1681
BD34 mUbc9 purified in this work using plasmid 1131
BD34 mSIM2 purified in this work using plasmid 1130
BD34 mSIM2* purified in this work using plasmid 1682
BD34 W2714A purified in this work using plasmid 1683
BD34 wt purified in this work using plasmid 1127
BD34PreTEV purified in this work using plasmid 1672
CAS Sebastian Richter‡
CFP-GAPtail common stock
Crm1 qm Iker Valle Aramburu‡ (lab rotation student in 2012) us-
ing plasmid 1697
Crm1 S391A purified in this work using plasmid 1694
Crm1 S391D purified in this work using plasmid 1695
Crm1 S391E purified in this work using plasmid 1696
Crm1 wt purified in this work using plasmid 29
GAPtail purified in this work using plasmid 1142
GST-RanBP1 Dr. Annette Flotho‡
His6-SUMO1(∆G)-GyrA-CBD Stefanie Sommer, Mootz group, University of Münster
His6-YFP-Sp100 common stock
His6Borealin/Survivin/
INCENP(1-58) complex
Andrea Frank and Dr. Annette Flotho‡ [Werner et al.,
2012]
Importin β Dr. Volkan Sakin‡
Importin 13 Dr. Volkan Sakin‡
NTF2 Sebastian Richter‡
PreScission common stock
Ran Q69L purified in this work using plasmid 248
Ran wt purified in this work using plasmid 1
RanGAP1 qm purified in this work using plasmid 1697
RanGAP1 tm purified in this work using plasmid 1132
continued on next page
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Protein Source
RanGAP1 wt purified in this work using plasmid 1180
SBP-TEVsite-Ubc9(C93TAG) Stefanie Sommer, Mootz group (University of Münster)
SENP1 (amino acids 419-644) common stock
SNP1 purified and kindly provided by Achim Dickmanns and
Ralf Ficner (MPI, Göttingen)
SUMO1 E67R purified in this work using plasmid 1317
SUMO1 F36L purified in this work using plasmid 1458
SUMO1 R63E purified in this work using plasmid 1671
SUMO1 wt purified in this work using plasmid 90
SUMO2 wt purified in this work using plasmid 134
TEV common stock
Transportin 1 Dr. Volkan Sakin‡
Ubc9 C93A purified in this work using plasmid 1205
Ubc9 C93A/K101R purified in this work using plasmid 1685
Ubc9 C93K purified in this work using plasmid 1686
Ubc9 C93K/K101R purified in this work using plasmid 1687
Ubc9 C93K/K101R/E118R/
E122R
purified in this work using plasmid 1688
Ubc9 C93K/K101R/L114Q/
G115S
purified in this work using plasmid 1689
Ubc9 E118R/E122R purified in this work using plasmid 1690
Ubc9 H20D kindly purified by Gerry Meese‡ using plasmid 124
Ubc9 H20D/C93K/K101R purified in this work using plasmid 1691
Ubc9 K101R purified in this work using plasmid 1692
Ubc9 L114Q/G115S purified in this work using plasmid 1693
Ubc9 wt purified in this work using plasmid 72
Ubc9-HA purified in this work using plasmid 824
YFP-SUMO1 common stock
‡ refers to current or former members of the Melchior lab. Proteins from the “common stock” were
purified alternatively by members of the Melchior group.
4.1.10 Cell lines
Table 15: Cell lines
Microbial strain
BL21(DE3) F- ompT hsdSB(rB- mB-) gal dcm (DE3)
DH5α F- ϕ80dlacZM15 (lacZyA-argF) U169 deoR recA1 endA1 hsdR17(rk-,
mk+) phoA supE44 thi-1 gyrA96 relA1 λ-
One Shot Inv110
(Invitrogen)
F’ tra∆36 proAB lacIq lac∆ M15 rpsL (StrR) thr leu endA thi-1
lacY galK galT ara tonA tsx dam dcm supE44 ∆(lac-proAB) ∆(mcrC-
mrr)102 : : ::Tn10 (TetR)
Rosetta F- ompT hsdSB(rB- mB-) gal dcm (DE3) pRARE (CmR)]
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Tg1 F’ traD36 proAB lacIqZ ∆M15] supE thi-1 ∆(lac-proAB) ∆(mcrB-
hsdSM)5(rk-, mk+)
XL10-Gold (Agi-
lent)
Tetr∆(mcrA)183 ∆(mcrCB-hsdSMR-mrr)173 endA1 supE44 thi-1 recA1
gyrA96 relA1 lac Hte F’ proAB lacIqZ∆M15 Tn10 (Tetr) Amy Camr
Mammalian cell line
HEK293T cells human embryonic kidney cell line
4.2 Molecular biological methods
Standard procedures in molecular biology were performed on the basis of Molec-
ular Cloning. A Laboratory Manual. Maniatis, T., Fritsch, E.F. and Sambrook, J.
(Cold Spring Harbor Laboratory, New York, 1982).
4.2.1 Culturing, storage and transformation of bacteria
Bacteria were propagated at 37◦C in LB medium supplemented with antibiotics
as required (ampicillin 100 µgml, kanamycin 30 µgml). Liquid cultures were shaken
at 110 rpm. For storage liquid cultures were supplemented with 50 % (v/v) glycerol
and stored at -80◦C.
For transformation, competent E.coli were thawed and incubated with the desired
plasmid DNA for 30 min on ice. The cells were heat-shocked at 42◦C for 30 sec,
then placed briefly on ice for the addition of 500 µl LB or SOC medium. The cells
were allowed to recover for 1 h by incubation at 37◦C and shaking at 950 rpm before
plating or inoculation of a liquid culture containing antibiotics for selection.
4.2.2 Mutagenesis
Primer design
Specific primers for mutagenesis reactions were designed according to the instruc-
tion manual of the Stratagene QuikChange Site-Directed Mutagenesis Kit. In short,
primers were designed:
- to contain the desired mutations in the middle with roughly 10-15 nu-
cleotides of correct sequence at the 5’ and the 3’ end,
- to have a length between 25 up to 55 nucleotides,
- to have a melting temperature of ≥ 78◦C,
- to have a GC content of about 40%,
- to end in one or more C or G bases.
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For single SSDM (singel site-directed mutagenesis) reactions, primer pairs where
chosen that contained the desired mutation and annealed to the same sequence on
opposite strands of the template plasmid. For MSDM (multi site-directed mutagenesis)
reactions, sets of up to five different mutagenesis primers were chosen that annealed
to the same strand of the template plasmid and did not overlap in sequence.
Primer design for I/DM (insertion/deletion mutagenesis) reactions was done ac-
cording to [Liu and Naismith, 2008] and otherwise was done according to the guide-
lines mentioned above. In short, primer pairs for insertions were designed so that
the forward primer contained the desired insertion in the middle with roughly 12
to 18 nucleotides of correct sequence at the 5’ and 3’ end, while the reverse primer
contained 3-5 nucleotides of the insertion at its 5’ end and roughly 45 nucleotides of
correct sequence at the 3’ end. Primer pairs for deletions were designed so that the
forward primer contained roughly 10 nucleotides before and after the desired dele-
tion at their 5’ ends followed by about another 40 nucleotides of correct sequence at
their 3’ ends.
Single site-directed mutagenesis
Single site-directed mutagenesis was performed by amplifying a template plasmid
in a thermocycler by Pfu Ultra with a pair of reverse complement primers containing
the desired mutation. In short, in a final volume of 37.5 µl a mix of 3.75 µl 10x Pfu
Ultra buffer (Agilent), 265 nM of both primers, 200 nM dNTPs, 6% v/v DMSO, 50
ng template plasmid and 0.25 µl Pfu Ultra (Agilent) was prepared on ice and split
into three 12.5 µl reactions.
Amplification was conducted using the following conditions: (a) initial denatura-
tion at 95◦C for 2 min; (b) 28 cycles of denaturation at 95◦C for 30 sec, annealing at
three different annealing temperatures for 45 sec (corresponding to the three 12.5 µl
reactions - usually at 55, 60 and 65◦C) and extension at 72◦C for 2 min/1 kb tem-
plate plasmid; (c) final extension at 72◦C for 12 min. Afterwards, reactions were
kept at 4◦C. The methylated template plasmid was then digested by 0.5 U DpnI
enzyme for 150 min at 37◦C. Each 12.5 µl reaction was then transformed into DH5α
cells and plated onto an LB Agar plate with antibiotics.
Multi site-directed mutagenesis
According to the QuikChange Multi Site-Directed Mutagenesis Kit, multi site-
directed mutagenesis was performed by amplifying a template plasmid in a thermo-
cycler by the QuickChange Multi enzyme blend with a set of up to five different
mutagenesis primers. In short, in a final volume of 12.5 µl a mix of 1.25 µl 10x
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QuickChange Multi reaction buffer, 265 nM of all primers, 0.5 µl dNTP mix, 0.35 µl
QuickSolution , 50 ng template plasmid and 0.5 µl QuickChange Multi enzyme blend
was prepared on ice.
Amplification was conducted using the following conditions: (a) initial denatura-
tion at 95◦C for 1 min; (b) 30 cycles of denaturation at 95◦C for 1 min, annealing at
55◦C for 1 min and extension at 65◦C for 2 min/1 kb template plasmid. Afterwards,
reactions were kept at 4◦C. The methylated template plasmid was then digested by
0.5 U DpnI enzyme for 150 min at 37◦C. The reaction was then transformed into
XL10-Gold cells and plated onto an LB Agar plate with antibiotics.
Insertion/deletion mutagenesis
According to [Liu and Naismith, 2008], insertion/deletion mutagenesis was per-
formed by amplifying a template plasmid in a thermocycler by Pfu DNA Polymerase
with a pair of partly overlapping primers containing the desired insertiondeletion.
In short, in a final volume of 37.5 µl a mix of 3.75 µl 10x Pfu DNA polymerase buffer
(Promega), 1 µM of both primers, 200 nM dNTPs, 0-4% v/v DMSO, 10 ng tem-
plate plasmid and 0.3 µl Pfu DNA polymerase (Promega) was prepared on ice and
split into three 12.5 µl reactions. Amplification was conducted using the following
conditions: (a) initial denaturation at 95◦C for 5 min; (b) 12 cycles of denatura-
tion at 95◦C for 1 min, annealing at three different annealing temperatures for 1
min (corresponding to the three 12.5 µl reactions - usually at 55, 60 and 65◦C) and
extension at 72◦C for 2 min/1 kb template plasmid; (c) final annealing at 45◦C for
1 min; (d) final extension at 72◦C for 30 min. Afterwards, reactions were kept at
4◦C. The methylated template plasmid was then digested by 0.5 U DpnI enzyme for
150 min at 37◦C. Each 12.5 µl reaction was then transformed into DH5α cells and
plated onto an LB Agar plate with antibiotics.
4.2.3 Restriction digestion of DNA by endonucleases
The enzymes and buffer system of New England Biolabs were used for DNA
restrictions. Reaction conditions were chosen according to the manufacturer’s in-
structions. For preparative restrictions, 20 µg DNA were digested in a volume of
90 µl in the presence of approximately 33 U of enzyme at 37◦C for 2-4 h; analytic
restrictions were carried out with 200 ng DNA in a volume of 20 µL using 5-8 U of
enzyme for 1-2 h. To avoid star activity, the volume of the enzyme never exceeded
1/10 of the reaction volume. For restriction digests involving the enzyme SexAI,
plasmids isolated from dam− and dcm− deficient One Shot Inv110 cells were used.
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4.2.4 Agarose gel electrophoresis and isolation of DNA
fragments
DNA fragments were separated by agarose gel electrophoresis. Depending on the
fragment size, 0.8-1.0% w/v agarose gels were used. DNA samples were supple-
mented with an appropriate amount of 6x DNA loading dye, were loaded on the
gel, and were separated at 80 Volt (running buffer: TAE). For visualization, DNA
was stained in a TAE bath containing 1 µg/ml ethidiumbromide and was detected
with UV light of 365 nm. Gel slices containing desired DNA fragments were ex-
cised and DNA was extracted using the NucleoSpin Extract II Kit according to the
manufacturer’s instructions. DNA was typically eluted in 20-40 µl of elution buffer.
4.2.5 Dephosphorylation of linearized DNA
In order to prevent self-ligation of blunt-ended vector, antarctic phosphatase (10
U in antarctic phosphatase buffer) was used to remove the phosphate from the 5’
end of DNA fragments (1 µg) by incubation at 37◦C for 1 h. The enzyme was
heat-inactivated at 65◦C for 10 min.
4.2.6 Ligation of DNA fragments
Ligations were performed using 600 ng of vector in a molar vector to insert ratio
of 1:1. Reactions were performed in a total volume of 20 µl containing 9 µl DNA
fragments, 10 µl 2x Quick Ligase buffer and 1 µl Quick Ligase. The ligation reaction
was performed at RT for 5-10 min and the entire mix was directly transformed into
competent cells.
4.2.7 Plasmid DNA preparation
Depending on the desired yields, transformed bacterial cells were raised in liquid
cultures of different volumes over night: 10 ml cultures for about 5 µg (Mini preps),
100 ml cultures for 6-30 µg (Midi preps) and 500 ml cultures for 150 µg (Maxi preps)
(the vast majority of plasmids used in this work are low-copy plasmids). Plasmid
preps were then performed using the NucleoBond PC kits (alkaline lysis method -
[Birnboim and Doly, 1979]) according to the manufacturer’s manual (PC 20 for Mini
preps, PC 100 for Midi prepss and PC 500 for Maxi preps) and finally dissolved in
sterile H2O. DNA concentration and purity was assessed by measuring absorption
at 260 and 280 nm via Nanodrop.
Plasmids for mammalian transfection were additionally purified by ethanol precip-
itation: the DNA was mixed with 1/10 volume of 3 M NaAcO pH 5.2 and vortexed.
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After the addition of 2.5 volumes of 100% ethanol and vortexing, the solution was
incubated for 15 min at -20◦C and then centrifuged for 10 min at 20.000 x g. The
pellet was washed with 70% ethanol and finally dissolved in sterile H2O.
4.2.8 DNA sequencing
For plasmid sequencing, 20 µl of 30-100 ng/µl plasmid DNA and 10 µl of 10 µM
of primer were sent to GATC Biotech. Sequences were analyzed using the software
tools ApE v2.0.38 and Serial Cloner 2.6.
4.3 Cell culture
4.3.1 Culturing of mammalian cells
HEK 293T cells were propagated in DMEM supplemented with 10 % (v/v) FBS,
1% penicillin-streptomycin and 2 mM L-glutamine at 37◦C and 5 % CO2 in either
10 cm dishes (with 10 ml medium) or 15 cm dishes (with 20 ml medium). Usually,
cells were split at a 1:10 ratio just before reaching confluency. For this purpose, cells
were washed with sterile PBS, detached from the culture dishes with trypsin/EDTA,
and diluted with fresh medium. If necessary, the cell density was determined after
trypsinization using a Neubauer counting chamber.
4.3.2 Transfection
For transient transfection of HEK 293T cells in a 15 cm dish with pEF-HA-
hRanBP2 plasmid variants, 24 µg of DNA and 50 µl of PEI transfection reagent were
diluted in 2.5 ml DMEM, incubated for 10-15 min at RT and afterwards again diluted
in 9 ml of DMEM supplemented with 10 % (v/v) FBS, 1% Penicillin-Streptomycin
and 2 mM L-glutamine. The mixture was then added to cells and medium exchange
after about 10 h.
To down-regulate endogenous genes, siRNA-mediated gene silencing was employed
[Elbashir et al., 2001]. In particular, siRNA oligonucleotides directed against hu-
man RanBP2 were employed. Oligonucleotides were ordered as 2’-deprotected and
pre-annealed duplexes in lyophilized form (siRanBP2, sequence sense strand 5’-
3’: CACAGACAAAGCCGUUGAA - according to [Hutten and Kehlenbach, 2006]).
Oligonucleotides were resuspended in RNAse-free H2O according to the manufac-
turer’s guidelines and stored in small aliquots at concentrations ranging from 20-
100 µM at -20◦C. For siRNA transfection of HEK 293T cells in a 15 cm dish, 300
pmol of siRNA were diluted in 1,7 ml OptiMEM and in parallel 33 µl Lipofectamin
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RNAiMAX were diluted in another 1,7 ml OptiMEM. The two dilutions were mixed
in a 1:1 ratio, incubated for 15 min at RT and added drop wise to 6,4 ml DMEM sup-
plemented with 10 % (v/v) FBS, 1% Penicillin-Streptomycin and 2 mM L-glutamine
on the cells. Medium was exchanged after 4-8 h. For an efficient downregulation of
RanBP2, the transfection procedure was repeated after 48 h; cells were split about
34 h after the first siRNA transfection in a ratio of 1:5.
The down-regualtion of endogenous RanBP2 by siRNA was combined with tran-
sient transfection of HA-hRanBP2 variants, as the latter were designed to be resis-
tant against siRanBP2 oligonucleotides. For the combined protocol, plasmid trans-
fection was performed 24 h after the first siRNA transfection.
4.3.3 Cell cycle arrest
Exponentially growing cells were arrested in prometaphase by addition of 150 ng/ml
nocodazole in DMEM supplemented with 10% v/v FBS, 1% Penicillin-Streptomycin
and 2 mM L-glutamine. After 18 h, mitotic cells were collected by washing them
off the dishes.
4.4 Biochemical methods
4.4.1 Measurement of protein concentrations
Generally, protein concentrations of purified recombinant proteins were deter-
mined by measuring the absorption 280 nm via Nanodrop. For each protein, a
theoretical absorption coefficient at 280 nm typically under reducing conditions was
calculated using the protein analysis tool ProtParam on the ExPASy server. With
the measured absorptions and the extinction coefficients, molar concentrations were
calculated according to the Lambert-Beer law. In case of protein mixture of unknown
composition, protein concentrations were determined using Bradford reagent (15 µl
sample mixed with 750 µl Bradfrod reagent) against a BSA standard curve.
4.4.2 SDS-PAGE and analysis
Sample preparation
Depending on their protein concentrations, samples were mixed with 2x or 4x
SDS sample buffer (gel pockets were loaded with upto 70 µl of sample). Samples
sensitive to reducing agents were prepared using non-reducing sample buffer. Before
loading, samples were boiled at 95◦C for several minutes; samples containing full-
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length, endogenous hRanBP2 were boiled at only 70◦C. For storage, samples were
flash-frozen in liquid nitrogen and kept at -80◦C.
SDS-PAGE
SDS-PAGE (sodium dodecyl sulfate-polyacrylamide gel electrophoresis) was per-
formed according to the system described by Laemmli [Laemmli, 1970]. In most
instances 5-20% continuous gradient gels were used; for samples containing mostly
smaller proteins (< 50 kDa) 12% gels were preferred. The gels were prepared in a
casting block fitting eight gels at once, equipped with an inlet at the lower border
of the glass plates and connecting the batch of gels via a rim at the central bottom
of the casting block allowing to fill a batch of gels simultaneously starting from the
bottom.
Equal volumes of 5% and 20% w/v polyacrylamide solutions in 0.4 M Tris-HCl pH
8.8, 0.1% w/v SDS were prepared together fitting the casting block. Polymerization
was started by adding APS and TEMED (each 0.06% w/v and v/v, respectively
for the 5% solution and 0.05% w/v and v/v for the 20% solution, respectively).
The solutions were filled into the casting block using a double-cylindrical gradient
mixer yielding a polyacrylamide gradient of 5% at the top to roughly 20% towards
the bottom of the gel. An overlay of 2-propanol was applied from the top, which
was thoroughly removed after polymerizing and the stacking gel (4% w/v polyacry-
lamide, 50 mM Tris-HCl pH 6.8, 0.1% w/v SDS, 0.1% w/v APS and 0.1% v/v
TEMED) was poured. Gels were run with Laemmli running buffer at 35 mA and
300 Volts per gel at RT.
Coomassie staining
Colloidal Coomassie staining technique according to [Neuhoff et al., 1985]: SDS-
PAGE gels were fixed in Coomassie fixing solution for 20-60 min, then rehydrated
in H2O for 10 min and then stained in Colloidal Coomassie solution for at least
over night. Afterwards, gels were destained and kept in 1% acetic acid. Coomassie
stained gels were scanned with LAS-4000 and graphic files adjusted in contrast and
brightness using Adobe Photoshop CS6.
Immunoblot
For immunoblot analysis, gels were transferred on nitrocellulose membranes after
SDS-PAGE. The gel/membrane ensemble was mounted between six Whatman paper
stacks soaked in blot buffer and proteins were transferred onto the membrane at 200
mA/300 V for 2 h in a semi-dry western blot apparatus [Kyhse-Andersen, 1984].
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Unspecific binding sites on the membrane were blocked by incubating for 30 min in
Blocking buffer. Primary and secondary antibodies were applied diluted in Blocking
buffer; the membrane was incubated with the primary antibody for at least 2 h at RT
or overnight at 4◦C and with the secondary antibody for 1 h at RT. The membrane
was washed extensively with PBST after each antibody incubation and with a final
washing step of PBS after secondary antibody incubation. Bound antibody was
detected by fluorescence using LI-COR Odyssey. Graphic files were adjusted in
contrast and brightness using Adobe Photoshop CS6.
4.4.3 Protein expression
Expression of unlabeled proteins
An E.coli strain suited for protein expression (commonly BL21(DE3) or Rosetta2
- see individual proteins for details) was transformed with the desired plasmid and
used to directly inoculate a pre-culture in LB medium supplemented with suitable
antibiotics. The pre-culture was grown over night at 37◦C. For the main culture,
cells were diluted 1:50 into fresh LB medium supplemented with antibiotics, 1 mM
MgCl2 and 0.1% w/v glucose and grown to an OD600nm of 0.6-0.8 before expression
of recombinant proteins was induced with 1 mM IPTG. Proteins were expressed
for 3-4 h at 37◦C, then harvested by centrifugation, resuspended in the appropriate
lysis buffer (typically 25 ml of lysis buffer without protease inhibitors and DTT per
l culture), flash-frozen with liquid nitrogen and stored at -80◦C until purification.
Deviations from this general expression protocol for each specific protein may be
found under 4.4.4.
Expression of 13C- and 15N-labeled proteins
For expression of 13C- and 15N-labeled proteins, an E.coli expression strain was
transformed with the desired plasmid for protein expression and plated on LB Agar
plates supplemented with antibiotics. Several single colonies were used to inoculate
a pre-culture in M9 medium supplemented with antibiotics, 4 g/l 13C-glucose and
5 g/l 15NH4Cl. The pre-culture was grown over night. Cells were diluted 1:50 into
fresh medium and expression was performed as described above.
Expression of 2H,15N-labeled and IVL-labeled proteins
For the expression of 2H,15N-labeled proteins, an E.coli expression strain was
transformed with the desired plasmid for protein expression and plated on LB Agar
plates made with 70% 2H2O supplemented with antibiotics. Several single colonies
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were used to inoculate a pre-pre-culture in LB medium made with 100% 2H2O
and supplemented with antibiotics. The pre-pre-culture was grown for 2-6 h, cells
were harvested by centrifugation and used to inoculate a pre-culture at an OD600nm
of around 0.015. The pre-culture was made from M9 medium supplemented with
antibiotics, 4 g/l 2H-glycerol and 5 g/l 15NH4Cl in 2H2O. Cells were grown to an
OD600nm between 0.2 and 0.6 and then diluted 1:10 into fresh medium. In the main
culture, cells were grown to an OD600nm between 0.8 and 1.1 before expression of
recombinant proteins was induced with 1 mM IPTG.
For IVL-labeled proteins, the medium of the main culture was supplemented with
120 mg/l 3-methyl-13C-3,4,4,4-2H2-α-ketoisovalerate (labeled precursor for leucine
and valine) and with 60 mg/l methyl-13C-3,3-2H2-α-ketobutyrate (labeled precursor
for isoleucine) 1 h prior to induction. Proteins were expressed for 8-12 h and then
treated as described above. The doubling time of bacteria in the medium described
here ranged from 3.5 to 6 h.
4.4.4 Protein purification
For protein purification, a resuspended bacterial pellet was thawed and supple-
mented with 1 mM DTT, and 1 mg/ml of each aprotinin, leupeptin, and pepstatin.
Typically, cells were lysed with EmulsionFlex and the lysate was cleared by cen-
trifugation for 1 h with 100,000 x g at 4◦C. The end of each purification protocol
typically entailed a gel filtration step, after which fractions containing the desired
protein were pooled, concentrated if necessary, flash-frozen and stored at -80◦C. In
the following, the purification protocols for the different recombinant proteins in
their wild-type form are listed. Typically, variants of a given protein were purified
by the same protocol, if they were in the same vector as the wild-type and if not
specifically mentioned otherwise.
Aos1/Uba2 - the SUMO E1 enzyme
The Aos1/Uba2 heterodimer was purified according to an established lab pro-
tocol [Pichler et al., 2002]. In short, the pET28a-His6-hAos1 and pET11d-hUba2
plasmids were co-transformed into Rosetta2 cells and double-transformed cells were
selected for by ampicillin and kanamycin. Protein expression was induced for 6 h
at 25◦C. For harvest, cells were resuspended in Ni-NTA buffer I. After cell lysis
and centrifugation, the supernatant was subjected to Ni pull-down over a column
using Ni-NTA agarose equilibrated in Ni-NTA buffer I (15 ml Ni-NT agarose per l
culture). The column was washed with Ni-NTA buffer II and protein eluted with
Ni-NTA buffer III. The protein-containing fractions were pooled, concentrated using
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a 30 kDa MWCO concentrator (Vivaspin) and applied to a Superdex200 GL gel fil-
tration column equilibrated in MonoQ buffer A I. The Aos1/Uba2 heterodimer peak
eluted at about 0.53 CV. To separate co-eluting free Aos1, Aos1/Uba2 peak frac-
tions were pooled, concentrated and applied to a MonoQ 5/50 GL anion exchange
column equilibrated in MonoQ buffer A I. Proteins were eluted by the application
of a linear gradient from 0-50% of MonoQ buffer A II (equivalent to 50-500 mM
NaCl) in 20 CV. Fractions containing equimolar amounts of His6-Aos1 and Uba2
eluted at about 310 mM NaCl. They were pooled and dialyzed against TB+++
supplemented with 2 mM DTT (instead of 1 mM DTT).
Crm1
Crm1 was purified according to an established lab protocol [Guan et al., 2000]. In
short, Tg1 cells transformed with the pQE60-hCrm1-His6 from a glycerol stock were
used to inoculate a pre-culture with LB medium supplemented with antibiotics,
1 mM MgCl2 and 0.1% w/v glucose. The pre-culture was grown until it became
slightly turbid (typically about 10 h). For Crm1 mutants, the mutant plasmid was
freshly transformed into Tg1 cells where the recovery after heat-shock was performed
by the addition of LB medium supplemented with 0.1% w/v glucose or with SOC.
For the main culture, cells were the diluted 1:100 into fresh medium and grown
over night without induction. For harvest, cells were resuspended in Crm1 buffer I.
After cell lysis and centrifugation, the supernatnat was subjected to pull-down over
a column using Ni-NTA agarose equilibrated in Crm1 buffer I (10 ml Ni-NT agarose
per l culture). The column was washed with Crm1 buffer II and protein eluted with
Crm1 buffer III. The protein-containing fractions were pooled, concentrated using
a 10 kDa MWCO concentrator (Vivaspin) and applied to a Superdex200 GL gel
filtration column equilibrated in TB+++. Crm1 typically eluted at 0.53 CV.
Ran
Ran was purified according to an established lab protocol [Melchior et al., 1993]. In
short, the pET11d-hRan plasmid was freshly transformed into BL21(DE3) cells,
which were then plated on a LB Agar plate supplemented with ampicillin. A single
colony was used to inoculate a pre-culture. Protein expression in the main culture
was induced by the addition of 600 µM IPTG. For harvest, cells were resuspended
in Ran lysis buffer. The supernatnat was subjected to anion exchange using DEAE-
Sepharose equilibrated in MonoQ buffer A I (10 ml DEAE-Sepharose per l culture).
The flow-through was subjected to (NH4)2SO4 precipitation: ground (NH4)2SO4
was gradually added to 53% saturation on ice whilst stirring for 1 h or over night
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(about 32 g (NH4)2SO4 per 100 ml flow-through). Afterwards, the precipitate was
collected by centrifugation at 100,000 x g for 20 min and resuspended in TB+++
(4 ml TB+++ per l culture). The suspension was clarified by centrifugation at
20,000 x g for 15 min and applied to a Superdex75 GL gel filtration column. Ran
typically eluted at 0.56 CV.
GTP loading of Ran was accomplished as follows: a protein solution of purified
Ran was diluted to 20-100 µM and supplemented with 50 mM HEPES pH 7.4, a 25-
fold molar excess over Ran of GTP, a 100-fold excess of ATP and a 600-fold excess of
EDTA. After incubation for 30 min at 30◦C, the loading reaction was quenched by
the addition of a 5-fold molar excess of Mg(AcO)2 over EDTA, concentrated using
a 5 kDa MWCO concentrator (Vivaspin) and applied to a HiTrap desalting column
equilibrated in MonoQ buffer B I. Protein-containing fractions were pooled and
applied to a MonoQ 5/50 GL anion exchange column equilibrated in MonoQ buffer
B I. Proteins were eluted by the application of a linear gradient from 0-30% of MonoQ
buffer B II (equivalent to 0-300 mM NaCl) in 20 CV. This step separated Ran-GDP
from Ran-GTP (Ran- and RanQ69L-GDP eluted at bout 100 mM NaCl, Ran-GTP
at about 160 mM NaCl and RanQ69L-GTP at about 200 mM NaCl). Peak fractions
were pooled, concentrated and applied to a Superdex75 GL gel filtration column
equilibrated in TB+++.
BD34 and related fragments
BD34 was purified according to an established lab protocol [Werner et al., 2012]. In
short, the pET23a-hBD34-His6 plasmid was transformed into Rosetta2(DE3) cells
and transformed cells were selected for by ampicillin. The medium of the main
culture was supplemented with 20 mM HEPES pH 7.4. Before induction, the cul-
ture was briefly placed on ice and supplemented wit 3% v/v ethanol. Protein was
expressed by the addition of 400 µM IPTG for 6 h at 25◦C. For harvest, cells were
resuspended in Ni-NTA buffer I. After cell lysis and centrifugation, the supernatnat
was subjected to Ni pull-down over a column using Ni-NTA agarose equilibrated
in Ni-NTA buffer I (10 ml Ni-NT agarose per l culture). The column was washed
with Ni-NTA buffer II and protein eluted with Ni-NTA buffer III. The protein-
containing fractions were pooled and concentrated using a 10 kDa MWCO concen-
trator (Vivaspin) and applied to a Superdex200 GL gel filtration column equilibrated
in TB+++. BD34 eluted at 0.46 CV.
In order to obtain a BD34 fragment which specifically lacked RanBD3 and/or
4, the BD34PreTEV variant was purified according to the same protocol. The
BD34PreTEV variant contains a PreScission protease site at amino acid 2474 (af-
ter RanBD3) and a TEV protease site at amino acid 2887 (before RanBD4). For
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cleavage, 1-11 µM purified BD34PreTEV were incubated in Protease buffer at 4◦C
over night with 0.75 µg/ml PreScission protease per µM and/or with 4 µg/ml TEV
protease per µM cleavage site. Cleavage reactions were concentrated using a 10 kDa
MWCO concentrator (Vivaspin) and applied to a Superdex200 GL gel filtration col-
umn equilibrated in TB+++. ∆BD3 eluted at 0.47 CV, ∆BD4 at 0.46 CV and
∆BD34 at 0.5 CV.
∆FG
∆FG was purified according to a modified version of an established lab protocol
[Pichler et al., 2002]. In short, the pGEX-3X-GST-h∆FG plasmids was transformed
into BL21(DE3) cells and transformed cells were selected for by ampicillin. For
harvest, cells were resuspended in GST buffer I. After cell lysis and centrifugation,
the supernatant was subjected to GST pull-down over a column using Glutathione-
Sepharose equilibrated in GST buffer I (up to 30 ml Glutathione-Sepharose per
l culture). The column was washed with GST buffer I and protein eluted with
GST buffer II. The protein-containing fractions were pooled and concentrated using
a 10 kDa MWCO concentrator (Vivaspin) and subjected to a HiTrap desalting
column equilibrated in Factor Xa buffer. Protein-containing fractions were pooled,
the concentration was measured and adjusted to 0.7-3 mg/ml.
The GST-tag was cleaved by incubation with Factor Xa (8 U/mg protein) over
night at 18◦C and slow rotation. The protease and free GST were removed by
incubation of the cleavage reaction with X arrest agarose (100 µl slurry per 4 U
Factor Xa) and with Glutathione-Sepharose (250 µl Glutathione-Sepharose per mg
protein) for 20 min at 4◦C and slow rotation. The supernatant was concentrated
using a 5 kDa MWCO concentrator (Vivaspin) and applied to a Superdex75 GL gel
filtration column equilibrated in TB+++. ∆FG eluted at 0.39 CV.
RanGAP1
RanGAP1 was purified according to an established lab protocol [Mahajan et al.,
1997]. In short, the pET11a-hRanGAP1 plasmid was transformed into Rosetta2(DE3)
cells and transformed cells were selected for by ampicillin. For harvest, cells were
resuspended in RanGAP1 buffer I. After cell lysis and centrifugation, the pellet was
homogenized and washed two times in RanGAP1 buffer II and one time in RanGAP1
buffer III; for homogenization, a douncer was used. After washing, the suspension
was centrifuged each time for 20 min with 100,000 x g at 4◦C. Finally, the pellet was
solubilized in RanGAP1 buffer IV (25 ml buffer per l culture). After centrifugation
at RT, the supernatant was dialyzed against RanGAP1 buffer V in four steps at
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4◦C (1 l buffer per step and l culture). For the first dialysis step, the buffer was
used at RT, for the latter steps, the buffer was pre-cooled to 4◦C. The dialyzed
protein solution was centrifuged again for 20 min with 100,00 x g at 4◦C and the
supernatant subjected to anion exchange over a column using Q-Sepharose equili-
brated in RanGAP1 buffer V (10 ml Q-Sepharose per l culture). The column was
washed with RanGAP1 buffer VI and protein eluted with RanGAP1 buffer VII. The
protein-containing fractions were pooled and concentrated using a 10 kDa MWCO
concentrator (Vivaspin) and applied to a Superdex200 GL gel filtration column equi-
librated in TB+++. RanGAP1 eluted at 0.59 CV.
GAPtail was purified according to an established lab protocol [Werner et al., 2009]. In
short, the pET23a-His6-hRanGAPtail plasmids was transformed into BL21(DE3)
cells and transformed cells were selected for by ampicillin. For harvest, cells were
resuspended in Ni-NTA buffer I. After cell lysis and centrifugation, the supernatnat
was subjected to Ni pull-down over a column using Ni-NTA agarose equilibrated
in Ni-NTA buffer I (5 ml Ni-NT agarose per l culture). The column was washed
with Ni-NTA buffer II and protein eluted with Ni-NTA buffer III. The protein-
containing fractions were pooled and concentrated using a 5kDa MWCO concentra-
tor (Vivaspin) and applied to a Superdex75 GL gel filtration column equilibrated in
TB+++. GAPtail eluted at 0.50 CV.
SUMO
Untagged SUMO was purified according to a modified version of an established
lab protocol [Pichler et al., 2002]. In short, the pET11a plasmids containing either
SUMO1 or SUMO2 were transformed into BL21(DE3) cells and transformed cells
were selected for by ampicillin. For harvest, cells were resuspended in MonoQ buffer
A I. After cell lysis, the buffer was supplemented with 1 mM MgCl2, 50 µM CaCl2
as well as several crumbs of DNAse I and then incubated at 4◦C for 45 min before
centrifugation. The supernatnat was subjected to anion exchange using DEAE-
Sepharose equilibrated in MonoQ buffer A I (5 ml DEAE-Sepharose per l culture).
The flow-through was concentrated using a 3 kDa MWCO concentrator (Vivaspin)
and applied to a Superdex200 GL gel filtration column equilibrated in TB+++;
SUMO1 and 2 eluted at 0.77 CV. Peak fractions were pooled, concentrated and ap-
plied to a Superdex75 GL gel filtration column equilibrated in TB+++. For SUMO
preps to be used in preparative Ubc9∼SUMO thioester mimic formation, the column
was equilibrated in Mimic buffer. SUMO1 eluted at 0.60 CV, SUMO2 at 0.61 CV.
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His6-SUMO was purified according to an established lab protocol [Meulmeester
et al., 2008]. In short, the pET28a plasmids containing either His6-SUMO1 or His6-
SUMO2 were transformed into BL21(DE3) cells and transformed cells selected for
by ampicillin. For harvest, cells were resuspended in Ni-NTA buffer I. After cell lysis
and centrifugation, the supernatant was subjected to Ni pull-down over a column
using Ni-NTA agarose equilibrated in Ni-NTA buffer I (5 ml Ni-NT agarose per l
culture). The column was washed with Ni-NTA buffer II and protein eluted with
Ni-NTA buffer III. The protein-containing fractions were pooled and concentrated
using a 3 kDa MWCO concentrator (Vivaspin) and applied to a Superdex75 GL gel
filtration column equilibrated in TB+++. His6-SUMO1 and 2 eluted at 0.60 CV.
Ubc9
Ubc9 was purified according to an established lab protocol [Pichler et al., 2002]. In
short, the pET23a-mUbc9 plasmid was transformed into BL21(DE3) cells and trans-
formed cells were selected for by ampicillin. For harvest, cell were resuspended in
Ubc9 buffer I. Cells expressing Ubc9 wt were not lyzed with EmulsionFlex, as Ubc9
leaks into the extracellular space after freezing/thawing.
To increase yields (e.g. for isotope-labeled proteins) or in the case of some Ubc9
variants (HA-tagged Ubc9 and H20D mutant), EmulsionFlex lysis was performed
after all. After cell lysis and centrifugation, the supernatnat was subjected to cation
exchange over a column using SP-Sepharose equilibrated in Ubc9 buffer I (5 ml SP-
Sepharose per l culture). The column was washed with Ubc9 buffer I and protein
eluted with Ubc9 buffer II. The protein-containing fractions were pooled and concen-
trated using a 5 kDa MWCO concentrator (Vivaspin) and applied to a Superdex75
GL gel filtration column equilibrated in TB+++; for Ubc9 C93K mutants to be
used in preparative in vitro SUMOylation reactions, the column was equilibrated in
mimic buffer. Typically, Ubc9 eluted at about 0.58 CV.
4.4.5 Preparative protein adduct/complex formation and
purification
RanGAP1*SUMO and GAPtail*SUMO
For preparative in vitro SUMOylation of RanGAP1 or GAPtail variants, a SUMOy-
lation reaction containing 10 µM target, 30 µM SUMO, 125 nM SUMO E1 enzyme,
125 nM Ubc9 wt and 3 mM ATP in SAB- was prepared and incubated for at
least 3 h at 30◦C. The SUMOylation reaction was concentrated using a Concen-
trator MWCO 5 kDa and applied to a Superdex200 (for RanGAP1*SUMO) or Su-
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perdex75 (for GAPtial*SUMO) GL gel filtration column. As protein precipitation
was observed during concentration in dependence of ATP, the reaction was dialyzed
against TB+++ at 4◦C in cases of large reaction volumes. RanGAP1*SUMO1
eluted at 0.56 CV, GAPtail*SUMO1 at 0.43 CV.
RanBP2 complexes
For preparative in vitro reconstitution of the RanBP2 complex variants, a complex
formation reaction was prepared in SAB- containing 15-30 µM RanGAP1*SUMO1
or GAPtail*SUMO1 variants as well as Ubc9 and RanBP2 variants (either BD34
or ∆FG variants) both in a molar excess of 20% over RanGAP1*SUMO1. The
reaction was incubated on ice over night and then applied to a MonoQ GL an-
ion exchange column equilibrated in MonoQ buffer C I. RanBP2 complex variants
built with RanGAP1*SUMO1 were eluted by the application of a linear gradient
from 30-55% of MonoQ buffer C II (equivalent to 300-550 mM NaCl) in 13 CV;
the BD34 complex (built with RanGAP1*SUMO1) eluted at about 440 mM NaCl.
RanBP2 GAPtail complex variants were eluted by the application of a linear gradi-
ent from 20-32% of MonoQ buffer C II (equivalent to 200-320 mM NaCl) in 13 CV;
the BD34/GAPtail*SUMO1/Ubc9 complex eluted at about 280 mM NaCl. Peak
fractions were pooled, concentrated and applied to a Superdex200 GL gel filtration
column equilibrated in TB+++. The RanBP2 complex variants eluted at 0.40 CV,
RanBP2 GAPtail complex variants eluted at 0.43 CV.
For preparative in vitro reconstitution of the BD34 complex bound to Crm1 and
RanQL for electron microscopy experiments, a complex formation reaction was pre-
pared in SAB- containing 10-20 µM purified BD34 complex (as described above),
Crm1 in a 1.5-fold molar excess and RanQL GTP in a 3-fold molar excess. The
reaction was incubated on ice over night and then applied to a MonoQ GL anion
exchange column equilibrated in MonoQ buffer C I without aprotinin, leupeptin and
pepstatin. Proteins were eluted by the application of a linear gradient from 30-50%
of MonoQ buffer C II without aprotinin, leupeptin and pepstatin (equivalent to
300-500 mM NaCl) in CV; the BD34 complex bound to Crm1 and RanQL eluted
at about 440 mM NaCl.
Ubc9-tri-SUMO1 - the triazole-linked thioester mimic
Preparation and purification of the triazole-linked Ubc9∼SUMO1 thioester mimic
was performed by Dr. Stefanie Sommer, Mootz group, University of Münster. The
protocol can be found in [Sommer et al., 2015]; an outline is given in Section 2.1.1.
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Ubc9-K*SUMO - the isopeptide-linked thioester mimic
The Protocol was adapted from [Plechanovová et al., 2012]. In short, for prepara-
tive in vitro SUMOylation of Ubc9 C93K/K101R, a reaction was prepared contain-
ing 50 µM Ubc9 C93K/K101R, 50 µM SUMO, 500 nM SUMO E1 enzyme and 5 mM
ATP in mimic buffer and incubated for 18-24 h at 30◦C.The SUMOylation reaction
was concentrated using a 5 kDa MWCO concentrator (Vivaspin) and applied to a
Superdex75 GL gel filtration column. As protein precipitation was observed during
concentration in dependence of ATP, the reaction was dialyzed against TB+++
at 4◦C in cases of large reaction volumes. Ubc9 C93K/K101R*SUMO1 eluted in
a broadened peak partly bound to free SUMO and Ubc9 C93K/K101R; the peak
overlapped with that of the SUMO E1 enzyme (see Section 2.1.1. Peak fractions
were pooled, concentrated and applied to a MonoQ GL anion exchange column equi-
librated in MonoQ buffer C I. Proteins were eluted by the application of a linear
gradient from 7.5-25% of MonoQ buffer C II (equivalent to 75-250 mM NaCl) 13 CV.
Ubc9 C93K/K101R*SUMO1 eluted at 180 mM NaCl. For buffer exchange, peak
fractions were pooled, concentrated and applied to a Superdex75 GL gel filtration
column equilibrated in TB+++. Due to non-covalent interactions in trans between
Ubc9 and SUMO, Ubc9 C93K/K101R*SUMO1 formed multimers; hence the elution
volume strongly depended on the concentration.
4.4.6 Analytical in vitro SUMOylation
Analytical in vitro SUMOylation reactions using recombinant protein were typi-
cally carried out in a volume of 12 µl by incubation at 30◦C. Reactions were stopped
by the addition of 12 µl 2x SDS sample buffer and loaded (20 µl) onto an SDS-PAGE
gel for immunoblot analysis; commonly, substrate SUMOylation and E3 ligase auto-
SUMOylation were analyzed.
Multiple turnover SUMOylation reactions
Multiple turnover SUMOylation reactions typically contained substrate (e.g. YFP-
Sp100), SUMO, the SUMO E1 enzyme, Ubc9 and an E3 ligase in SAB+ at indicated
concentration. For in vitro SUMOylation of Borealin, reactions were prepared in
PIPES buffer at indicated concentrations. Reactions were started by the addition
of 5 mM ATP.
CHAPTER 4 MATERIALS & METHODS 161
Single turnover SUMOylation reactions
For single turnover SUMOylation reactions, the Ubc9∼SUMO thioester was pre-
formed for 10 min at 30◦C in a reaction containing 1.6 µM SUMO E1 enzyme, 8 µM
Ubc9, 24 µM SUMO and 5 mM ATP in SAB+ supplemented with 0.1 mM DTT
(instead of 1 mM). The preforming reaction was quenched by the addition of 60 mM
EDTA.
The quenched preforming reaction was diluted 1:16 into a SUMOylation reaction
containing 500 nM substrate and 25 nM E3 ligase in Single turnover buffer and
incubated at 30◦C as indicated. For E3 ligase-independent SUMOylation reactions,
the preforming reaction was diluted 1:3.2 into reactions containing 1 µM substrate
in Single turnover buffer. For analysis of the thioester itself, reactions were stopped
by the addition of non-reducing sample buffer and analyzed by αUbc9 immunoblot.
4.4.7 Isopeptidase protection assay
Since RanGAP1*SUMO1 in the endogenous RanBP2 complex is protected from
demodification by isopeptidases [Zhu et al., 2009],complex stability was assessed by
an isopeptideas protection assay. Reactions (20 µl) containing 50 nM recombinant
RanBP2 complex in SAB+ were incubated with 150 nM SENP1 (catalytic fragment)
or SAB+ (negative control) at 30◦C for 30 min. Reactions were stopped by the
addition of 20 µl 2x SDS sample buffer and loaded (20 µl) onto an SDS-PAGE gel
for αRanGAP1 immunoblot analysis.
4.4.8 Gel filtration binding assay
Due to the high Stokes radius of the BD34 complex, i.e. its early elution volume
on Superdex200 gel filtration column (which was still well after the void volume, but
clearly separable from most other recombinant proteins used in this work), binding
to it was assessed by co-migration on gel filtration (see Figure 64 as example). Gel
filtration binding assays were performed by preparing 60 µl binding reactions con-
taining all recombinant binding partners in SAB+ and incubating them on ice over
night, if not stated otherwise (concentrations of the binding partners are given for
each experiment in the Results chapter). Of the binding reactions 50 µl were applied
to a Superdex200 5/150 GL or Superose 6 PC 3.2/300 GL gel filtration column equi-
librated in TB+++. Peak fractions of 63 µl were collected and supplemented with
21 µl of 4x SDS sample buffer; typically, 35 µl of each collected sample were run on
an SDS PAGE gel and analyzed by Colloidal Coomassie staining or immunoblot. For
proteins and protein complexes eluting at a similar volume as ovalbumin, reactions
were set up with SAB-.
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Figure 64: Validation of gel filtration-based binding assays. Gel filtration profiles of the
BD34 complex (1 µM), Crm1 (2 µM) and a binding reaction of BD34 complex + Crm1 (1 and
2 µM, respectively) on Superdex200 5/150 GL gel filtration column were recorded at 280 nm. The
grey box indicates the 60 µl peak fraction of the BD34 complex, which is typically collected for gel
filtration binding assays.
Ratjadone A-treatment of Crm1
The Leptomycin B-analogon Ratjadone A binds specifically and covalently to
the cargo-binding site of Crm1, thus inhibiting the formation of an export complex
[Köster et al., 2003]. In order to inhibit Crm1 for in vitro binding assays, recombinant
protein was diluted to a concentration of 6 µM in SAB+, supplemented with 4-fold
molar excess of Ratjadone A and incubated for 20 min at RT. Mock-treated Crm1
was supplemented with the same volume of methanol. Ratjadone A and mock
treatments were always performed directly before the addition of Crm1 to binding
assay reactions.
Export complex formation
For testing the binding of Crm1-dependent export complexes to RanBP2 complex
variants, an export complex was freshly pre-formed by incubating Crm1 (2 µM), Ran
(5 µ) and SNP1 (4 µM) in SAB+ for 20 min at RT. Afterwards the RanBP2 complex
variant was added and binding assays were performed as described above.
4.4.9 Electron microscopy
Sample preparation
For electron microscopy grid preparation, 50 µl of BD34 complex bound to Crm1
and RanQL at 400 nM freshly purified from MonoQ GL column (see Section 4.4.5)
were incubated with 125 mM glutaraldehyde for 10 min on ice (in MonoQ buffer
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C I without aprotinin, leupeptin and pepstain from MonoQ run). The cross-linking
reaction was quenched by the addition of 1 M Tris pH 7.4 and incubation for 20 min
on ice. For buffer exchange, the cross-linking reaction was applied to Superdex200
5/150 gel filtration column equilibrated in TB+++. The cross-linked complex eluted
at 0.40 CV. Freshly cross-linked complexes were spread on electron microscopy grids
and stained with 3% uranyl acetate.
Electron microscopy and single particle analysis
Images were acquired in a Zeiss 910 microscope equipped with a field emission gun
and a energy filter operating at 120keV (Sesam). Processing of the data was per-
formed with standard programs (EMAN2 [Tang et al., 2007] and RELION [Scheres,
2015]). These steps were performed by Hrishikesh Das and Götz Hofhaus.
4.4.10 Microscale thermophoresis experiments
Microsscale thermophoresis was used in this work to measure the interaction in so-
lution between (fluorescent) Crm1-Cy3 (see below) and (non-fluorescent) BD34 and
RanQ69L GTP. To that end, sets of sixteen 20 µl binding reactions were prepared
each containing 20 nM Crm1-Cy3 in SAB+. Each reaction set was supplemented
with a 1:1 dilution series of BD34 (wt or mFG12) ranging from 10 µM to 0.6 nM
in the presence or absence of 30 µM RanQ69L GTP. The binding reactions were
incubated over night on ice and loaded into MO-K002 Monolith NT.115 Standard
Treated Capillaries directly prior to measurements. Measurements were conducted
on a Monolith NT.115 with a laser power of 70% and an LED power of 20%; the
time before laser-on was set to 5 sec, the laser-on time to 15 sec and the final laser-off
time to 5 sec. Data were evaluated in the "Hot/Cold" mode (hot region: over 1 sec
right before laser on; cold region: over 1 sec after 14 sec after laser on) and analyzed
with the NTAnalysis Software.
Data were analyzed using the NTAnalysis Software and GraphPad Prism 5. Val-
ues from at least five measurements per experiment were normalized according to
the minimal and maximal values. Mean values were calculated, sigmoidally fitted
and KD ± standard error values deduced. Thermophoresis equipment was kindly
provided by the group of Felix Wieland (BZH, Heidelberg).
Fluorescent labeling of Crm1
For microscale thermophoresis experiments, Crm1 was fluorescently labeled with
primary amino group-specific Cy3-NHS-ester monoreactive dye according the the
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manufacturer’s manual. In short, 3 nmol purified Crm1 were applied to a Su-
perdex200 5/150 GL gel filtration column equilibrated in 100 mM boric acid pH
8.6 for buffer exchange. Peak fractions were pooled and concentrated to 8 µM. The
lyophilized Cy3-NHS-ester was dissolved in 100 mM boric acid pH 8.6 (one vial
dissolved in 1 ml) and mixed in a ratio of 1:1 v/v with the protein solution. After
incubation at RT for 30 min, the labeling reaction was quenched by the addition of
100 mM Tris-HCl pH 7.5, 1 mM DTT and 1 mg/ml of each aprotinin, leupeptin,
and pepstatin. Excess dye was separated from the labeled protein by Superdex200
5/150 GL gel filtration column equilibrated in TB+++. According to absorption
of the labeled protein at 280 nm (protein) and at 552 nm (Cy3 dye), each Crm1
molecule was on average labeled by about 6 molecules of Cy3 with this protocol.
4.4.11 FRET
The Melchior lab has developed an enzymatic assay based on the radiation-free
excitation of YFP-SUMO when conjugated in a SUMOylation reaction to CFP-
GAPtail [Bossis et al., 2005, Stankovic-Valentin et al., 2009]. The exerted FRET
signal of the conjugated CFP-GAPtail*YFP-SUMO can be used to monitor the
kinetics of a SUMOylation reaction between.
In this work, FRET experiments were used to compare the activtiy of SUMO E2
conjugating enzyme variants. SUMOylation reactions (20 µl) were prepared with
the SUMO1 E1 enzyme (25 nM), a Ubc9 variant (4 nM), YFP-SUMO1 (1 µM) and
CFP-GAPtail (500 nM) in SAB+ buffer in 384well plates. Reactions were started
by automatic addition of ATP (5 µl, 5 mM). Fluorescence after excitation at 430
nm was measured every 30 sec for 30 min at 485 and 527 nm by microplate reader.
The ratio of emission (527 nm/485 nm) was plotted versus time.
4.4.12 Mammalian cell lysate and extract preparation
For IP experiments cell extracts were prepared from nocodazole-arrested HEK
293T cells. Cells were washed off the dishes by pipetting and collected by centrifu-
gation at 200 x g at RT for 5 min. Cells were washed three times with PBS at
RT and counted. The cell pellet from one 15 cm dish was resuspended in 500 µl
TB+++ supplemented with 50 mM NaF, 1 mM Pefa bloc and phosphatase in-
hibitor cocktail I (Sigma, 1:100 dilution). Lysis was achieved by the addition of 1 µl
of a 10% digitonin solution per 5 · 106 cells followed by a 20 min incubation on ice.
Lysates were cleared by three steps of centrifugation at 4◦C: 10 min at 300 x g, 30
min at 25,000 x g, 60 min at 100,000 x g. Extracts were either directly used for IP
experiments or flash-frozen in liquid nitrogen and stored at -80◦C.
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4.4.13 Immunoprecipitation
Immunoprecipitations were typically performed from one 15 cm dish or 500 µl of
HEK 293T cell extract using 12.5-15 µl αHA-sepharose beads. The beads were in-
cubated with the cell extracts for 3 h rotating slowly at 4◦C. Beads were collected by
centrifugation in a swing-out rotor with 200 x g at 4◦C for 5 min. The supernatant
was removed and the beads washed four times with TB+++. During the last wash-
ing step, beads were transferred to a fresh tube to minimizes unspecific background
and bound protein was eluted with 50 µl 2x SDS sample buffer. Typically, 50% of
the eluate was loaded onto an SDS-PAGE gel for immunoblot analysis together with
2.5% of input and flow-through material.
Crm1 and RanBP2 bands of correct sizes were quantified using ImageJ. The Crm1-
signal was normalized to the RanBP2-signal of the same sample and means ± S.E.M
of three experiments were calculated. Statistical analysis in form of a two-tailed Stu-
dent’s t-est with a significance level of 5% was performed using Excel.
4.5 NMR experiments
Nuclear magnetic resonance (NMR) experiments were performed by Léo Nesme
of the Carlomagno group (EMBL, Heidelberg) on Bruker Avance III 600, 700 and
800 MHz spectrometers, equipped with HCN triple-resonance cryo-probes at 300 K.
The backbone assignments of free 13C/15N-labeled proteins (i.e. GAPtail, SUMO1
and Ubc9 see also 4.4.3) were confirmed from deposited chemical shift using classical
NMR experiments: HNCA [Grzesiek and Bax, 1992] and 15N-HSQC-NOESY and
then extended to the side chain assignment of isolucines, leucines and valines using
(H)CC(CO)NH-TOCSY and H(CCCO)NH-TOCSY [Grzesiek et al., 1993, Monte-
lione et al., 1992] and HCCH-TOCSY. Sample concentrations were 0.4, 0.8 and
0.2 mM for GAPtail, Ubc9 and SUMO1, respectively. Prior to measurements, sam-
ples were run on Superdex75 or Superdex200 10/300 GL gel filtration columns equi-
librated in NMR buffer I for buffer exchange.
In order to assign methyl chemical shifts of GAPtail and Ubc9 in the RanBP2
∆FGGAPtail complex, 2H,15N-labeled Ubc9 was titrated onto SUMOylated and IVL-
labeled GAPtail(*SUMO1) and 2H,15N-labeled GAPtail*SUMO1 onto IVL-labeled
Ubc9, respectively. The methyl groups of SUMO1 in the RanBP2 ∆FG GAPtail
complex showed sufficient similarity to the free form to assign them confidently
without a reference titration.
To characterize the binding interface between the RanBP2 ∆FG GAPtail complex
(72 kDa) and Ubc9∼SUMO1 thioester mimic (29 kDa), all proteins were 2H,15N-
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labeled and used to reconstitute three different ∆FG GAPtail complexes: one with
GAPtail, one with SUMO1 and one with Ubc9 specifically IVL-labeled (due to the
great distance between GAPtail and RanBP2 as suggested by the structure of the
RanBP2 complex, the RanBP2 ∆FG fragment for the complex with IVL-labeled
GAPtail was expressed as an unlabeled protein with LB/H2O medium). Prior to
all measurements involving 2H,15N- and IVL-labeled proteins, samples were run
on Superdex75 or Superdex200 10/300 GL gel filtration columns equilibrated in
NMR buffer II for buffer exchange. The methyl resonances were detected in two-
dimensional 13C/1H HMQC experiments [Bax et al., 1983]. Sample concentrations
were between 20 and 80µM. Fully 2H,15N-labeled thioester mimic was then titrated
up to a 4 molar equivalent of RanBP2 ∆FG GAPtail complex. The NMR data
were processed by Léo Nesme of the Carlomagno group using NMRPipe39 [Delaglio
et al., 1995] and analyzed with CCPNMR.
Table 17: Overview of titrations for NMR measurements
Measured entity Titrated with Titration steps
(concentration) 2H,15N-
labeled
(molar equivalents)
RanBP2 complex with IVL-labeled GAP-
tail (60 µM)
thioester mimic 0.0; 0.2; 0.3; 0.5; 0.7; 1.0; 2.0; 4.0
RanBP2 complex with IVL-labeled Ubc9
(77 µM)
thioester mimic 0.0; 0.2; 0.4; 0.8; 1.0; 1.5; 3.0
RanBP2 complex with IVL-labeled
SUMO1 (73 µM)
thioester mimic 0.0; 0.2; 0.4; 0.8; 1.0; 2.0; 4.0
IVL-labeled Ubc9 (85 µM) GAPtail*SUMO1 0.0; 0.2; 0.4; 0.8; 1.0; 1.5; 3.0
SUMOylated IVL-labeled GAPtail
(51 µM)
Ubc9 0.0; 0.2; 0.4; 0.8; 1.0; 1.5; 2.0
Appendix
In order to dissect the binding between the RanBP2 complex and interaction part-
ners (Crm1 or the isopeptide-linked Ubc9∼SUMO1 thioester mimic) cross-link/mass
spectrometry experiments were performed [Bui et al., 2013] and [Walzthoeni et al.,
2012]. These experiments were conducted in collaboration with Alexander von Ap-
pen of the group of Martin Beck (EMBL, Heidelberg).
For this, interacting proteins were co-purified, treated by bi-functional lysine-
specific, isotope-labeled cross-linkers and subjected to mass spectrometry analysis.
Cross-linkers connected to peptides from different proteins/protein regions were then
identified by mass spectrometry analysis due to their isotope-labeling. The method
thus can give information about spatial proximity within protein complexes. The
detailed methodology of these experiments and their results are described here. Un-
fortunately, these experiments did not yield a considerable gain of information in
identifying interaction surfaces in the RanBP2 complex and its interaction partners.
4.6 Methods
4.6.1 Sample preparation
Purification of the BD34 complex bound to Crm1 and RanQL
The BD34 complex bound to Crm1 and RanQL was formed and purified as de-
scribed in Section 4.4.5. The freshly prepared complex from MonoQ (70 µg) was
applied to a Superdex200 GL gel filtration column equilibrated in Cross-link buffer.
The complex eluting at 0.40 CV was directly used in a cross-link reaction.
Purification of the ∆FG complex bound to Ubc9-K*SUMO1
The ∆FG/RanGAP1*SUMO1/Ubc9 complex (=∆FG complex) was co-purified
with the isopeptide-linked Ubc9∼SUMO1 thioester mimic. To that end, a 500
µl binding reaction was set up containing 3 µM ∆FG complex and 9 µM Ubc9
K*SUMO1 in TB+++. The reaction was concentrated to 50 µl using a 10 kDa
MWCO concentrator (Vivaspin) and applied to a Superdex200 5/150 GL gel filtra-
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tion column equilibrated in Cross-link buffer. The ∆FG complex/Ubc9 K*SUMO1
complex eluted at 0.43 CV. The two peak fractions contained equimolar amounts
of the ∆FG complex and Ubc9-K*SUMO1, were pooled (130 µl with 5.5 µM) and
directly used in a cross-link reaction.
In order to distinguish cross-linked peptides of Ubc9 and SUMO1 derived from
the ∆FG complex from those of the thioester mimic, one experiment was conducted
with a thioester mimic made from 15N-labeled proteins (expressed in M9 medium
with 15NH4Cl - see Section 4.4.3. As control, the experiment was repeated with
14N-labeled proteins (expressed in LB medium) in the thioester mimic and with the
∆FG complex alone.
4.6.2 Cross-linking
Co-purified protein complexes were cross-linked using disuccinimidyl suberate
(DSS) H12/D12 and/or disuccinimidyl glutarate (DSG) H6/D6. DSS and DSG are
homobifunctional cross-linkers with primary amino group-specific N-hydroxysuccinimide
(NHS) ester reactive groups; DSS H12/D12 is a 1:1 molar ratio mixture of proto-
nated and deuterated DSS (likewise for DSG H6/D6). For cross-link reactions,
typically 100 µg protein were incubated at 37◦C and 600 rpm shaking with 1.6 mM
cross-linker dissolved in dimethylformamide and pre-diluted in H2O directly prior
to addition. The cross-linker was added in eight steps of 0.2 mM every 4 min. The
cross-linking reaction was quenched by supplementing it with 50 mM (NH4)2CO3
and incubating it at 37◦C and 600 rpm shaking for another 10 min.
4.6.3 Mass spectrometry
Proteins were denatured with 8 M urea and 0.2% w/v RapiGest. Proteins were
reduced with 10 mM DTT at 37◦C for 30 min and subsequently alkylated with
15 mM iodoacetamide for 30 min at RT in the dark. For digestion, the samples were
diluted to 1.5 M urea and incubated with 1% w/w LysC. Digestion was stopped
by acidification with 1% v/v formic acid. Peptides were purified using a Superdex
Peptide PC 3.2/30 gel filtration column equilibrated in Peptide buffer. LC-MS/MS
analysis was carried out as described in [Bui et al., 2013]. MS Data was searched
using xQuest and posterior probabilities were calculated using xProphet. The results
were filtered using the following parameters: FDR = 0.05, min delta score = 0.95,
MS1 tolerance window 4 to 7 ppm.
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4.7 Results
4.7.1 BD34 complex bound to Crm1 and RanQL
The outcomes of cross-link/mass spectrometry experiments for the BD34 complex
bound to Crm1 and RanQL were satisfactory from a technical point of view (Figure
A1 and Table A1). A number of specific cross-links between proteins that are known
to interact, could be identified and thus served as controls, e.g. between the IR region
of the BD34 fragment and SUMO1 as well as Ubc9. Striking were some cross-linking
hotspots, e.g lysine 406 in the flexible acidic linker region of RanGAP1. A cross-link
preference of Crm1 and RanQL for RanBD3 (over RanBD4) of BD34 was observed.
To what extend this finding reflects a possible binding preference for this RanBD
remains however unclear, as the absence of a cross-link in these experiments can
have numerous reasons apart from a lack of interaction.
BD34
1 200 400 600 768
RanGAP1
1 200 400 587
SUMO1
1 101
Ubc9
1 158
Crm1
1 200 400 600 800 1000 1071
Ran
1 216
Figure A1: Results from cross-link/mass spectrometry experiment for BD34 complex
bound to Crm1 and RanQL. Schemnatic depiction of cross-links. All proteins are shown in a
linearized form. Inter-protein cross-links are depcited by orange lines, intra-protein cross-links by
purple arches.
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4.7.2 ∆FG complex bound to Ubc9-K*SUMO1
In order to reduce complexity of the cross-linking the ∆FG complex bound to
Ubc9-K*SUMO1, here only the DSS cross-linker was used. The outcomes of the
experiment was satisfactory from a technical point of view (Figure A2, Table A1
and A3). While employing the 15N-labeled the thioester in these experiments to dis-
tinguish the two Ubc9 and SUMO1 molecules was performed, efforts to modify mass
spectrometry analysis in a way that recognizes 14N/15N-mix cross-linked peptides is
still ongoing. Shown here are hence the results for the (unlabeled) ∆FG complex
alone without and with the thioester mimic.
The addition of the thioester mimic showed several new cross-links, one between
Ubc9 and SUMO1. Between which Ubc9 and SUMO1 molecule this cross-link took
place can however not be determined by these results. Interstingly, the addition
of the thioester mimic induced several new cross-linkes between RanGAP1 and the
∆FG fragment. Whether or not thioester binding in fact brings RanGAP1 and the
nucleoporin closer together is a highly interesting, yet open question.
BD34 complex BD34 complex + Ubc9-K*SUMO1
Figure A2: Results from cross-link/mass spectrometry experiment for ∆FG complex
bound to Ubc9-K*SUMO1. Schemnatic depiction of cross-links. All proteins are shown in a
linearized form. Inter-protein cross-links are depcited by green lines, intra-protein cross-links by
purple arches.
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